

chain nodes :

7 15

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

2-7 4-15 7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

2-7 4-15 7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom 13:Atom 15:Atom

Generic attributes :

15:

Saturation : Unsaturated

10/552,317

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10552317.str



chain nodes :

7 15

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

2-7 7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

2-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 15:Atom 16:Atom

Generic attributes :

15:

Saturation : Unsaturated


L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

10/552,317

```
=> d 14
L4 HAS NO ANSWERS
L1          SCR 1840
L2          SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3          STR
```



Structure attributes must be viewed using STN Express query preparation.
L4 QUE L3 AND L1 NOT L2

```
=> s 14 sss sam
SAMPLE SEARCH INITIATED 12:28:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      2625 TO ITERATE
```

76.2% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   49427 TO   55573
PROJECTED ANSWERS:      1219 TO   2351
```

L5 50 SEA SSS SAM L3 AND L1 NOT L2

```
=> => ....Testing the current file.... screen
```

ENTER SCREEN EXPRESSION OR (END):end

```
=> screen 1840
```


L6 SCREEN CREATED

```
=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
```

L7 SCREEN CREATED

```
=>
Uploading C:\Program Files\Stnexp\Queries\10552317 (a).str
```

10/552,317



chain nodes :

7 15

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

2-7 4-15 7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

2-7 4-15 7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 15:Atom

Generic attributes :

15:

Saturation : Unsaturated

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 12:34:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2625 TO ITERATE

76.2% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 49427 TO 55573

PROJECTED ANSWERS: 1131 TO 2229

L10 50 SEA SSS SAM L8 AND L6 NOT L7

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840


L11 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10552317 (b).str



chain nodes :

7 15

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

2-7 4-15 7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

2-7 4-15 7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 15:Atom

Generic attributes :

15:

Saturation : Unsaturated

L13 STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12


=> d l14

L14 HAS NO ANSWERS

L11 SCR 1840

L12 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L13 STR



Structure attributes must be viewed using STN Express query preparation.

L14 QUE L13 AND L11 NOT L12

=> s l14 sss sam

SAMPLE SEARCH INITIATED 12:34:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2625 TO ITERATE

76.2% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 49427 TO 55573

PROJECTED ANSWERS: 1131 TO 2229

L15 50 SEA SSS SAM L13 AND L11 NOT L12

=> s l10 sss ful

FULL SEARCH INITIATED 12:35:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 55025 TO ITERATE

100.0% PROCESSED 55025 ITERATIONS

1559 ANSWERS

SEARCH TIME: 00.00.01

L16 1559 SEA SSS FUL L8 AND L6 NOT L7

=> => s l16

10/552,317

L17 74 L16

=> d 117 1-74 bib,ab,hitstr

L17 ANSWER 1 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:1280561 CAPLUS
 DN 149:493700
 TI 2-(Morpholin-4-yl)pyrimidine derivatives as PI3K inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
 IN Baker, Stewart James; Goldsmith, Paul John; Hancox, Timothy Colin; Pegg, Neil Anthony; Shuttleworth, Stephen Joseph; Dechaux, Elsa Amandine; Krintel, Sussie Lerche; Price, Stephen; Large, Jonathan Martin; McDonald, Edward
 PA Piramed Limited, UK; The Institute of Cancer Research
 SO PCT Int. Appl., 93pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2008125833 | A1 | 20081023 | WO 2008-GB1292 | 20080414 |
| W: AE, AG, AL, AM, AN, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI GB 2007-7086 | A | 20070412 | | |
| GB 2007-7613 | A | 20070419 | | |

OS MARPAT 149:493700

AB The invention provides compds. of formula I and their pharmaceutically acceptable salts. These compds. are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurol. disorders. Compds. of formula I wherein R2 is bonded at position 2, R1 is bonded at position 5 or 6; or R1 is bonded at position 2, R2 is bonded at position 6; R1 is (un)substituted -(CH2)m-Y-R3, (un)substituted -[(hetero)arylene-(CH2)n]pNH2 and derivs., -CONH2 and derivs. and -O(CRaRb)n-R3; R2 is (un)substituted indolyl; Y is a direct bond, (un)substituted -O(CH2)n-, (un)substituted -O(CH2)nNH- and derivs., (un)substituted -NH(CH2)n- and derivs., (un)substituted NH(CH2)nO(CH2)n- and derivs., etc.; m is 1-3; n is 0-3; p is 0-1; one of Ra and Rb is H, the other one is (un)substituted C1-6 alkyl; or each of Ra and Rb is independently (un)substituted C1-6 alkyl; R3 is unsatd. 5- to 12-membered carbocyclic or heterocyclic ring and (un)substituted saturated 5- to 7-membered N-containing heterocyclic ring; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by Suzuki coupling of (6-chloro-2-morpholin-4-yl)pyrimidin-4-yl)-(2-pyridin-3-ylethyl)amine with 6-fluoro-4-(4,4,5,5-tetramethyl[1,2,3]dioxaborolan-2-yl)-1H-indole. All the invention compds. were evaluated for their PI3K inhibitory activity. From the assay, it was determined that II and other

tested compds. exhibited the IC50 values of 5 - 500 nM.


IT 1072269-15-8P, N-(1-Benzylpiperidin-4-yl)-N-[4-(1H-indol-4-yl)-6-(morpholin-4-yl)pyrimidin-2-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of morpholinylpyrimidine derivs. as PI3K inhibitors useful in the treatment of diseases)

RN 1072269-15-8 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-4-yl)-6-(4-morpholinyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:1248534 CAPLUS

DN 149:471494

TI Preparation of N-acylazetidine MEK inhibitors and 4-aryl-2-aminopyrimidine or 4-aryl-2-aminoalkylpyrimidine JAK-2 inhibitors and their combinations useful for treating neoplasm

IN Lamb, Peter

PA Exelixis, Inc., USA

SO PCT Int. Appl., 623pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2008124085 | A2 | 20081016 | WO 2008-US4434 | 20080403 |
| W: AE, AG, AL, AM, AO, AT, AU , AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2007-921878P P 20070403

OS MARPAT 149:471494

AB The invention provides methods of treating a disease, particularly cancer, by administering a therapeutically effective amount of a MEK inhibitor, e.g., I [A = (un)substituted phenylene; X = halo; R3 = H, halo, OH, alkoxy, amino; R4 = H, NH2 and derivs., CONH2 and derivs., cycloalkyl, etc.; or R3CR4 = CO, C(:NOH); R7 = halo] or a pharmaceutical acceptable salt or solvate, or a pharmaceutical composition containing I and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a KAK-2 inhibitor II [D, E = independently halo, CF3, (heterocyclo)alkyl; or DCCE = 5-7 membered heteroaryl, heterocycloalkyl; L = a bond, O, NH; Z = alkoxy, cycloalkyl, (un)substituted heteroaryl, heterocycloalkyl; Z and R25 together with the C's to which they are attached form an (un)substituted 5-6 membered heterocycloalkyl, heteroaryl, cycloalkyl; n = 0-4 and each n is independently selected when >1 n is present; R1 = H; R2 = substituted Ph, 6-aminopyridin-2-yl, 4-aminopyrimidin-6-yl, phenylsulfonylamino, etc.] or a pharmaceutical acceptable salt or solvate, or a pharmaceutical composition containing II and a pharmaceutically acceptable carrier and in combination with other cancer treatments. Example compound III was prepared by amidation of 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoic acid with azetidin-3-ol hydrochloride. Example compound IV was prepared by cross-coupling of 2,4-dichloropyrimidine with 4-(acetylamino)phenylboronic acid; the resulting N-[4-(2-chloropyrimidin-4-yl)phenyl]acetamide underwent amination with N-Boc-1,3-diaminobenzene to give compound IV. I were evaluated for their MEK inhibitory activity and II for their JAK-2 inhibitory activity.


IT 945754-01-8P, Ethyl 4-[[4-[4-(acetylamino)phenyl]pyrimidin-2-yl]amino]piperidine-1-carboxylate 945754-03-0P,

1,1-Dimethylethyl 4-[[4-[4-(acetylamino)phenyl]pyrimidin-2-yl]amino]piperidine-1-carboxylate 945755-25-9P,
 N-[4-[2-[(Piperidin-4-yl)amino]pyrimidin-4-yl]phenyl]acetamide 945755-26-0P, N-[4-[2-[[1-[(2,6-Dichlorophenyl)carbonyl]piperidin-4-yl]amino]pyrimidin-4-yl]phenyl]acetamide 945756-08-1P,
 (2,6-Dichlorophenyl)[4-[[4-[4-(methyl)thiophen-2-yl]pyrimidin-2-yl]amino]piperidin-1-yl]methanone 945756-10-5P,
 (2,6-Dichlorophenyl)[4-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]methanone 945756-14-9P,
 (2,6-Dichlorophenyl)[4-[[4-[5-(methyl)thiophen-2-yl]pyrimidin-2-yl]amino]piperidin-1-yl]methanone 1071297-52-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(JAK-2 inhibitor; preparation of N-acylazetidine MEK inhibitors and 4-aryl-2-aminopyrimidine or 4-aryl-2-aminoalkylpyrimidine JAK-2 inhibitors and methods of using their combinations for treating neoplasm)


RN 945754-01-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 945754-03-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 945755-25-9 CAPLUS

CN Acetamide, N-[4-[2-(4-piperidinylamino)-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 945755-26-0 CAPLUS

CN Acetamide, N-[4-[2-[[1-(2,6-dichlorobenzoyl)-4-piperidinyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 945756-08-1 CAPLUS

CN Methanone, (2,6-dichlorophenyl)[4-[[4-(4-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 945756-10-5 CAPLUS


CN Methanone, (2,6-dichlorophenyl)[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 945756-14-9 CAPLUS

CN Methanone, (2,6-dichlorophenyl)[4-[[4-(5-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)

pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 1071297-52-3 CAPLUS

CN Methanone, (2,6-dichlorophenyl)[4-[[4-(4-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 945756-08-1


CMF C21 H20 Cl2 N4 O S



CM 2

CRN 64-19-7

CMF C2 H4 O2



IT 945756-45-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-acylazetidine MEK inhibitors and 4-aryl-2-aminopyrimidine or 4-aryl-2-aminoalkylpyrimidine JAK-2 inhibitors and methods of using their combinations for treating neoplasm)

RN 945756-45-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thienyl)-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)

10/552,317



● HCl

L17 ANSWER 3 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:1039048 CAPLUS
 DN 149:307871
 TI 4-(Pyrrolopyridinyl)pyrimidin-2-ylamine derivatives as cell proliferation inhibitors, their preparation, pharmaceutical compositions, and use as antitumor agents
 IN Dorsch, Dieter; Sirrenberg, Christian; Mueller, Thomas J. J.; Merkul, Eugen
 PA Merck Patent G.m.b.H., Germany
 SO Ger. Offen., 32pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|-----------------|------|--|----------------------|----------|
| PI | DE 102007008419 | A1 | 20080828 | DE 2007-102007008419 | 20070221 |
| | WO 2008101587 | A1 | 20080828 | WO 2008-EP634 | 20080128 |
| | W: | | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | |
| | RW: | | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |

PRAI DE 2007-102007008419 A 20070221

AB The invention relates to 4-(pyrrolopyridinyl)pyrimidin-2-ylamines of formula I, which are inhibitors of cell proliferation/cell vitality and can be used for treatment of tumors. In compds. I, R1 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; A is C1-10 alkyl, where one or two CH2 groups may be replaced by O- or S-atoms and/or by -CH=CH- groups and 1-7 H atoms may be replaced by F; n is 0-2; R6 is H or C1-6 alkyl; Ar is (un)substituted C5-14 aryl; Het is (un)substituted mono- or bicyclic heterocyclyl or heteroaryl containing 1-4 heteroatoms selected from N, O, and S; R2 is H or A; R3 and R4 are independently selected from H, halo, cyano, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, and -[C(R6)2]n-cycloalkyl; R5 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; including pharmaceutically acceptable derivs., solvates, salts, tautomers, and stereoisomers thereof. The invention also relates the preparation of I, pharmaceutical compns. comprising at least one compound I, optionally in combination with other active agents, along with carriers and/or adjuvants, if necessary, as well as to the use of the compns. for the treatment of tumors, tumor growth, tumor metastasis, and/or AIDS. Palladium-catalyzed carbonylation of tert-Bu 3-iodopyrrolo[3,2-c]pyridine-1-carboxylate with trimethylsilylacetylene and carbon monoxide resulted in the formation of ketone II, which underwent heterocyclization with phenylguanidinium carbonate to give pyrimidine III. The compds. of the invention have antiproliferative activity, e.g., compound III expressed IC50 values between 10 nM and 1 μ M for inhibition of cell proliferation of intestinal, ovarian, prostate, and breast cancer cell lines.

IT 1050373-17-5P, 2-((4-Pyridinyl)amino)-4-(1H-pyrrolo[3,2-c]pyridin-


3-yl)pyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of (pyrrolopyridinyl)pyrimidinylamines as cell proliferation inhibitors useful as antitumor agents)

RN 1050373-17-5 CAPLUS

CN 2-Pyrimidinamine, N-4-pyridinyl-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)- (CA INDEX NAME)




L17 ANSWER 4 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:1039047 CAPLUS
 DN 149:307870
 TI 4-(Pyrrolopyridinyl)pyrimidin-2-ylamine derivatives as cell proliferation inhibitors, their preparation, pharmaceutical compositions, and use as antitumor agents
 IN Dorsch, Dieter; Sirrenberg, Christian; Mueller, Thomas J. J.; Merkul, Eugen
 PA Merck Patent G.m.b.H., Germany
 SO PCT Int. Appl., 70pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2008101587 | A1 | 20080828 | WO 2008-EP634 | 20080128 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM DE 102007008419 A1 20080828 DE 2007-102007008419 20070221 PRAI DE 2007-102007008419 A 20070221 | | | | |

OS MARPAT 149:307870

AB The invention relates to 4-(pyrrolopyridinyl)pyrimidin-2-ylamines of formula I, which are inhibitors of cell proliferation/cell vitality and can be used for treatment of tumors. In compds. I, R1 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; A is C1-10 alkyl, where one or two CH2 groups may be replaced by O- or S-atoms and/or by -CH=CH- groups and 1-7 H atoms may be replaced by F; n is 0-2; R6 is H or C1-6 alkyl; Ar is (un)substituted C5-14 aryl; Het is (un)substituted mono- or bicyclic heterocyclyl or heteroaryl containing 1-4 heteroatoms selected from N, O, and S; R2 is H or A; R3 and R4 are independently selected from H, halo, cyano, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, and -[C(R6)2]n-cycloalkyl; R5 is H, A, -[C(R6)2]n-Ar, -[C(R6)2]n-Het, or -[C(R6)2]n-cycloalkyl; including pharmaceutically acceptable derivs., solvates, salts, tautomers, and stereoisomers thereof. The invention also relates the preparation of I, pharmaceutical compns. comprising at least one compound I, optionally in combination with other active agents, along with carriers and/or adjuvants, if necessary, as well as to the use of the compns. for the treatment of tumors, tumor growth, tumor metastasis, and/or AIDS. Palladium-catalyzed carbonylation of tert-Bu 3-iodopyrrolo[3,2-c]pyridine-1-carboxylate with trimethylsilylacetylene and carbon monoxide resulted in the formation of ketone II, which underwent heterocyclization with phenylguanidinium carbonate to give pyrimidine III. The compds. of the invention have antiproliferative activity, e.g., compound III expressed IC50 values between 10 nM and 1 μ M for inhibition of cell proliferation of intestinal, ovarian, prostate, and breast cancer cell lines.

IT 1050373-17-5P, 2-((4-Pyridinyl)amino)-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)pyrimidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (pyrrolopyridinyl)pyrimidinylamines as cell proliferation inhibitors useful as antitumor agents)
RN 1050373-17-5 CAPLUS
CN 2-Pyrimidinamine, N-4-pyridinyl-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:979351 CAPLUS

DN 149:268069

TI Pyridine derivatives as PI3K inhibitors and their preparation,
pharmaceutical compositions and use in the treatment of diseases

IN Pecchi, Sabina; Ni, Zhi-Jie; Burger, Matthew; Wagman, Allan; Atallah,
Gordana; Bartulis, Sarah; Ng, Simon; Pfister, Keith B.; Smith, Aaron;
Zhang, Yanchen; Merritt, Hanne; Voliva, Charles

PA Novartis Vaccines and Diagnostics, Inc., USA

SO PCT Int. Appl., 99pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2008098058 | A1 | 20080814 | WO 2008-US53190 | 20080206 |
| | W: | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRAI US 2007-888465P P 20070206


OS MARPAT 149:268069

AB The invention relates to compds. of formula I and their pharmaceutically acceptable salts and prodrugs thereof, which are phosphatidylinositol 3 kinase (PI3K) inhibitors; to compns. of the compds., either alone or in combination with at least one addnl. therapeutic agent, with a pharmaceutically acceptable carrier; to uses of the compds., either alone or in combination with at least one addnl. therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases. Compds. of formula I wherein X is N, Y is (un)substituted CH; or Y is N, X is (un)substituted CH; Z is N and (un)substituted CH; R1 is H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted alkoxy, (un)substituted (hetero)aryl, etc.; R2 and R4 are independently H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted alkoxy, (un)substituted (hetero)aryl, (un)substituted (un)substituted heterocyclyl, (un)substituted cycloalkyl, etc.; R3 is H, (un)substituted alkyl, (un)substituted -CO-alkyl, (un)substituted 3- to 7-membered cycloalkyl and (un)substituted 4- to 7-membered heterocyclyl; and their stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by Suzuki coupling of 2-chloro-4-(morpholin-4-yl)-6-(tetrahydro-2H-pyran-4-yloxy)pyrimidine with 5-[4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-yl)]-4-(trifluoromethyl)-2-pyridylamine. All the invention compds. were evaluated for their PI3K inhibitory activity.

IT 1045860-82-9P, 6-(Morpholin-4-yl)-2-[[3-(trifluoromethyl)pyridin-4-yl]amino]-4,5'-bipyrimidine-2'-amine 1045860-84-1P,
 6-(Morpholin-4-yl)-2-[[8-(trifluoromethyl)quinolin-4-yl]amino]-4,5'-bipyrimidine-2'-amine 1045860-94-3P,
 2'-(Methylamino)-6-(morpholin-4-yl)-2-[[3-(trifluoromethyl)pyridin-4-yl]amino]-4,5'-bipyrimidine 1045860-96-5P,
 2'-(Methylamino)-6-(morpholin-4-yl)-2-[[8-(trifluoromethyl)quinolin-4-yl]amino]-4,5'-bipyrimidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyridine derivs. as PI3K inhibitors useful in the treatment of diseases)
 RN 1045860-82-9 CAPLUS
 CN [4,5'-Bipyrimidine]-2,2'-diamine, 6-(4-morpholinyl)-N2-[3-(trifluoromethyl)-4-pyridinyl]- (CA INDEX NAME)




RN 1045860-84-1 CAPLUS
 CN [4,5'-Bipyrimidine]-2,2'-diamine, 6-(4-morpholinyl)-N2-[8-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)




RN 1045860-94-3 CAPLUS
 CN [4,5'-Bipyrimidine]-2,2'-diamine, N2'-methyl-6-(4-morpholinyl)-N2-[3-(trifluoromethyl)-4-pyridinyl]- (CA INDEX NAME)

10/552,317



RN 1045860-96-5 CAPLUS

CN [4,5'-Bipyrimidine]-2,2'-diamine, N2'-methyl-6-(4-morpholinyl)-N2-[8-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:806540 CAPLUS
 DN 149:128862
 TI Preparation of pyridinyl-substituted pyrimidine derivatives as inhibitors of cyclin-dependently kinase (CDK)
 IN Beckwith, Rohan Eric John; Curtis, Daniel Tim; Harrington, Edmund; Hinrichs, Jurgen Hans-Hermann; Tallarico, John Anthony
 PA Novartis AG, Switz.
 SO PCT Int. Appl., 113pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2008079933 | A2 | 20080703 | WO 2007-US88292 | 20071220 |
| | WO 2008079933 | A3 | 20081204 | | |
| | W: | AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |

PRAI US 2006-871471P P 20061222

OS MARPAT 149:128862

AB Title compds. I [m = 0-1; n = 0-1; A1, A2, A3 and A4 independently = C, CH or N; R1-9 independently = H, halo, (un)substituted amino, alkyl, alkoxy, aryl or cycloalkyl], and their pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates are prepared as inhibitors of cyclin-dependently kinase (CDK). Thus, e.g., II was prepared by Suzuki reaction of 2,4-dichloropyrimidine with (3-methoxy-4-pyridinyl)boronic acid followed by condensation reaction with 2-chloro-4-(3-methoxypyridin-4-yl)pyrimidine. Select compds. of I were tested for their inhibitory activity in CDKs kinase assays, e.g., II showed IC50 value of < 5 μ M for CDK1. As inhibitor of CDK, I should prove useful for the treatment, prevention and/or amelioration of protein kinases CDKs-associated diseases such as cancer, inflammation, cardiac hypertrophy, and HIV.

IT 1035944-57-0P, [4-(2-Methoxypyridin-3-yl)pyrimidin-2-yl](pyridin-4-yl)amine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinyl-substituted pyrimidine derivs. as inhibitors of cyclin-dependently kinase (CDK))

RN 1035944-57-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methoxy-3-pyridinyl)-N-4-pyridinyl- (CA INDEX NAME)


10/552,317



L17 ANSWER 7 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:796822 CAPLUS
 DN 149:128848
 TI Preparation of 5-cyano-4-(pyrrolo[2,3-b]pyridin-3-yl)pyrimidines as
 polo-like kinase (PLK) inhibitors.
 IN Mortimore, Michael; Young, Stephen Clinton; Everitt, Simon Robert Lorrie;
 Knegtel, Ronald; Pinder, Joanne Louise; Rutherford, Alistair Peter;
 Durrant, Steven; Brenchley, Guy; Charrier, Jean Damien; O'Donnell, Michael
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 191pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2008079346 | A1 | 20080703 | WO 2007-US26190 | 20071221 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2006-876307P | P | 20061221 | | |
| | US 2007-922291P | P | 20070406 | | |
| | US 2007-947707P | P | 20070703 | | |
| | US 2007-989014P | P | 20071119 | | |
| OS | MARPAT 149:128848 | | | | |
| AB | Title compds. [I; R1 = H, halo, (substituted) alipharyl, aliphatyloxy; R2 = NR4R5, OR6, SR6, etc.; R4 = H, (substituted) alipharyl; R5 = (substituted) alipharyl, mono- or bicycyl; R4R5 = atoms to form (substituted) mono- or bicycyl; R6 = H, (substituted) alkyl, aryl(alkyl), heteroaryl(alkyl)], were prepared Thus, 2-methylsulfonyl-4-(1-tosyl-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile (preparation given) was microwaved with PhCH2NH2 and diisopropylamine in THF at 100° for 10 min. to give a residue which was stirred with LiOH in THF/H2O for 1 h to give 36% 2-benzylamino-4-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile. I inhibited PLK1 with Ki in the range of <3 nM to >40 nM. | | | | |
| IT | 1036024-59-5P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyanopyrrolopyridinylpyrimidines as polo-like kinase inhibitors) | | | | |
| RN | 1036024-59-5 CAPLUS | | | | |
| CN | 5-Pyrimidinecarbonitrile, 2-[(1-methyl-4-piperidinyl)amino]-4-[5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]- (CA INDEX NAME) | | | | |

10/552,317




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 8 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:668211 CAPLUS
 DN 149:215067
 TI IRAK-4 inhibitors. Part II: A structure-based assessment of
 imidazo[1,2-a]pyridine binding
 AU Buckley, George M.; Ceska, Thomas A.; Fraser, Joanne L.; Gowers, Lewis;
 Groom, Colin R.; Higuieruelo, Alicia Perez; Jenkins, Kerry; Mack, Stephen
 R.; Morgan, Trevor; Parry, David M.; Pitt, William R.; Rausch, Oliver;
 Richard, Marianna D.; Sabin, Verity
 CS UCB, Cambridge, CB21 6GS, UK
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(11), 3291-3295
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 AB A potent IRAK-4 inhibitor was identified through routine project cross
 screening. The binding mode was inferred using a combination of in silico
 docking into an IRAK-4 homol. model, surrogate crystal structure anal. and
 chemical analog SAR.
 IT 882732-18-5P 1042224-61-2P
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (IRAK-4 inhibitors: structure-based assessment of
 imidazo[1,2-a]pyridine binding)
 RN 882732-18-5 CAPLUS
 CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-4-piperidinyl- (CA INDEX
 NAME)




RN 1042224-61-2 CAPLUS
 CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-methyl-N-4-piperidinyl-
 (CA INDEX NAME)



IT 882562-92-7
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (IRAK-4 inhibitors: structure-based assessment of
 imidazo[1,2-a]pyridine binding)
 RN 882562-92-7 CAPLUS
 CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-
 pyrimidinyl)amino]-N-methyl- (CA INDEX NAME)




IT 882563-97-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (IRAK-4 inhibitors: structure-based assessment of
 imidazo[1,2-a]pyridine binding)
 RN 882563-97-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-
 pyrimidinyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 9 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:398762 CAPLUS
 DN 148:552748
 TI Pyrimidine-based inhibitors of CaMKII δ
 AU Mavunkel, Babu; Xu, Yong-jin; Goyal, Bindu; Lim, Don; Lu, Qing; Chen, Zheng; Wang, Dan-Xiong; Higaki, Jeffrey; Chakraborty, Indrani; Liclican, Albert; Sideris, Steve; Laney, Maureen; Delling, Ulrike; Catalano, Rosanne; Higgins, Linda S.; Wang, Hui; Wang, Jing; Feng, Ying; Dugar, Sundeep; Levy, Daniel E.
 CS Scios, Inc., Fremont, CA, 94555, USA
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(7), 2404-2408
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 148:552748
 AB Non-ATP competitive pyrimidine-based inhibitors of CaMKII δ were identified. Computational studies were enlisted to predict the probable mode of binding. The results of the computational studies led to the design of ATP competitive inhibitors with optimized hinge interactions. Inhibitors of this class possessed improved enzyme and cellular activity compared to early leads.
 IT 1026028-75-0P 1026028-77-2P 1026028-78-3P
 1026028-79-4P 1026028-81-8P 1026028-82-9P
 1026028-84-1P 1026028-85-2P 1026028-88-5P
 1026028-90-9P 1026028-91-0P 1026028-92-1P
 1026028-94-3P 1026028-95-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pyrimidine-based inhibitors of CaMKII δ)
 RN 1026028-75-0 CAPLUS
 CN 2,4-Pyridinediamine, N4-[4-(3-fluorophenyl)-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1026028-77-2 CAPLUS
 CN 2,4-Pyridinediamine, N4-(4-[1,1'-biphenyl]-3-yl-2-pyrimidinyl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-78-3 CAPLUS

CN 2,4-Pyridinediamine, N4-[4-(3-methylphenyl)-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-79-4 CAPLUS

CN 2,4-Pyridinediamine, N4-[4-(4-chlorophenyl)-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-81-8 CAPLUS

CN Benzoic acid, 4-[2-[[2-[[[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-82-9 CAPLUS

CN Benzoic acid, 4-[2-[[2-[[[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-84-1 CAPLUS

CN Benzoic acid, 3-[2-[[2-[[[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-85-2 CAPLUS

CN Benzeneacetic acid, 4-[2-[[2-[[[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-88-5 CAPLUS

CN 2,4-Pyridinediamine, N4-[4-[4-(dimethylamino)phenyl]-2-pyrimidinyl]-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-90-9 CAPLUS

CN Benzamide, N-methyl-4-[2-[[2-[[[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-91-0 CAPLUS

CN 2,4-Pyridinediamine, N2-[(1S)-1-phenylethyl]-N4-[4-[4-(2H-tetrazol-5-yl)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1026028-92-1 CAPLUS

CN Benzamide, N-hydroxy-4-[2-[[2-[[[(1S)-1-phenylethyl]amino]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1026028-94-3 CAPLUS
 CN Benzoic acid, 4-[2-[(2-amino-4-pyridinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1026028-95-4 CAPLUS
 CN Benzoic acid, 4-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)




IT 1026029-53-7P 1026029-57-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (pyrimidine-based inhibitors of CaMKIIδ)
 RN 1026029-53-7 CAPLUS
 CN Benzoic acid, 4-[2-[(2-amino-4-pyridinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)

10/552,317



RN 1026029-57-1 CAPLUS


CN Benzoic acid, 4-[2-(4-pyridinylamino)-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:319382 CAPLUS
 DN 148:331703
 TI Preparation of aminopyrimidinylbenzotriazoles as kinase modulators
 IN Goldstein, David Michael; Gong, Leyi; Michoud, Christophe; Palmer, Wylie
 Solang; Sidduri, Achyutharao
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 91pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2008028860 | A1 | 20080313 | WO 2007-EP59040 | 20070830 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | US 20080103142 | A1 | 20080501 | US 2007-899758 | 20070907 |
| PRAI | US 2006-843090P | P | 20060908 | | |
| OS | MARPAT 148:331703 | | | | |
| AB | Title compds. [I; R = alkyl, hydroxyalkyl, (substituted) triazolylalkyl, tetrazolylalkyl, dioxopyrrolidinylalkyl, etc.; R1 = H, halo, alkyl, amino; R2 = H, alkyl; R3 = halo, NO2, alkyl, cyano, amino, OH, alkoxy, etc.; m = 0-2], were prepared Thus, title compound (II) showed JNK kinase inhibitory activity with p(JNK1) = 0.0194. | | | | |
| IT | 1011529-79-5P 1011530-00-9P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of aminopyrimidinylbenzotriazoles as kinase modulators) | | | | |
| RN | 1011529-79-5 CAPLUS | | | | |
| CN | 2-Pyrimidinamine, 4-(1H-benzotriazol-1-yl)-N-4-piperidinyl- (CA INDEX NAME) | | | | |



RN 1011530-00-9 CAPLUS
 CN 1-Piperidineacetamide, 4-[[4-(1H-benzotriazol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



IT 1011530-73-6P
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (prophetic intermediate; preparation of aminopyrimidinylbenzotriazoles as
 kinase modulators)
 RN 1011530-73-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-benzotriazol-1-yl)-2-
 pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:163603 CAPLUS

DN 148:230184

TI Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases

IN Ward, Keith W.; Hu, Zhenze; Phillips, Gary; Kerppola, Raili

PA USA

SO U.S. Pat. Appl. Publ., 53pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|----------------|--|----------|-----------------|----------|
| PI | US 20080031884 | A1 | 20080207 | US 2007-832294 | 20070801 |
| | WO 2008021729 | A2 | 20080221 | WO 2007-US74943 | 20070801 |
| | WO 2008021729 | A3 | 20081009 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |

PRAI US 2006-836078P P 20060807

OS MARPAT 148:230184

AB A composition for treating, reducing, ameliorating, or alleviating a back-of-the-eye condition or disorder that has an etiol. in inflammation comprises a dissociated glucocorticoid receptor agonist ("DIGRA"). The compns. also can include other anti-inflammatory agents, anti-angiogenic agents, or combinations thereof. The composition can be formulated for topical application, injection, or implantation. The composition can be administered alone or in combination with another procedure chosen to enhance the outcome of the treatment.


IT 496795-25-6, 4-(2-Phenyl-1H-imidazol-1-yl)-N-pyridin-4-ylpyrimidin-2-amine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases)

RN 496795-25-6 CAPLUS


CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)

10/552,317




L17 ANSWER 12 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:9637 CAPLUS
 DN 148:121721
 TI Preparation of imidazolyl-pyrimidine derivatives as GSK3 inhibitors
 IN Burrows, Jeremy; Huerta, Fernando; Rein, Tobias; Rotticci, Didier; Staaf, Karin; Turek, Dominika
 PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2008002245 | A2 | 20080103 | WO 2007-SE621 | 20070626 |
| | WO 2008002245 | A3 | 20080214 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| | US 20080188503 | A1 | 20080807 | US 2007-769113 | 20070627 |
| PRAI | US 2006-816755P | P | 20060627 | | |
| OS | MARPAT 148:121721 | | | | |
| AB | Title compds. I [ring A = (un)substituted heterocyclyl or carbocyclyl; R2 = halo, NO2, CF3, OCF3 or CN; R3 = Me, (un)substituted alkyl, alkenyl, alkynyl, 6-membered non-aromatic carbocyclyl or heterocyclyl; R4 = H, CN, (un)substituted alkyl or haloalkyl], and their pharmaceutically acceptable salts, are prepared and disclosed as glycogen synthase kinase 3 (GSK3) inhibitors. Thus, e.g., a multi-step synthesis was given to prepare II starting from 5-methyl-4-aminoisoxazole and tetrahydro-2H-pyran-4-one. All the exemplar compds. were evaluated for their GSK3 inhibitory activity in GSK3 β inhibition assays with typical Ki values ranging from 0.001 to 10,000 nM. For instance, II exhibited a Ki value of 49 nM. I should prove useful in treatment and prevention of GSK3 associated diseases including Alzheimer's disease. | | | | |
| IT | 1000773-98-7P, [5-Fluoro-4-[2-methyl-3-(tetrahydropyran-4-yl)-3H-imidazol-4-yl]pyrimidin-2-yl](pyridin-4-yl)amine 1000774-00-4P, tert-Butyl 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]piperidine-1-carboxylate RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of imidazolyl-pyrimidine derivs. as GSK3 inhibitors in treatment and prevention of GSK3 associated diseases including Alzheimer's disease) | | | | |
| RN | 1000773-98-7 CAPLUS | | | | |
| CN | 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-4-pyridinyl- (CA INDEX NAME) | | | | |



RN 1000774-00-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 1000774-02-6P, N-(1-Acetylpiperidin-4-yl)-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-04-8P, N-(1-Benzylpiperidin-4-yl)-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-05-9P, N-(1-Benzoylpiperidin-4-yl)-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-06-0P, 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylacetyl)piperidin-4-yl]pyrimidin-2-amine
 1000774-07-1P, Benzyl 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]piperidine-1-carboxylate
 1000774-08-2P, 5-Fluoro-N-[1-(methylsulfonyl)piperidin-4-yl]-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-09-3P, 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(trifluoroacetyl)piperidin-4-yl]pyrimidin-2-amine
 1000774-10-6P, 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylsulfonyl)piperidin-4-yl]pyrimidin-2-amine
 1000774-11-7P, N-[1-(Benzylsulfonyl)piperidin-4-yl]-5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
 1000774-17-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolyl-pyrimidine derivs. as GSK3 inhibitors in treatment and prevention of GSK3 associated diseases including Alzheimer's disease)


RN 1000774-02-6 CAPLUS

CN Ethanone, 1-[4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 1000774-04-8 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidiny]- (CA INDEX NAME)




RN 1000774-05-9 CAPLUS

CN Methanone, [4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]phenyl- (CA INDEX NAME)




RN 1000774-06-0 CAPLUS

CN Ethanone, 1-[4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]-2-phenyl- (CA INDEX NAME)




RN 1000774-07-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester
(CA INDEX NAME)




RN 1000774-08-2 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-(methylsulfonyl)-4-piperidinyl]-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 1000774-09-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[4-[[5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 1000774-10-6 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 1000774-11-7 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-[1-[(phenylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 1000774-17-3 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-4-pyridinyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

L17 ANSWER 13 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1396177 CAPLUS
 DN 148:55085
 TI 2-Heterocyclylamino-4-imidazolylypyrimidines as agents for the inhibition
 of cell proliferation and their preparation
 IN Jones, Clifford; Pass, Martin; Rudge, David
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 131pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2007138268 | A1 | 20071206 | WO 2007-GB1906 | 20070524 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRAI US 2006-803283P P 20060526
 US 2006-868540P P 20061204

OS MARPAT 148:55085

AB Compds. of formula I: which possess cell cycle inhibitory activity are described. Compds. of formula I wherein ring A is 5- to 7-membered saturated heterocycle; R1 is H, C1-6 alkyl, C1-6 alkanoyl, carbamoyl, etc.; R2 is halo, NO2, CN, OH, amino, carboxyl, carbamoyl, etc.; m is 0 - 4; R3 is halo, CN and amino; n is 0 - 2; R4 is Et, n-Pr, i-Pr, Bu, i-Bu, s-Bu, t-Bu, cyclopropyl, etc.; R5 is Me, Et, i-Pr, CF3, CHF2, etc.; and their pharmaceutically acceptable salts, and in vivo hydrolyzable esters thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their inhibitory activity of cell proliferation (some data given).


IT 959790-81-9P 959790-82-0P 959790-83-1P
 959791-15-2P 959791-49-2P 959791-50-5P
 959791-51-6P 959791-52-7P 959791-53-8P
 959791-54-9P 959791-60-7P 959791-98-1P
 959791-99-2P 959792-08-6P 959792-09-7P
 959792-11-1P 959792-13-3P 959792-26-8P
 959792-28-0P 959792-34-8P 959792-75-7P
 959792-76-8P 959792-79-1P 959792-80-4P
 959792-99-5P 959793-00-1P 959793-04-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of
 (heterocyclylamino)imidazolylypyrimidines as cell proliferation
 inhibitors)

RN 959790-81-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-

5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 959790-82-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 959790-83-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloropropyl)sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-15-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-(ethenylsulfonyl)-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-49-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-50-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-51-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 959791-52-7 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-4-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 959791-53-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[2-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959791-54-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[2-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-60-7 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[4-[[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-98-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-99-2 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 959792-08-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[(3-methyl-3-nitrobutyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-09-7 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[(3-methyl-3-nitrobutyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-11-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-amino-3-methylbutyl)sulfonyl]-4-piperidinyl]-5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-13-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-amino-3-methylbutyl)sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-26-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 959792-28-0 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 959792-34-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloropropyl)sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-75-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 959792-76-8 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(4-piperidinylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 959792-79-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, phenylmethyl ester, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-80-4 CAPLUS


CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)

Relative stereochemistry.




RN 959792-99-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 959793-00-1 CAPLUS

CN 2-Pyrimidinamine, 4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-4-piperidinyl- (CA INDEX NAME)



RN 959793-04-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloropropyl)sulfonyl]-4-piperidinyl]-4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro- (CA INDEX NAME)



IT 959790-84-2P 959790-85-3P 959790-86-4P
 959790-87-5P 959790-88-6P 959790-89-7P
 959790-90-0P 959790-91-1P 959790-92-2P
 959790-93-3P 959790-94-4P 959790-95-5P
 959790-96-6P 959790-97-7P 959790-98-8P
 959790-99-9P 959791-00-5P 959791-01-6P
 959791-02-7P 959791-03-8P 959791-04-9P
 959791-05-0P 959791-06-1P 959791-07-2P
 959791-08-3P 959791-09-4P 959791-10-7P
 959791-11-8P 959791-12-9P 959791-13-0P
 959791-14-1P 959791-16-3P 959791-17-4P
 959791-18-5P 959791-19-6P 959791-20-9P
 959791-21-0P 959791-23-2P 959791-24-3P
 959791-25-4P 959791-26-5P 959791-27-6P
 959791-28-7P 959791-29-8P 959791-30-1P
 959791-31-2P 959791-32-3P 959791-33-4P
 959791-34-5P 959791-35-6P 959791-36-7P
 959791-37-8P 959791-38-9P 959791-39-0P
 959791-40-3P 959791-41-4P 959791-42-5P
 959791-43-6P 959791-44-7P 959791-45-8P
 959791-46-9P 959791-47-0P 959791-48-1P
 959791-55-0P 959791-56-1P 959791-57-2P
 959791-58-3P 959791-59-4P 959791-61-8P
 959791-62-9P 959791-63-0P 959791-64-1P


959791-65-2P 959791-66-3P 959791-67-4P
 959792-00-8P 959792-01-9P 959792-02-0P
 959792-04-2P 959792-06-4P 959792-15-5P
 959792-17-7P 959792-19-9P 959792-21-3P
 959792-22-4P 959792-24-6P 959792-25-7P
 959792-27-9P 959792-29-1P 959792-30-4P
 959792-31-5P 959792-32-6P 959792-33-7P
 959792-35-9P 959792-36-0P 959792-37-1P
 959792-38-2P 959792-39-3P 959792-40-6P
 959792-41-7P 959792-42-8P 959792-43-9P
 959792-44-0P 959792-45-1P 959792-46-2P
 959792-47-3P 959792-48-4P 959792-49-5P
 959792-50-8P 959792-51-9P 959792-52-0P
 959792-53-1P 959792-54-2P 959792-55-3P
 959792-56-4P 959792-57-5P 959792-58-6P
 959792-59-7P 959792-60-0P 959792-61-1P
 959792-62-2P 959792-63-3P 959792-64-4P
 959792-65-5P 959792-66-6P 959792-67-7P
 959792-68-8P 959792-69-9P 959792-70-2P
 959792-71-3P 959792-72-4P 959792-73-5P
 959792-74-6P 959792-77-9P 959792-78-0P
 959792-81-5P 959792-82-6P 959792-83-7P
 959792-85-9P 959792-87-1P 959792-89-3P
 959792-91-7P 959792-93-9P 959792-95-1P
 959792-97-3P 959793-01-2P 959793-02-3P
 959793-03-4P 959793-05-6P 959793-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of (heterocyclylamino)imidazolylpyrimidines as
 cell proliferation inhibitors)


RN 959790-84-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-
 (phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 959790-85-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-
 (1-pyrrolidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959790-86-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(4-methyl-1-piperazinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959790-87-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(4-morpholinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959790-88-6 CAPLUS

CN 1-Piperazineethanol, 4-[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]- (CA INDEX NAME)




RN 959790-89-7 CAPLUS

CN 1-Butanol, 2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-90-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-[(2-methoxy-1-methylethyl)amino]propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959790-91-1 CAPLUS

CN 2-Propanol, 1-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-92-2 CAPLUS

CN 1-Propanol, 2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-93-3 CAPLUS


CN 1-Butanol, 3-methyl-2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-94-4 CAPLUS
 CN 1-Propanol, 2-methyl-2-[[3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959790-95-5 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[[3-[(2-methoxyethyl)amino]propyl]sulfonyl]-4-piperidiny]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 959790-96-6 CAPLUS
 CN 1-Propanol, 3-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]sulfonyl]- (CA INDEX NAME)




RN 959790-97-7 CAPLUS
 CN 1-Piperidinesulfonamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959790-98-8 CAPLUS

CN 1-Piperidinesulfonamide, N,N-dimethyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959790-99-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959791-00-5 CAPLUS

CN 1-Piperidinecarboxamide, N,N-dimethyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959791-01-6 CAPLUS


CN 1-Piperidinecarboxamide, N-methyl-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 959791-02-7 CAPLUS
 CN Methanone, (hexahydro-4-methyl-1H-1,4-diazepin-1-yl) [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 959791-03-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 959791-04-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-05-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[[[(2R)-1-ethyl-2-pyrrolidinyl]methyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 959791-06-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 959791-07-2 CAPLUS


CN Methanone, [(3S)-3-(dimethylamino)-1-pyrrolidinyl][4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-08-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 959791-09-4 CAPLUS

CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 959791-10-7 CAPLUS

CN 1-Butanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-(4-morpholinyl)- (CA INDEX NAME)




RN 959791-11-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 959791-12-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-(1-methylethyl)-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-13-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(2-phenylethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 959791-14-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959791-16-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-methyl-1-piperazinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-17-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(1-pyrrolidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-18-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-[(2-methoxyethyl)amino]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-19-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-thiomorpholinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-20-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-21-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-[methyl(1-methylethyl)amino]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-23-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(1-azetidiny)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-24-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-morpholinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959791-25-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-methyl-1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959791-26-5 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-(hexahydro-1H-azepin-1-yl)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 959791-27-6 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-(diethylamino)ethyl]sulfonyl]-4-piperidinyl]-4-

[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-28-7 CAPLUS

CN 2-Piperazinone, 4-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)



RN 959791-29-8 CAPLUS


CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(tetrahydro-1,4-oxazepin-4(5H)-yl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959791-30-1 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-[(3R)-3-fluoro-1-pyrrolidinyl]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-31-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(4-fluoro-1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-32-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(7-azabicyclo[2.2.1]hept-7-yl)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-33-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(cyclopropylmethylamino)ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-34-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-[(cyclopropylmethyl)methylamino]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-35-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)




RN 959791-36-7 CAPLUS

CN Ethanone, 1-[4-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 959791-37-8 CAPLUS

CN 5H-1,4-Diazepin-5-one, hexahydro-1-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)




RN 959791-38-9 CAPLUS

CN Ethanone, 1-[hexahydro-4-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]-1H-1,4-diazepin-1-yl]- (CA INDEX NAME)




RN 959791-39-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-propyl-1-piperidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959791-40-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(tetrahydro-1,4-thiazepin-4(5H)-yl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959791-41-4 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-(2-azabicyclo[2.2.2]oct-2-yl)ethyl]sulfonyl]-4-piperidinyl]-

piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 959791-42-5 CAPLUS


CN 4-Piperidinecarbonitrile, 1-[2-[[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]ethyl]- (CA INDEX NAME)



RN 959791-43-6 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[2-[(3S)-3-fluoro-1-pyrrolidinyl]ethyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-44-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 959791-45-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 959791-46-9 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 959791-47-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-(2-methoxyethyl)-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959791-48-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 959791-55-0 CAPLUS

CN Ethanone, 2-(dimethylamino)-1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 959791-56-1 CAPLUS

CN 1-Propanone, 3-(dimethylamino)-1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 959791-57-2 CAPLUS

CN 1-Butanone, 4-(dimethylamino)-1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 959791-58-3 CAPLUS


CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-3-piperidiny)- (CA INDEX NAME)



RN 959791-59-4 CAPLUS


CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl][(2S)-1-methyl-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-61-8 CAPLUS

CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-piperidinyl)- (CA INDEX NAME)




RN 959791-62-9 CAPLUS

CN 1-Propanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-(1-piperazinyl)- (CA INDEX NAME)




RN 959791-63-0 CAPLUS

CN 1-Propanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-(4-piperidinyl)- (CA INDEX NAME)



RN 959791-64-1 CAPLUS


CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl](4-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 959791-65-2 CAPLUS

CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3S)-3-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959791-66-3 CAPLUS


CN Ethanone, 1-[4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3R)-3-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959791-67-4 CAPLUS

CN Methanone, [4-[[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-morpholinyl- (CA INDEX NAME)




RN 959792-00-8 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 959792-01-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-morpholinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-02-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(4-methyl-1-piperidiny)ethyl]sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 959792-04-2 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-N-[1-[[2-(dimethylamino)ethyl]sulfonyl]-4-piperidiny]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-06-4 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(1-pyrrolidiny)ethyl]sulfonyl]-4-piperidiny]- (CA INDEX NAME)




RN 959792-15-5 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-N-[1-[[3-(dimethylamino)-3-methylbutyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-17-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(dimethylamino)-3-methylbutyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-19-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-N-[1-[[3-(dimethylamino)propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-21-3 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-pyrrolidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-22-4 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-piperidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-24-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(4-methyl-1-piperazinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-25-7 CAPLUS


CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
N-[1-[3-(4-morpholinyl)propyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)

RN 959792-27-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 959792-29-1 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)


RN 959792-30-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(dimethylamino)ethyl)sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-31-5 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[2-(1-pyrrolidinyl)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-32-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(7-azabicyclo[2.2.1]hept-7-yl)ethyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-33-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[2-(2-azabicyclo[2.2.2]oct-2-yl)ethyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-35-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(dimethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-36-0 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-pyrrolidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-37-1 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-(1-piperidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-38-2 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
 N-[1-[[3-(4-methyl-1-piperazinyl)propyl]sulfonyl]-4-piperidinyl]- (CA
 INDEX NAME)




RN 959792-39-3 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
 N-[1-[[3-(4-morpholinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959792-40-6 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[[3-(2-azabicyclo[2.2.2]oct-2-yl)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
 (CA INDEX NAME)




RN 959792-41-7 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[[3-(7-azabicyclo[2.2.1]hept-7-yl)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
 (CA INDEX NAME)




RN 959792-42-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopropylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-43-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopentylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-44-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclobutylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 959792-45-1 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-[[3-[(1-methylethyl)amino]propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-46-2 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[[3-[(2-methylpropyl)amino]propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-47-3 CAPLUS

CN Propanenitrile, 3-[[3-[[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]methylamino]- (CA INDEX NAME)




RN 959792-48-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(1-azetidiny)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-49-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(ethylmethyamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-50-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(diethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-51-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-[(cyclopropylmethyl)amino]propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-52-0 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-[[3-[(2-methoxyethyl)methylamino]propyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-53-1 CAPLUS

CN Propanenitrile, 3-[ethyl[3-[[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]propyl]amino]- (CA INDEX NAME)




RN 959792-54-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopentylmethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-55-3 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclopropylmethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-56-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-(cyclobutylmethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-57-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3-
[(cyclopropylmethyl)methylamino]propyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-
[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-58-6 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-
imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA
INDEX NAME)




RN 959792-59-7 CAPLUS

CN 1-Piperidinesulfonamide, N-[2-(diethylamino)ethyl]-4-[[5-fluoro-4-[2-
methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA
INDEX NAME)




RN 959792-60-0 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 959792-61-1 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 959792-62-2 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 959792-63-3 CAPLUS

CN 1-Piperidinesulfonamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 959792-64-4 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 959792-65-5 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[3-[(3S)-3-fluoro-1-pyrrolidinyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959792-66-6 CAPLUS

CN 1-Piperidinesulfonamide, N-[3-(dimethylamino)propyl]-4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-methyl-
(CA INDEX NAME)




RN 959792-67-7 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-
(CA INDEX NAME)




RN 959792-68-8 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 959792-69-9 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-N-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 959792-70-2 CAPLUS


CN 2-Pyrimidinamine, N-[1-[[(3R)-3-(dimethylamino)-1-pyrrolidinyl]sulfonyl]-4-piperidinyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959792-71-3 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-[1-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 959792-72-4 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[(4-methyl-1-piperazinyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959792-73-5 CAPLUS

CN 1-Piperidinesulfonamide, N-[2-(dimethylamino)ethyl]-4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 959792-74-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]methyl]-, phenylmethyl ester (CA INDEX NAME)




RN 959792-77-9 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[1-[(1-methyl-4-piperidinyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 959792-78-0 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-N-[1-[[1-(1-methylethyl)-4-piperidinyl]sulfonyl]-4-piperidinyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 959792-81-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-(methylsulfonyl)-, (1α, 5α, 6α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-82-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-[[2-(1-pyrrolidinyl)ethyl]sulfonyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-83-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[2-(dimethylamino)ethyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-85-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[2-(7-azabicyclo[2.2.1]hept-7-yl)ethyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-87-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-[[3-(1-pyrrolidinyl)propyl]sulfonyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-89-3 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-3-[[3-(1-piperidinyl)propyl]sulfonyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-91-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(cyclopentylmethylamino)propyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-93-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(2,5-dimethyl-1-pyrrolidinyl)propyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-95-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(dimethylamino)propyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)


Relative stereochemistry.



RN 959792-97-3 CAPLUS


CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[3-(7-azabicyclo[2.2.1]hept-7-yl)propyl]sulfonyl]-N-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]-, (1 α ,5 α ,6 α)- (CA INDEX NAME)

Relative stereochemistry.




RN 959793-01-2 CAPLUS

CN 2-Pyrimidinamine, 4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-[1-(methanesulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 959793-02-3 CAPLUS

CN 2-Pyrimidinamine, 4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-[1-[[2-(1-pyrrolidiny)ethyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 959793-03-4 CAPLUS

CN 2-Pyrimidinamine, 4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-N-[1-[[2-(dimethylamino)ethyl]sulfonyl]-4-piperidinyl]-5-fluoro- (CA INDEX NAME)




RN 959793-05-6 CAPLUS

CN 2-Pyrimidinamine, 4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-N-[1-[[3-(dimethylamino)propyl]sulfonyl]-4-piperidinyl]-5-fluoro- (CA INDEX NAME)



RN 959793-06-7 CAPLUS

CN 2-Pyrimidinamine, 4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-[1-[[3-(1-pyrrolidinyl)propyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1303167 CAPLUS

DN 147:541894

TI 4-Pyrimidine-5-aminopyrazole compounds as JNK modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Chen, Peng; Hong, Yufeng; Humphries, Paul Stuart; Johnson, Theodore Otto, Jr.; Lafontaine, Jennifer Anne; Liu, Song; Lunney, Elizabeht Ann

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 196pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007129195 | A2 | 20071115 | WO 2007-IB1158 | 20070427 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2006-746464P P 20060504

OS MARPAT 147:541894

AB The invention relates to compds. with the formula I, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compns. comprising the compds. of formula I and methods of treating a condition that is mediated by the modulation of JNK, the method comprising administering to a mammal an effective amount of a compound of formula I. Compds. of formula I wherein Z is C and N; R1 is H and halo; R2 is H, CF3, CHF2, CH2F, CF3O, C1-6 alkoxy, etc.; R3 is H, C1-6 alkyl, CF3, CHF2, CH2F, CF3O, etc.; R3 is C1-6 alkyl, (un)substituted C0-5alkyl-C3-10 cycloalkyl, (un)substituted C0-6 alkyl-C6-10 aryl, etc.; R7 is H and C16 alkyl; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their JNK modulatory activity. From the assay, it was determined that compound II exhibited Ki values of 7 nM and

40

nM against JNK-1 and JNK-2, resp.

IT 956715-04-1P 956715-10-9P 956715-14-3P
 956715-26-7P 956715-36-9P 956715-52-9P
 956715-53-0P 956715-86-9P 956715-87-0P
 956715-98-3P 956716-43-1P 956716-47-5P
 956716-48-6P 956716-49-7P 956716-50-0P
 956716-51-1P 956716-53-3P 956716-54-4P
 956716-56-6P 956716-58-8P 956716-60-2P
 956716-62-4P 956716-73-7P 956716-75-9P
 956716-77-1P 956716-79-3P 956719-12-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(drug candidate; preparation of (aminopyrazolyl)pyrimidinamines as JNK modulators useful in the treatment of diseases)

RN 956715-04-1 CAPLUS


CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]-3-(methylsulfonyl)-, (1 α , 5 α , 6 α)- (CA INDEX NAME)

Relative stereochemistry.




RN 956715-10-9 CAPLUS

CN Benzonitrile, 3-[[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidiny]sulfonyl]- (CA INDEX NAME)




RN 956715-14-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(3-pyridinylsulfonyl)-4-piperidiny]- (CA INDEX NAME)




RN 956715-26-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 956715-36-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(3-pyridazinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956715-52-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(2-pyridinylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956715-53-0 CAPLUS

CN Ethanone, 1-[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 956715-86-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956715-87-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(2-methoxyethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956715-98-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-43-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, 2-methylpropyl ester (CA INDEX NAME)




RN 956716-47-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, phenylmethyl ester (CA INDEX NAME)




RN 956716-48-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-49-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-50-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(phenylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-51-1 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(4-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-53-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(2-methylpropyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-54-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[(2-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-56-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 956716-58-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956716-60-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-62-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-73-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(5-thiazolylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-75-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-[1-(3-pyridinylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956716-77-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 956716-79-3 CAPLUS

CN 1-Butanone, 1-[4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)



RN 956719-12-3 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-5-(methylamino)-1H-pyrazol-4-yl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



IT 956722-16-0P 956722-17-1P 956722-18-2P


956722-19-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (aminopyrazolyl)pyrimidinamines as JNK modulators useful in the treatment of diseases)


RN 956722-16-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-4-piperidinyl-
(CA INDEX NAME)




RN 956722-17-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 956722-18-2 CAPLUS


CN 2-Pyrimidinamine, 4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 956722-19-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[5-amino-1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/552,317



L17 ANSWER 15 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1274821 CAPLUS
 DN 147:491698
 TI Combination therapy for diseases involving angiogenesis comprising agents
 inhibiting VEGF activity, agents blocking VEGF receptor, and agents
 reducing VEGF expression
 IN Ward, Keith W.; Tyle, Praveen
 PA USA
 SO U.S. Pat. Appl. Publ., 14pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 20070258976 | A1 | 20071108 | US 2007-733282 | 20070410 |
| | WO 2007130842 | A2 | 20071115 | WO 2007-US67497 | 20070426 |
| | WO 2007130842 | A3 | 20080529 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| PRAI | US 2006-797608P | P | 20060504 | | |

AB A composition useful for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis comprises at least two therapeutic agents selected from the group consisting of compds. that interact with and inhibit a downstream activity of extracellular VEGF, compds. that interact with at least a VEGF receptor and render it substantially unavailable for interacting with VEGF, and compds. that reduce a level of expression of VEGF. More particularly, the present invention relates to such compns. and methods that target two or more modes of action of VEGF in ocular diseases involving angiogenesis. The invention also includes a method for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis using such a composition. Thus, a composition of the present invention comprised (in wt%): Macugen 0.2, trehalose 2, sodium acetate 0.24, 4-(2-phenyl-1H-imidazol-1-yl)-N-pyridin-4-ylpyrimidin-2-amine (a tyrosine kinase inhibitor) 0.3, normal saline 97.26.

IT 496795-25-6, 4-(2-Phenyl-1H-imidazol-1-yl)-N-pyridin-4-ylpyrimidin-2-amine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy for diseases involving angiogenesis comprising agents inhibiting VEGF activity, agents blocking VEGF receptor, and agents reducing VEGF expression)

RN 496795-25-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)

10/552,317



L17 ANSWER 16 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1237247 CAPLUS

DN 147:502360

TI Imidazoloxazole and imidazolothiazole compounds as RAF inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Lapierre, Jean-Marc; Namdev, Nivedita D.; Ashwell, Mark A.; France, Dennis S.; Wu, Hui; Hutchins, Patrick M.; Tandon, Manish; Liu, Yanbin; Link, Jeff S.; Ali, Syed M.; Brassard, Chris J.; Nicewonger, Robb B.; Filikov, Anton; Carazza, Rebecca J.

PA Arqule Inc., USA

SO PCT Int. Appl., 195pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|--|-----------------|----------|
| PI | WO 2007123892 | A2 | 20071101 | WO 2007-US9348 | 20070416 |
| | WO 2007123892 | A3 | 20080131 | | |
| | W: | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | |
| | RW: | | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | |
| | US 20070281955 | A1 | 20071206 | US 2007-785163 | 20070416 |
| PRAI | US 2006-792314P | P | 20060417 | | |

OS MARPAT 147:502360

AB The invention provides imidazoloxazole and imidazolothiazole compds. of formula I and their synthesis. Compds. of formula I are capable of inhibiting the activity of RAF kinase, such as B-RAV600E. The compds. are useful for the treatment of cell proliferative disorders such as cancer. Compds. of formula I wherein X is O, SO₀-2; E and F are independently (CH₂)₁₋₃; Z is H, bond, CO, CONH and derivs., SO₂, CONHSO₂, etc.; R₁ is (CH₂)₀₋₃-CONH₂ and derivs., NHCONH₂ and derivs., NHCSNH₂ and derivs., etc.; R₂ is H, (CH₂)₀₋₃-CONH₂ and derivs., NHCONH₂ and derivs., NHCSNH₂ and derivs., etc.; R₃ and R₄ are independently H, (un)substituted lower alkyl, etc.; R₁₂ is (un)substituted lower alkyl, (un)substituted (hetero)aryl, and (un)substituted heterocyclyl; R₁₃ is H, C₁-8 (fluoro)alkyl, C₃-8 (fluoro), cycloalkyl, (halo)aryl and (halo)heteroaryl; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All of the invention compds. were evaluated for their RAF inhibitory activity (some data given).

IT 815595-25-6P 815595-26-7P 815595-33-6P
815595-34-7P 815595-49-4P 815595-53-0P
815595-56-3P 815595-57-4P 815595-61-0P
815595-62-1P 815595-63-2P 815595-64-3P
815595-65-4P 815595-66-5P 815596-92-0P
815596-93-1P 815596-94-2P 815596-95-3P


815596-96-4P 815597-01-4P 885046-43-5P
885046-44-6P 885046-48-0P 885046-49-1P
885046-54-8P 885046-56-0P 885046-58-2P
885046-60-6P 885046-61-7P 885046-62-8P
885046-63-9P 885046-64-0P 885046-65-1P
885046-66-2P 885046-67-3P 885046-68-4P
885046-69-5P 885046-70-8P 885046-71-9P
885046-72-0P 885046-73-1P 885046-74-2P
885046-75-3P 885046-76-4P 885046-77-5P
885046-79-7P 885046-80-0P 885046-81-1P
885046-82-2P 885046-83-3P 885046-84-4P
885046-85-5P 885046-86-6P 885046-87-7P
885046-88-8P 885046-89-9P 885046-90-2P
885046-91-3P 885046-92-4P 885046-93-5P
885046-94-6P 885047-07-4P 885047-08-5P
885047-09-6P 885047-10-9P 885047-11-0P
885047-24-5P 885047-25-6P 885047-26-7P
885047-27-8P 885047-28-9P 885047-29-0P
885047-30-3P 885047-34-7P 885047-35-8P
885047-36-9P 885047-37-0P 885047-38-1P
885047-39-2P 885047-40-5P 885047-41-6P
885047-42-7P 885047-43-8P 885047-44-9P
885047-45-0P 885047-46-1P 885047-47-2P
885047-48-3P 885047-49-4P 885047-50-7P
885047-51-8P 885047-52-9P 885047-53-0P
885047-54-1P 885047-55-2P 885047-56-3P
885047-57-4P 885047-59-6P 885047-60-9P
885047-61-0P 885047-62-1P 885047-63-2P
885047-64-3P 885047-65-4P 885047-66-5P
885047-83-6P 885047-84-7P 885047-85-8P
885047-95-0P 885048-01-1P 885048-02-2P
885048-06-6P 885048-12-4P 885048-13-5P
885048-15-7P 885048-32-8P 885048-34-0P
885048-35-1P 885048-36-2P 885048-38-4P
885048-41-9P 885048-43-1P 885048-44-2P
885048-49-7P 885048-52-2P 885048-58-8P
885048-64-6P 885048-69-1P 885048-71-5P
885048-76-0P 885048-78-2P 885048-80-6P
956025-01-7P 956026-67-8P 956026-68-9P
956026-69-0P 956026-70-3P 956026-71-4P
956026-72-5P 956026-73-6P 956026-74-7P
956026-75-8P 956026-76-9P 956026-85-0P
956026-88-3P 956026-89-4P 956026-90-7P
956026-91-8P 956026-92-9P 956026-94-1P
956026-95-2P 956026-96-3P 956026-97-4P
956026-99-6P 956027-05-7P 956027-09-1P
956027-10-4P 956027-11-5P 956027-12-6P
956027-13-7P 956027-15-9P 956027-21-7P
956027-22-8P 956027-23-9P 956027-24-0P
956027-25-1P 956027-26-2P 956027-31-9P
956027-54-6P 956027-60-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of imidazoloxazole and imidazolothiazole
compds. as RAF kinase inhibitors useful in treatment of diseases)


RN 815595-25-6 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-26-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-33-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-34-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-49-4 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-53-0 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-56-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-57-4 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-61-0 CAPLUS

CN 2-Pyrimidinamine, N-4-piperidinyl-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 815595-62-1 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-63-2 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(methanesulfonyl)-4-piperidinyl]-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)



RN 815595-64-3 CAPLUS
 CN Ethanone, 1-[4-[[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-65-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methanesulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-66-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815596-92-0 CAPLUS

CN Methanone, (4-fluorophenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815596-93-1 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815596-94-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 815596-95-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 815596-96-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 815597-01-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(methanesulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 885046-43-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885046-44-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885046-48-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-49-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885046-54-8 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl](4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-56-0 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]phenyl- (CA INDEX NAME)




RN 885046-58-2 CAPLUS

CN Ethanone, 2-(4-chlorophenoxy)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-60-6 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-8-quinolinyl- (CA INDEX NAME)




RN 885046-61-7 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-piperidinyl- (CA INDEX NAME)




RN 885046-62-8 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-methoxy- (CA INDEX NAME)




RN 885046-63-9 CAPLUS

CN Methanone, cyclohexyl[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-64-0 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)




RN 885046-65-1 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-furyl- (CA INDEX NAME)




RN 885046-66-2 CAPLUS

CN 1-Piperidinecarboxamide, N-cyclohexyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-67-3 CAPLUS

CN 1-Piperidinecarboxamide, N-butyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-68-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 885046-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885046-70-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 885046-71-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methylphenyl)- (CA INDEX NAME)




RN 885046-72-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-73-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-74-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-75-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885046-76-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 885046-77-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(3,5-dimethyl-4-isoxazolyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-79-7 CAPLUS

CN Ethanone, 2-(4-fluorophenyl)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-80-0 CAPLUS

CN 1-Butanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 885046-81-1 CAPLUS

CN Methanone, (4-fluorophenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-82-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885046-83-3 CAPLUS

CN 1-Piperidinecarboxamide, N-(cyclohexylmethyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-84-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-(4-fluorophenyl)ethyl]-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-85-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[5-methyl-2-(trifluoromethyl)-3-furanyl]- (CA INDEX NAME)




RN 885046-86-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-87-7 CAPLUS

CN 1-Propanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-88-8 CAPLUS

CN 1-Propanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-phenyl- (CA INDEX NAME)




RN 885046-89-9 CAPLUS

CN Ethanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 885046-90-2 CAPLUS


CN 1-Propanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 885046-91-3 CAPLUS


CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-(2S)-2-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 885046-92-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(3,4-difluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 885046-93-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 885046-94-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-


yl]-2-pyrimidinyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885047-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 885047-08-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(4-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-09-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-10-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-methoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-24-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-25-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-26-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-27-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3,5-dichlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-28-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-29-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-30-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-34-7 CAPLUS

CN Methanone, (4-amino-3,5,6-trichloro-2-pyridinyl) [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-35-8 CAPLUS

CN Methanone, (2,6-dimethoxyphenyl) [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-36-9 CAPLUS

CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 885047-37-0 CAPLUS

CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]- (CA INDEX NAME)




RN 885047-38-1 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-39-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885047-40-5 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(4-methyl-2-pyrimidinyl)thio]- (CA INDEX NAME)




RN 885047-41-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-42-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-43-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 885047-44-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-45-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-46-1 CAPLUS

CN Methanone, [4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny] 4-(diethylamino)phenyl]- (CA INDEX NAME)




RN 885047-47-2 CAPLUS

CN Methanone, [4-(dimethylamino)phenyl] 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]- (CA INDEX NAME)




RN 885047-48-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidiny]- (CA INDEX NAME)




RN 885047-49-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-50-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-51-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885047-52-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(5-chloro-2-methoxyphenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-53-0 CAPLUS

CN Acetamide, N-[5-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-4-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 885047-54-1 CAPLUS

CN Benzoic acid, 4-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-55-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-56-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-methoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-57-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 885047-59-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-60-9 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-furanylmethyl)-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-61-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(2-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-62-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,6-difluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-63-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-64-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-phenoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[4-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-66-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-83-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-84-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-85-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-95-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-naphthalenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-01-1 CAPLUS

CN Ethanone, 2-[4-(dimethylamino)phenyl]-1-[4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885048-02-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-06-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-12-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885048-13-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-15-7 CAPLUS

CN 2-Pyrimidinamine, 4-(6-[1,1'-biphenyl]-4-yl)imidazo[2,1-b]thiazol-5-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-32-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885048-34-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-35-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-36-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(6-[1,1'-biphenyl]-4-yl)imidazo[2,1-b]thiazol-5-yl)-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885048-38-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-41-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885048-43-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-44-2 CAPLUS

CN Benzoic acid, 4-[[4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885048-49-7 CAPLUS

CN Acetamide, N-[4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)




RN 885048-52-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885048-58-8 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-64-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-69-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-71-5 CAPLUS

CN Phenol, 4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-76-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-78-2 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-80-6 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956025-01-7 CAPLUS


CN Phenol, 5-[5-[2-[[1-(cyclopropylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]-2-fluoro- (CA INDEX NAME)



RN 956026-67-8 CAPLUS
 CN 2-Pyrimidinamine, N-(1-ethyl-4-piperidiny)-4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 956026-68-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-(1,1-dimethylethyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-69-0 CAPLUS
 CN Butanoic acid, 4-amino-4-[[[4-[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidiny]carbonyl]amino]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 956026-70-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-71-4 CAPLUS

CN Benzonitrile, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956026-72-5 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956026-73-6 CAPLUS

CN Benzonitrile, 3-[5-[2-(4-piperidinylamino)-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956026-74-7 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-, methyl ester (CA INDEX NAME)




RN 956026-75-8 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956026-76-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(2-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 956026-85-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956026-88-3 CAPLUS

CN Phenol, 3-[5-[2-[[1-(cyclopropylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956026-89-4 CAPLUS

CN 1-Piperidineethanol, α -[(4-chlorophenoxy)methyl]-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-90-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956026-91-8 CAPLUS

CN 1-Piperidineethanol, α -[(4-chlorophenoxy)methyl]-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-92-9 CAPLUS

CN Benzamide, 4-[[4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 956026-94-1 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)




RN 956026-95-2 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)




RN 956026-96-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4-chlorophenyl)sulfonyl]-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-97-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4-chlorophenyl)sulfonyl]-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956026-99-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956027-05-7 CAPLUS

CN Phenol, 3-[5-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 956027-09-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4-chlorophenyl)sulfonyl]-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-10-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 956027-11-5 CAPLUS

CN 2-Pyrimidinamine, N-[1-(cyclopropylsulfonyl)-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 956027-12-6 CAPLUS

CN Phenol, 3-[5-[2-[[1-(cyclopropylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)




RN 956027-13-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 956027-15-9 CAPLUS

CN Phenol, 3-[5-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]oxazol-6-yl]- (CA INDEX NAME)




RN 956027-21-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-(cyclopropylsulfonyl)-4-piperidinyl]-4-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 956027-22-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 956027-23-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 956027-24-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 956027-25-1 CAPLUS

CN 1-Piperidinecarboxamide, N-cyclopentyl-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-26-2 CAPLUS

CN 1-Piperidinecarboxamide, N-butyl-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-31-9 CAPLUS

CN 1-Piperidinecarboxamide, N-cyclohexyl-4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956027-54-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-, propyl ester (CA INDEX NAME)



RN 956027-60-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(3-hydroxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



L17 ANSWER 17 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1092913 CAPLUS

DN 147:406847

TI Pyrimidine, quinazoline, pteridine and triazine derivatives as SST
receptor modulators and their preparation

IN Binggeli, Alfred; Christ, Andreas; Maerki, Hans-Peter; Martin, Rainer
Eugen

PA Switz.

SO U.S. Pat. Appl. Publ., 91pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 20070225271 | A1 | 20070927 | US 2007-724688 | 20070315 |
| | AU 2007229555 | A1 | 20071004 | AU 2007-229555 | 20070319 |
| | WO 2007110340 | A2 | 20071004 | WO 2007-EP52571 | 20070319 |
| | WO 2007110340 | A3 | 20071115 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| | EP 2001867 | A2 | 20081217 | EP 2007-727049 | 20070319 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| | IN 2008DN08153 | A | 20081121 | IN 2008-DN8153 | 20080929 |
| | KR 2008104074 | A | 20081128 | KR 2008-726236 | 20081027 |
| PRAI | EP 2006-111751 | A | 20060327 | | |
| | WO 2007-EP52571 | W | 20070319 | | |

OS CASREACT 147:406847; MARPAT 147:406847

AB This invention is concerned with compds. of formula I, and pharmaceutically acceptable salts thereof. Compds. of formula I wherein A is O and NH; R1 is H, C1-7 alkoxy, and halo; R2 is C2-7 alkyl, C2-7 alkenyl, C1-7 (halo)alkyl, etc.; R3 is H, C1-7 alkyl, OH, C1-7 alkoxy, C2-7 alkenyloxy, halo, etc.; R4 is H, OH, C1-7 alkoxy, amino, nitro, etc.; R5 is H, halo, C1-7 alkoxy, and C1-7 alkoxy-C1-7 alkoxy; G is (un)substituted pyrimidine, (un)substituted quinazoline, (un)substituted pteridine, (un)substituted triazine, etc.; and their pharmaceutically acceptable salts thereof, are claimed. The invention further relates to pharmaceutical compns. containing such compds., to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their SST-5 modulatory activity (some data given).

IT 951000-57-0P 951000-72-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine, quinazoline, pteridine and triazine derivs. as SST receptor modulators)


RN 951000-57-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-ethoxy-4-methoxyphenyl)methyl]-4-piperidinyl]-4-(2-thienyl)- (CA INDEX NAME)



RN 951000-72-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chloro-3-ethoxyphenyl)methyl]-4-piperidinyl]-4-(2-thienyl)- (CA INDEX NAME)



L17 ANSWER 18 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1060802 CAPLUS

DN 147:385972

TI Pyrazole compounds as Raf inhibitors and their preparation, pharmaceutical compositions and use in the treatment of abnormal cell growth

IN Bennett, Michael John; Cho-Schultz, Sujin; Deal, Judith Gail; King, Stephen Joseph; Marrone, Tami Jo; Palmer, Cynthia Louise; Romines, William Henry, III; Rui, Eugene Yuanjin; Sutton, Scott Channing; Zhender, Luke Raymond

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 110pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2007105058 | A2 | 20070920 | WO 2007-IB561 | 20070305 |
| | WO 2007105058 | A3 | 20071221 | | |
| | W: | AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |
| PRAI | US 2006-782786P | P | 20060316 | | |
| | US 2007-886561P | P | 20070125 | | |

OS MARPAT 147:385972

AB The invention is directed to compds. of formula I, and to salts and solvates thereof, their synthesis, and their use as Raf inhibitors. Compds. of formula I wherein R1 is H, OH, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, CN, NH2 and derivs., etc.; each R2 is independently H, halo, C1-6 alkyl, C2-6 alkenyl, C2-8 alkynyl; C2-8 alkoxy, and CN; R3 is H and NH(CH2)0-4R7; R4 is C1-6 alkylthio, C1-6 alkoxy, H, OH, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, CN, NH2 and derivs., etc.; R7 is H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, NH2 and derivs., etc.; m is 0, 1, 2 and 3; n is 0, 1, 2, 3 and 4; X is N and CH; and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by addition of 4-picoline to Me 4-chloro-3-methylbenzoate; the resulting 1-(3-chloro-5-methoxyphenyl)-2-(pyridin-4-yl)ethanone underwent condensation with DMF di-Me acetal to give the corresponding dicarbonyl derivative, which underwent cyclization with hydrazine to give 4-[3-(3-chloro-5-methoxyphenyl)-1H-pyrazol-4-yl]pyridine, which underwent demethylation to give compound II. All the invention compds. were evaluated for their Raf kinase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 values of 0.448 μ M against pMEK and 0.42 μ M against pERK. Compound II also exhibited a Ki value of 0.0147 μ M and 91 % inhibition at 1 μ M concentration of b-Raf.

IT 950524-86-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(drug candidate; preparation of pyrazoles as Raf inhibitors useful in the treatment of abnormal cell growth)

RN 950524-86-4 CAPLUS

CN Phenol, 3-chloro-5-[1-ethyl-4-[2-[(1-methyl-4-piperidiny)amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



L17 ANSWER 19 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:998153 CAPLUS
 DN 147:344090
 TI Preparation of multi-cyclic compounds useful in treatment of oncol.
 diseases related to kinase activity
 IN Cee, Victor J.; Deak, Holly L.; Geuns-Meyer, Stephanie D.; Hodous, Brian
 L.; Nguyen, Hanh Nho; Olivieri, Philip R.; Patel, Vinod F.; Romero, Karina
 PA Amgen Inc., USA
 SO PCT Int. Appl., 104pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2007100646 | A1 | 20070907 | WO 2007-US4700 | 20070222 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | US 20070213325 | A1 | 20070913 | US 2007-709994 | 20070221 |
| | AU 2007221294 | A1 | 20070907 | AU 2007-221294 | 20070222 |
| | EP 1994030 | A1 | 20081126 | EP 2007-751460 | 20070222 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| PRAI | US 2006-776507P | P | 20060224 | | |
| | US 2007-709994 | A | 20070221 | | |
| | WO 2007-US4700 | W | 20070222 | | |

OS CASREACT 147:344090; MARPAT 147:344090

AB The title compds. I [A = (un)substituted benzimidazolyl, imidazolyl, triazolyl; B = phenylene, pyridylene, etc.; C1 = N or CR10; C2 = N or CH; D = (un)substituted pyrimidinyl, indazolyl, etc.; L1, L2 = NR3, O, S, C(O), S(O), SO2 or CR3R3; R3, R4 = H, halo, haloalkyl, etc.] which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases, were prepared Thus, reacting 4-[2-(4-aminophenoxy)pyridin-3-yl]pyrimidin-2-amine with 2-chloro-5-phenyl-1,3,4-thiadiazole afforded II. The compds. I are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, resp., to treat cancer and cancer-related diseases. For example, II was found to have IC50 of less than or equal to 5 μ M in the Aurora kinase A HTRF assay. The invention also includes pharmaceutical compns. comprising compds. I, and methods of treating disease states related to the activity of various protein kinases.

IT 948563-40-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of novel multicyclic compds. useful in treatment of oncol. diseases related to kinase activity)

RN 948563-40-4 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-[[3-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-pyridinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 20 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:874444 CAPLUS

DN 147:257789

TI 4-Aryl-2-aminopyrimidines or 4-aryl-2-aminoalkylpyrimidines as JAK-2 modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Mann, Grace; Aay, Naing; Arcalas, Arlyn; Brown, S. David; Chan, Wai Ki Vicky; Chen, Jeff; Du, Hongwang; Epshteyn, Sergey; Forsyth, Timothy; Galan, Adam A.; Huynh, Tai Phat; Ibrahim, Mohamed Abdulkader; Johnson, Henry William Beecroft; Kane, Brian; Kearney, Patrick; Kim, Byung Gyu; Koltun, Elena; Leahy, James William; Lee, Matthew Sangyup; Lewis, Gary L.; Meyr, Lisa E.; Noguchi, Robin Tammie; Pack, Michael; Ridgway, Brian Hugh; Shi, Xian; Woolfrey, John; Zhou, Peiwen

PA Exelixis, Inc., USA

SO PCT Int. Appl., 586 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2007089768 | A2 | 20070809 | WO 2007-US2515 | 20070130 |
| | WO 2007089768 | A3 | 20070920 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| | AU 2007209928 | A1 | 20070809 | AU 2007-209928 | 20070130 |
| | CA 2640398 | A1 | 20070809 | CA 2007-2640398 | 20070130 |
| | EP 1979329 | A2 | 20081015 | EP 2007-717132 | 20070130 |
| | R: | | | | |
| | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| PRAI | US 2006-763426P | P | 20060130 | | |
| | US 2006-785239P | P | 20060323 | | |
| | US 2006-840420P | P | 20060825 | | |
| | WO 2007-US2515 | W | 20070130 | | |

OS MARPAT 147:257789

AB This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having formula I, pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof, and methods of use thereof. Compds. of formula I wherein D and E are independently H, halo, CF₃, heterocycloalkyl and alkyl; DE taken together to form 5- to 7-membered heteroaryl and 5- to 7-membered heterocycloalkyl; L is a bond, O and NH; Z is alkoxyl, cycloalkyl, (un)substituted heteroaryl, aryl, (un)substituted heterocycloalkyl; Z-R25 taken together to form 5- to 6-membered (hetero)cycloalkyl, and 5- to 6-membered heteroaryl; n is 0, 1, 2, 3, and 4; R1 is H; R2 is (un)substituted (hetero)aryl, (un)substituted alkylaryl; R25 is alkyl, alkenyl, halo, haloalkyl, amino, etc.; and their

pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cross-coupling of 2,4-dichloropyrimidine with 4-(acetylamino)phenylboronic acid; the resulting N-[4-(2-chloropyrimidin-4-yl)phenyl]acetamide underwent amination with N-Boc-1,3-diaminobenzene to give compound II. All the invention compds. were evaluated for their JAK-2 inhibitory activity.

IT 945754-01-8P 945754-03-0P 945755-25-9P


945755-26-0P 945756-08-1P 945756-10-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aryl(amino)pyrimidines and aryl(aminoalkyl)pyrimidines as JAK-2 modulators useful in the treatment of diseases)


RN 945754-01-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 945754-03-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 945755-25-9 CAPLUS


CN Acetamide, N-[4-[2-(4-piperidinylamino)-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 945755-26-0 CAPLUS
 CN Acetamide, N-[4-[2-[[1-(2,6-dichlorobenzoyl)-4-piperidinyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 945756-08-1 CAPLUS
 CN Methanone, (2,6-dichlorophenyl)[4-[[4-(4-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 945756-10-5 CAPLUS
 CN Methanone, (2,6-dichlorophenyl)[4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



IT 945756-14-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of aryl(amino)pyrimidines and aryl(aminoalkyl)pyrimidines as JAK-2 modulators useful in the treatment of diseases)

RN 945756-14-9 CAPLUS
 CN Methanone, (2,6-dichlorophenyl)[4-[[4-(5-methyl-2-thienyl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




IT 945756-45-6

RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of aryl(amino)pyrimidines and
 aryl(aminoalkyl)pyrimidines as JAK-2 modulators useful in the treatment
 of diseases)

RN 945756-45-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thienyl)-N-4-piperidinyl-, hydrochloride
 (1:1) (CA INDEX NAME)



● HCl

L17 ANSWER 21 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:640266 CAPLUS

DN 147:52920

TI Preparation of pyrimidine compounds as p38 MAP kinase inhibitors

IN Kubo, Akira; Nakane, Akira; Nakajima, Tatsuo; Murakami, Takaaki; Miyoshi, Hidetaka; Ogasawara, Akito

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 60pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|-----------------|----------|
| PI | JP 2007145819 | A | 20070614 | JP 2006-290675 | 20061026 |
| PRAI | JP 2005-313670 | A | 20051028 | | |
| OS | MARPAT 147:52920 | | | | |

AB Title compds. I [R1 = H, halo, nitro, etc.; p = 1, 2; Z = -O-, -N(R2)-; R2 = H, alkyl, alkanoyl; ring A = Q, etc.; R3 = (CH2)n-RA; RA = H, (un)substituted alkyl, (un)substituted alkoxyalkyl, etc.; n = 0-4; Q1 = H, halo, cyano, etc.; ring B = cycloalkane, saturated hetero-monocycle containing nitrogen atom; X = CH, N; Y = single bond, SO2, CO; ring C = aromatic hydrocarbon ring, (un)substituted heterocycle] and their pharmaceutically acceptable salts were prepared For example, reaction of compound II [R = NH2] with 2-chloroethylisocyanate afforded compound II [R = 2-oxo-1-imidazolidinyl]. In TNF α production-inhibition assays, compound II [R = 1,1-dioxo-2-isothiazolidinyl] showed 100% inhibitory activity.


IT 869220-92-8P 869221-34-1P 869221-35-2P
869221-36-3P 869221-37-4P 869221-38-5P
869221-39-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine compds. as p38 MAP kinase inhibitors)

RN 869220-92-8 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-thienylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 869221-34-1 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-4-piperidinyl]amino]-4-

pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-35-2 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-36-3 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/552,317




● HCl

RN 869221-37-4 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(phenylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869221-38-5 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-naphthalenylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-39-6 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-pyridinylcarbonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 775575-82-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrimidine compds. as p38 MAP kinase inhibitors)
 RN 775575-82-1 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]- (CA INDEX NAME)


10/552,317



L17 ANSWER 22 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:602630 CAPLUS
 DN 147:211828
 TI Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors
 AU Alam, Mahbub; Beevers, Rebekah E.; Ceska, Tom; Davenport, Richard J.; Dickson, Karen M.; Fortunato, Mara; Gowers, Lewis; Haughan, Alan F.; James, Lynwen A.; Jones, Mark W.; Kinsella, Natasha; Lowe, Christopher; Meissner, Johannes W. G.; Nicolas, Anne-Lise; Perry, Benjamin G.; Phillips, David J.; Pitt, William R.; Platt, Adam; Ratcliffe, Andrew J.; Sharpe, Andrew; Tait, Laura J.
 CS UCB, Granta Park, Great Abington, Cambridge, CB21 6GS, UK
 SO Bioorganic & Medicinal Chemistry Letters (2007), 37(12), 3463-3467
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 147:211828
 AB The development of a series of aminopyrimidines, e.g., I, as inhibitors of c-Jun N-terminal kinases is described. The synthesis, in vitro inhibitory values for JNK1, JNK2 and CDK2, and the in vitro inhibitory value for a c-Jun cellular assay were discussed.
 IT 882563-01-1
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)
 RN 882563-01-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




IT 882563-40-8P 882565-39-1P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)
 RN 882563-40-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882565-39-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




IT 882562-75-6P 882562-82-5P 882562-91-6P
 882562-98-3P 882563-10-2P 882563-12-4P
 882563-14-6P 882564-23-0P 882564-31-0P
 882564-35-4P 882564-39-8P 882565-41-5P
 882566-85-0P 945016-58-0P 945016-59-1P
 945016-60-4P 945016-61-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines with indole derivs. or (bromo)imidazopyridine followed by substitution with aminopiperidines, and their antiinflammatory activity as JNK inhibitor and SAR)


RN 882562-75-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 882562-82-5 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-3-yl)-5-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-91-6 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-98-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-10-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882563-12-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 882563-14-6 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882564-23-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-methyl-1-piperazinyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-31-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882564-35-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 882564-39-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)- (CA INDEX NAME)




RN 882565-41-5 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-85-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-pyrazolo[1,5-a]pyridin-3-yl-2-pyrimidinyl)amino]- (CA INDEX NAME)




RN 945016-58-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-methyl-1-piperidinyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 945016-59-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 945016-60-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 945016-61-5 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




IT 882562-77-8P 882563-09-9P 882563-38-4P
 1004524-90-6P 1004526-40-2P 1004527-41-6P
 1004529-44-5P 1004529-53-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aminopyrimidine derivs. using coupling of chloropyrimidines
 with indole derivs. or (bromo)imidazopyridine followed by substitution
 with aminopiperidines, and their antiinflammatory activity as JNK
 inhibitor and SAR)
 RN 882562-77-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-
 pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882563-09-9 CAPLUS
 CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-4-piperidinyl- (CA INDEX
 NAME)




RN 882563-38-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1004524-90-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-indol-3-yl)-5-methyl-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1004526-40-2 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-3-yl)-5-methyl-N-4-piperidinyl- (CA INDEX NAME)



RN 1004527-41-6 CAPLUS


CN 2-Pyrimidinamine, 4-(1H-indol-3-yl)-N-4-piperidinyl- (CA INDEX NAME)



RN 1004529-44-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/552,317



RN 1004529-53-6 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-1-yl)-N-4-piperidinyl- (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 23 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:510085 CAPLUS
 DN 146:501070
 TI Pyrimidinyl-thiophenes as kinase modulators and their preparation,
 pharmaceutical compositions and use in the treatment of diseases mediated
 by kinase activity
 IN Arnold, William D.; Chen, Chixu; Gradl, Stefan N.; Hopkins, Stephanie A.;
 Steensma, Ruow W.; Tomimoto, Masaki; Wilson, Mark E.
 PA SGX Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 144pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007053776 | A1 | 20070510 | WO 2006-US43047 | 20061102 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| CA 2628474 | A1 | 20070510 | CA 2006-2628474 | 20061102 |
| US 20070117800 | A1 | 20070524 | US 2006-556033 | 20061102 |
| EP 1948647 | A1 | 20080730 | EP 2006-836919 | 20061102 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| PRAI US 2005-733585P | P | 20051103 | | |
| WO 2006-US43047 | W | 20061102 | | |

OS MARPAT 146:501070

AB The invention provides pyrimidinyl-thiophene kinase modulators v of formula I which can be used to treat diseases mediated by kinase activity. Compds. of formula I wherein A is (un)substituted (hetero)aryl; R1 is H, F, Br, OH and derivs., (CH2)nNH2 and derivs., CN, NO2, CF3, (un)substituted alkyl, etc.; R2, R3 and R4 are independently H, halo, OH and derivs., NH2 and derivs., CN, NO2, CF3, (un)substituted alkyl, etc.; n is 0 to 5; are claimed. Example compound II was prepared by amidation of 5-(2-methylsulfanylpurimidin-4-yl)thiophene-2-sulfonyl chloride with dimethylamine; the resulting 5-(2-methylsulfanylpurimidin-4-yl)thiophene-2-sulfonic acid dimethylamide underwent oxidation to 5-(2-methylsulfonylpurimidin-4-yl)thiophene-2-sulfonic acid dimethylamide, which underwent nucleophilic aromatic substitution with 1-(3-aminophenyl)ethanol. All the invention compds. were evaluated for their kinase inhibitory activity (data given).

IT 936134-72-4P 936137-13-2P 936137-14-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinylthiophenes as kinase modulators

useful in treatment of diseases - mediated by kinase activity)


RN 936134-72-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(1-piperidinylsulfonyl)-2-thienyl]-N-4-pyridinyl-
(CA INDEX NAME)



RN 936137-13-2 CAPLUS


CN 2-Thiophenecarboxamide, N-(2-cyanoethyl)-N-ethyl-5-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 936137-14-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[(1R)-1-phenylethyl]-5-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 24 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:259691 CAPLUS
 DN 146:316944
 TI Novel imidazo based heterocycles as kinase inhibitors and their
 preparation, pharmaceutical compositions and use in the treatment of
 inflammatory and proliferative diseases
 IN Brienlinger, Eric C.; Calderwood, David J.; Frank, Kristine E.;
 Betschmann, Patrick; Hirst, Gavin C.; Morytko, Michael J.; Dixon, Richard
 W.
 PA Abbott Laboratories, USA
 SO PCT Int. Appl., 150 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|--|------------------|----------|
| PI | WO 2007028051 | A2 | 20070308 | WO 2006-US34275 | 20060901 |
| | WO 2007028051 | A3 | 20071101 | | |
| | W: | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | |
| | RW: | | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | |
| | CA 2620223 | A1 | 20070308 | CA 2006-2620223 | 20060901 |
| | US 20070099925 | A1 | 20070503 | US 2006-514626 | 20060901 |
| | EP 1928237 | A2 | 20080611 | EP 2006-824879 | 20060901 |
| | R: | | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, MK, RS | | |
| | MX 200802979 | A | 20080512 | MX 2008-2979 | 20080229 |
| | CN 101291582 | A | 20081022 | CN 2006-80038658 | 20080417 |
| PRAI | US 2005-714016P | P | 20050902 | | |
| | US 2006-837560P | P | 20060814 | | |
| | WO 2006-US34275 | W | 20060901 | | |

OS MARPAT 146:316944

AB The invention is directed to imidazopyrazine and imidazopyrimidine compds. of formula I, wherein the variables are as defined herein. The compds. of formula I are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and

diseases and proliferative disorders and conditions, for example, cancers. Compds. of formula I wherein Z is (un)substituted (hetero)aryl; X and Y are independently N, CR₄ and N-oxide, provided that X and Y cannot both be CR₄ or both cannot be N-oxide; A is N, CR₄ and N-oxide; R₁, R₄ and R₁₀ are independently H, OH, F, Cl, Br, I, CF₃, CN, NO₂, NH₂, (un)substituted aryloxy, etc.; Q is NH and derivs., O, S or a bond; L is a bond, C1-6 alkyl, CO, CO₂, CONH, SO, or SO₂; R₃ is H, CONH₂ and derivs., NHCHO and derivs., NHCO₂H and derivs., CO₂H and derivs., (un)substituted aryl, etc.; and their pharmaceutically acceptable salts, metabolites, isomers and

prodrugs thereof, are claimed. Example compound II was prepared by amination of 2-(4-fluorophenyl)-3-[2-(methanesulfonyl)pyrimidin-4-yl]imidazo[1,2-a]pyrazine with tert-Bu 4-aminopiperidine-1-carboxylate. All the invention compds. were evaluated for their kinase inhibitory activity.

IT 928315-08-6P 928316-07-8P 928316-23-8P


928316-51-2P 928318-77-8P 928318-80-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of imidazopyrimidine and imidazopyrazine derivs. as kinase inhibitors useful in the treatment of inflammatory and proliferative diseases)


RN 928315-08-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928316-07-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(2-phenylimidazo[1,2-a]pyrazin-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928316-23-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928316-51-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928318-77-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 928318-80-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-N-4-piperidinyl- (CA INDEX NAME)



IT 928315-41-7P 928315-56-4P 928315-65-5P
 928315-68-8P 928316-09-0P 928316-12-5P
 928316-21-6P 928316-24-9P 928316-25-0P
 928316-35-2P 928316-40-9P 928316-44-3P
 928316-47-6P 928316-54-5P 928317-09-3P
 928318-78-9P 928318-81-4P 928318-86-9P
 928318-88-1P 928318-89-2P 928318-97-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of imidazopyrimidine and imidazopyrazine
 derivs. as kinase inhibitors useful in the treatment of inflammatory
 and proliferative diseases)
 RN 928315-41-7 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[2-(4-fluorophenyl)imidazo[1,2-
 a]pyrazin-3-yl]-2-pyrimidinyl]-8-methyl- (CA INDEX NAME)




RN 928315-56-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-(1-
 methyl-4-piperidinyl)- (CA INDEX NAME)




RN 928315-65-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 928315-68-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)




RN 928316-09-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidinyl]-4-(2-phenylimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)




RN 928316-12-5 CAPLUS

CN Ethanone, 1-[4-[[4-(2-phenylimidazo[1,2-a]pyrazin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 928316-21-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-(methanesulfonyl)-4-piperidinyl]-4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 928316-24-9 CAPLUS


CN 2-Pyrimidinamine, N-(1-methyl-4-piperidinyl)-4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 928316-25-0 CAPLUS


CN Ethanone, 1-[4-[[4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-2-

pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 928316-35-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidinyl]-4-[2-[3-(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)




RN 928316-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(3-methylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928316-44-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928316-47-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928316-54-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]-8-methyl- (CA INDEX NAME)




RN 928317-09-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928318-78-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 928318-81-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-phenylimidazo[1,2-a]pyrazin-3-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 928318-86-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 928318-88-1 CAPLUS

CN Ethanone, 1-[4-[[4-[2-(4-fluorophenyl)-8-methylimidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-hydroxy- (CA INDEX NAME)




RN 928318-89-2 CAPLUS

CN Ethanone, 2-hydroxy-1-[4-[[4-[2-(2-naphthalenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 928318-97-2 CAPLUS

CN Ethanone, 1-[4-[[4-[2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 25 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:61837 CAPLUS

DN 146:156236

TI Cellular cholesterol absorption modifiers, and their therapeutic use

IN Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.

PA Kalypsys, Inc., USA

SO PCT Int. Appl., 300pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2007008541 | A2 | 20070118 | WO 2006-US26242 | 20060705 |
| | WO 2007008541 | A3 | 20070726 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |
| PRAI | US 2005-697659P | P | 20050708 | | |
| | US 2005-697686P | P | 20050708 | | |
| | US 2005-697814P | P | 20050708 | | |
| | US 2005-727646P | P | 20051017 | | |
| | US 2006-782303P | P | 20060313 | | |
| OS | MARPAT 146:156236 | | | | |
| AB | The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis. | | | | |
| IT | 920527-98-6 920528-07-0 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (cholesterol absorption modifiers and therapeutic use) | | | | |
| RN | 920527-98-6 CAPLUS | | | | |
| CN | 1-Piperidinecarboxylic acid, 4-[[4-(2,5-dimethoxyphenyl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME) | | | | |

10/552,317



RN 920528-07-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-difluorophenyl)-6-methyl-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 26 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1226019 CAPLUS

DN 146:7975

TI Preparation of pyrrolopyridines as protein kinase inhibitors

IN Okram, Barun; Ren, Pingda; Gray, Nathanael S.

PA IRM LLC, Bermuda; The Scripps Research Institute

SO PCT Int. Appl., 51pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|--|------------------|----------|
| PI | WO 2006124863 | A2 | 20061123 | WO 2006-US18868 | 20060515 |
| | WO 2006124863 | A3 | 20070125 | | |
| | W: | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | RW: | | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | AU 2006247322 | A1 | 20061123 | AU 2006-247322 | 20060515 |
| | CA 2608333 | A1 | 20061123 | CA 2006-2608333 | 20060515 |
| | EP 1896470 | A2 | 20080312 | EP 2006-759904 | 20060515 |
| | R: | | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | |
| | JP 2008540664 | T | 20081120 | JP 2008-512430 | 20060515 |
| | MX 200714327 | A | 20080211 | MX 2007-14327 | 20071115 |
| | KR 2008016643 | A | 20080221 | KR 2007-729309 | 20071214 |
| | IN 2007DN09783 | A | 20080118 | IN 2007-DN9783 | 20071217 |
| | CN 101218241 | A | 20080709 | CN 2006-80025008 | 20080108 |
| | US 20080300267 | A1 | 20081204 | US 2008-914210 | 20080402 |
| PRAI | US 2005-681853P | P | 20050516 | | |
| | WO 2006-US18868 | W | 20060515 | | |

OS MARPAT 146:7975

AB The title compds. I-III [n = 0-2; R1 = halo, (halo)alkyl, (halo)alkoxy; R2 = (un)substituted arylalkyl or heteroaryl; X = CR7 or N (wherein R7 = H, alkyl)], useful in treating or preventing diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the CDKs, Aurora, Jak2, Rock, CAMKII, FLT3, Tie2, TrkB, FGFR3 and KDR kinases, were prepared. E.g., a multi-step synthesis of IV, starting from 7-azaindole, was given. Compds. I-III showed IC50's in the range of 10 nM to 2 μ M when tested in FGFR3 enzymic assay. Pharmaceutical compns. comprising compds. I-III are disclosed.

IT 915414-31-2P 915414-32-3P 915414-33-4P
915414-35-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridines as novel protein kinase inhibitors useful

in treatment and prevention of diseases associated with abnormal or deregulated protein kinase activity)


RN 915414-31-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-methyl-4-pyridinyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)




RN 915414-32-3 CAPLUS

CN 2-Pyrimidinamine, N-(2-chloro-4-pyridinyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)



RN 915414-33-4 CAPLUS


CN 2-Pyrimidinamine, N-(2-methoxy-4-pyridinyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)



RN 915414-35-6 CAPLUS

CN 2-Pyrimidinamine, N-4-pyridinyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (CA INDEX NAME)

10/552,317



L17 ANSWER 27 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:796732 CAPLUS

DN 145:211069

TI Preparation of phenyl-substituted pyrimidines as kinase inhibitors for treating an inflammatory disorder and/or cancer

IN Wrobelski, Stephen T.; Lin, Shuqun; Leftheris, Katerina; He, Liqi; Seitz, Steven, P.; Lin, Tai-An; Vaccaro, Wayne

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 216pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2006084017 | A2 | 20060810 | WO 2006-US3659 | 20060202 |
| | WO 2006084017 | A3 | 20061214 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | US 20060178388 | A1 | 20060810 | US 2006-344881 | 20060201 |
| | EP 1848714 | A2 | 20071031 | EP 2006-734200 | 20060202 |
| | R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | |
| | JP 2008530012 | T | 20080807 | JP 2007-554206 | 20060202 |
| PRAI | US 2005-650077P | P | 20050204 | | |
| | US 2006-344881 | A | 20060201 | | |
| | WO 2006-US3659 | W | 20060202 | | |

OS MARPAT 145:211069

AB The title compds. I [two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is CR1; R1 = H, CN; n = 0-3; R2 = alkyl, cycloalkyl, alkenyl, etc.; G = (un)substituted monocyclic 5-6 membered heteroaryl; Z = H, alkyl, cycloalkyl, etc.; with provisos], useful for inhibiting p38 kinase, LIM kinase 1, and/or LIM kinase 2 (no specific data given), were prepared E.g., a multi-step synthesis of II, starting from n-propylthiourea, was given. Also disclosed are pharmaceutical compns. containing compds. I, and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.


IT 905296-27-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of phenyl-substituted pyrimidines as p38 kinase and LIM kinases inhibitors for treating an inflammatory disorder and cancer)

RN 905296-27-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(2-chlorophenyl)-6-[2-(propylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 905296-26-6P 905296-37-9P 905296-51-7P
 905296-76-6P 905299-23-2P 905299-60-7P
 905299-61-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of phenyl-substituted pyrimidines as p38 kinase and LIM kinases
 inhibitors for treating an inflammatory disorder and cancer)
 RN 905296-26-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-chlorophenyl)-N-4-piperidinyl-6-[2-(propylamino)-5-
 thiazolyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 905296-25-5
 CMF C21 H25 Cl N6 S




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 905296-37-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chloro-4-fluorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 905296-51-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chlorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 905296-76-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chlorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 905299-23-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chloro-4-fluorophenyl)-6-[2-[(1-methylethyl)amino]-5-thiazolyl]-N-4-piperidinyll- (CA INDEX NAME)



RN 905299-60-7 CAPLUS


CN Urea, N-ethyl-N'-[[2-[6-[2-[(1-methylethyl)amino]-5-thiazolyl]-2-[[1-(1-methylethyl)-4-piperidinyll]amino]-4-pyrimidinyl]phenyl]methyl]- (CA INDEX NAME)



10/552,317

RN 905299-61-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[2-
[[[(ethylamino)carbonyl]amino]methyl]phenyl]-6-[2-[(1-methylethyl)amino]-5-
thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



L17 ANSWER 28 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:655649 CAPLUS
 DN 145:124591
 TI Preparation of pyrimidine derivatives as protein kinase inhibitors
 IN Sun, Piaoyang; Lv, Aifeng; Yang, Baohai; Hu, Chunyong
 PA Peop. Rep. China
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA Chinese
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2006069525 | A1 | 20060706 | WO 2005-CN2308 | 20051226 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | CN 1939910 | A | 20070404 | CN 2005-10107402 | 20050930 |
| | CA 2602738 | A1 | 20060706 | CA 2005-2602738 | 20051226 |
| | CN 1972917 | A | 20070530 | CN 2005-80020883 | 20051226 |
| | EP 1840122 | A1 | 20071003 | EP 2005-822296 | 20051226 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| | JP 2008526692 | T | 20080724 | JP 2007-548675 | 20051226 |
| | US 20080312251 | A1 | 20081218 | US 2008-794250 | 20080219 |
| PRAI | CN 2004-10103077 | A | 20041231 | | |
| | CN 2005-10107402 | A | 20050930 | | |
| | WO 2005-CN2308 | W | 20051226 | | |
| OS | MARPAT 145:124591 | | | | |
| AB | The title pyrimidine derivs. I [wherein R1 = (un)substituted (hetero)aryl or heterocycle; R2 and R3 = independently H, halo, NH2, CN, etc.; R4 = H, halo, NH2, alkyl, etc.; R5 = H, halo, NO2, CN, alkoxy, etc.; R6 = H, (un)substituted (cyclo)alkyl, (hetero)aryl, heterocycle, etc.; Q and Z = independently (hetero)aryl or heterocycle; L = (un)substituted -NHCO-, -CONH-, -NHSO2-, -NHSO2-, etc.; m and n = independently 0-3] or pharmaceutically acceptable salts thereof were prepared as protein kinase inhibitors. For example, II•CH3SO3H was prepared in a multi-step synthesis. II•CH3SO3H showed inhibitory activity with IC50 of 0.008 μM against K562 human cell. The title compds. are useful for treatment of proliferative disease (no data). Formulation of II•CH3SO3H as tablet was described. | | | | |
| IT | 895519-94-5P 895519-95-6P 895519-96-7P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of pyrimidine derivs. as protein kinase inhibitors) | | | | |
| RN | 895519-94-5 CAPLUS | | | | |

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[5-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-2-pyridinyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 895519-95-6 CAPLUS

CN 2-Pyridinecarboxamide, 5-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 895519-96-7 CAPLUS

CN 2-Pyridinecarboxamide, 5-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



IT 895520-02-2


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as protein kinase inhibitors)

RN 895520-02-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)

10/552,317



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 29 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:627482 CAPLUS
 DN 145:103701
 TI Preparation of pyrimidinyl based heterocycles and their use in the
 treatment of inflammation, and as antiviral and therapeutic agents
 IN Hong, Fang-Tsao; Liao, Hongyu; Lopez, Patricia; Tadesse, Seifu; Tamayo,
 Nuria A.
 PA Amgen Inc, USA
 SO PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2006069258 | A1 | 20060629 | WO 2005-US46652 | 20051220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20060161001 | A1 | 20060720 | US 2005-312292 | 20051219 |
| AU 2005319137 | A1 | 20060629 | AU 2005-319137 | 20051220 |
| CA 2591946 | A1 | 20060629 | CA 2005-2591946 | 20051220 |
| EP 1833831 | A1 | 20070919 | EP 2005-855245 | 20051220 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| PRAI US 2004-637845P | P | 20041220 | | |
| US 2005-312292 | A | 20051219 | | |
| WO 2005-US46652 | W | 20051220 | | |

OS MARPAT 145:103701

AB Nitrogen-containing heterocycles such as I-III are prepared and used as prodrugs

in the treatment of inflammation disorders, as well as, but not limited to antiviral agents and therapeutic agents. Thus, I-III can be used to inhibit the production of TNF- α or IL-1- β , in glucagon binding assays, as COX-1 and/or COX-2 inhibitors, or in a Raf-kinase inhibition assay (no data). Finally, said compds. are also useful therapeutic prodrugs in the treatment of inflammation, acute or chronic myelogenous leukemia, type I and II diabetes, Alzheimer's disease, stroke, myocardial infarction, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus, influenza, adenovirus, and the herpes viruses.


IT 894791-80-1P 894791-81-2P 894791-82-3P
 894792-73-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinyl based heterocycles and their use in the treatment of inflammation, and as antiviral and therapeutic agents)


RN 894791-80-1 CAPLUS

CN 1-Propanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-[(1-methylethyl)amino]- (CA INDEX NAME)




RN 894791-81-2 CAPLUS

CN 1-Propanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-(methylamino)- (CA INDEX NAME)




RN 894791-82-3 CAPLUS

CN 1-Propanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-(ethylamino)- (CA INDEX NAME)




RN 894792-73-5 CAPLUS

CN Ethanone, 1-[4-[[4-(6,7-dihydro-2-phenyl-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 894791-78-7 CAPLUS

CN Ethanone, 2-amino-1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 894791-79-8 CAPLUS

CN 1-Propanone, 3-bromo-1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 894791-91-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-5-fluoro-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894791-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-((3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-5-fluoro-N-4-piperidinyl)- (CA INDEX NAME)




RN 894791-97-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-((3,4-dihydro-7-phenyl-1,5-naphthyridin-1(2H)-yl)-2-pyrimidinyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894791-98-1 CAPLUS

CN 2-Pyrimidinamine, 4-((3,4-dihydro-7-phenyl-1,5-naphthyridin-1(2H)-yl)-N-4-piperidinyl)- (CA INDEX NAME)




RN 894791-99-2 CAPLUS

CN Ethanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,5-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 894792-21-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,8-naphthyridin-1(2H)-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894792-28-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,8-naphthyridin-1(2H)-yl)-6-methyl-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 894792-42-8 CAPLUS
 CN 1,8-Naphthyridine-3-carboxylic acid,
 8-[2-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-4-
 pyrimidinyl]-5,6,7,8-tetrahydro-2-phenyl-, ethyl ester (CA INDEX NAME)



RN 894792-55-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(3,4-dihydro-7-phenyl-1,8-naphthyridin-
 1(2H)-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 894792-71-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(6,7-dihydro-2-phenyl-8H-pyrimido[5,4-
 b][1,4]oxazin-8-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA
 INDEX NAME)



RN 894792-72-4 CAPLUS

CN 2-Pyrimidinamine, 4-(6,7-dihydro-2-phenyl-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-N-4-piperidinyl- (CA INDEX NAME)




IT 894791-93-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyrimidinyl based heterocycles and their use in the treatment of inflammation, and as antiviral and therapeutic agents)

RN 894791-93-6 CAPLUS

CN Ethanone, 1-[4-[[4-(3,4-dihydro-7-phenyl-1,6-naphthyridin-1(2H)-yl)-5-fluoro-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 30 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:608560 CAPLUS

DN 145:83228

TI Preparation of pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases

IN Charrier, Jean-Damien; Durrant, Steven; Ramaya, Sharn; Jimenez, Juan-Miguel; Rutherford, Alistair

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2006065946 | A1 | 20060622 | WO 2005-US45336 | 20051215 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | AU 2005316540 | A1 | 20060622 | AU 2005-316540 | 20051215 |
| | CA 2591413 | A1 | 20060622 | CA 2005-2591413 | 20051215 |
| | US 20060183911 | A1 | 20060817 | US 2005-304057 | 20051215 |
| | EP 1831168 | A1 | 20070912 | EP 2005-854119 | 20051215 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| | JP 2008524233 | T | 20080710 | JP 2007-546878 | 20051215 |
| | MX 200707330 | A | 20071004 | MX 2007-7330 | 20070618 |
| | IN 2007KN02260 | A | 20070817 | IN 2007-KN2260 | 20070619 |
| | NO 2007003628 | A | 20070716 | NO 2007-3628 | 20070716 |
| | KR 2007095952 | A | 20071001 | KR 2007-716337 | 20070716 |
| | CN 101111479 | A | 20080123 | CN 2005-80047554 | 20070731 |
| PRAI | US 2004-636754P | P | 20041216 | | |
| | US 2005-673870P | P | 20050422 | | |
| | WO 2005-US45336 | W | 20051215 | | |

OS MARPAT 145:83228

AB The title compds. I [R3, R4 = H, halo or alkyl optionally substituted with halo, alkyl, OCH3, NO2, NH2, CN, NHCH3, SCH3, or N(CH)2; R2 = 3-8 membered saturated, partially unsatd., or fully unsatd. monocyclic ring having 0-3 heteroatoms independently selected from N, O, or S, or 8-12 membered saturated, partially unsatd., or fully unsatd. bicyclic ring system having 0-5 heteroatoms independently selected from N, O, or S; X1, X2 = C(O), NR, or SO2 (wherein one of X1 or X2 = NR and other of X1 or X2 = C(O) or SO2); R1 = TQ (T = a bond or alkylene wherein up tp 3 methylene units are optionally replaced by O, S, CS, etc.; Q = H, alkyl, 3-8 membered saturated, partially unsatd., or fully unsatd. monocyclic ring having 0-3 heteroatoms independently selected from N, O, or S, or 8-12 membered saturated, partially

unsatd., or fully unsatd. bicyclic ring system having 0-5 heteroatoms independently selected from N, O, or S)] which are effective as inhibitors of Tec family (e.g., Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk) protein kinases, were prepared. Thus, reacting amrinone with 4-tert-butylbenzoyl chloride afforded 9% II which showed K_i between 0.1 μM and 1 μM against ITK. The compds. I and their pharmaceutically acceptable compns. are useful for treating or preventing a variety of diseases, disorders or conditions, including, but not limited to, an autoimmune, inflammatory, proliferative, or hyperproliferative disease or an immunol.-mediated disease.


IT 893436-12-9P 893436-30-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridones as inhibitors of Tec family protein kinases useful for treating and preventing inflammatory, proliferative, hyperproliferative, autoimmune or immunol.-mediated disease)


RN 893436-12-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[5-[[4-(1,1-dimethylethyl)benzoyl]amino]-1,6-dihydro-6-oxo-3-pyridinyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 893436-30-1 CAPLUS


CN Benzamide, N-[1,2-dihydro-2-oxo-5-[2-(4-piperidinylamino)-4-pyrimidinyl]-3-pyridinyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 31 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:439442 CAPLUS
 DN 144:468188
 TI Preparation of pyrimidinyl-substituted fused pyrroles for treatment of
 kinase disorders
 IN Huang, Shenlin; Lin, Ronghui; Connolly, Peter J.; Emanuel, Stuart L.;
 Middleton, Steven A.
 PA Janssen Pharmaceutica, N.V., Belg.
 SO PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2006050076 | A1 | 20060511 | WO 2005-US38905 | 20051028 |
| | W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | US 20060183900 | A1 | 20060817 | US 2005-260986 | 20051028 |
| PRAI | US 2004-623654P | P | 20041029 | | |
| OS | CASREACT 144:468188; MARPAT 144:468188 | | | | |
| AB | Title compds. [I; A, B, C = CH, N; D = N, CR4; R1 = H, halo, OH, cyano, NO2, 1-3 of (substituted) alkyl, alkenyl, alkynyl, alkoxy, amino, sulfonylamino, alkylthio, carboxamide, etc.; R2 = (substituted) cycloalkyl, aryl, heteroaryl, heterocyclyl, alkyl; R3 = H, alkyl, alkoxyalkyl, haloalkyl hydroxyalkyl, CO2H, alkoxyalkyl, CHO, CONH2, SO2NH2, etc.; R4 = H, alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, hydroxyalkoxy, CO3H, alkoxyalkyl, etc.], were prepared Thus, 2-[4-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamino]phenyl]ethanol [preparation from 7-azaindole, 2,4-dichloropyrimidine, and 2-(4-aminophenyl)ethanol given] inhibited CDK1 with IC50 = 0.019 µM. | | | | |
| IT | 886547-58-6P 886547-63-3P 886547-65-5P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of pyrimidinyl-substituted fused pyrroles for treatment of kinase disorders) | | | | |
| RN | 886547-58-6 CAPLUS | | | | |
| CN | 2-Pyrimidinamine, N-(1-methyl-4-piperidinyl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)- (CA INDEX NAME) | | | | |




RN 886547-63-3 CAPLUS

CN Ethanone, 1-[4-[[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 886547-65-5 CAPLUS

CN 2-Pyrimidinamine, N-4-piperidinyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 32 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:380989 CAPLUS

DN 144:432824

TI Preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as inhibitors of p38 MAP kinase

IN Ashwell, Mark; Tandon, Manish; Lapierre, Jean-Marc

PA Arqule, Inc., USA

SO PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2006044869 | A1 | 20060427 | WO 2005-US37390 | 20051019 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | CA 2584368 | A1 | 20060427 | CA 2005-2584368 | 20051019 |
| | EP 1809636 | A1 | 20070725 | EP 2005-815645 | 20051019 |
| | R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | |
| | JP 2008517064 | T | 20080522 | JP 2007-537967 | 20051019 |
| PRAI | US 2004-619876P | P | 20041019 | | |
| | WO 2005-US37390 | W | 20051019 | | |

OS CASREACT 144:432824; MARPAT 144:432824

AB The title compds. I [wherein X = O, S, SO, or SO₂; Ar = 2,3-dihydrobenzo[1,4]dioxin-6-yl, benzo[1,3]dioxol-5-yl, or (un)substituted aryl; R1 = H, CN, CO₂H, halo, alkyl, etc.; R2 = (un)substituted alkyl, cycloalkyl, heterocyclyl, or aryl; R3 = H, (un)substituted alkyl, cycloalkyl, aryl, or heteroaryl] or pharmaceutically acceptable salts or prodrugs thereof are prepared as inhibitors of the p38 MAP kinase. For example, the compound II was prepared in a multi-step synthesis. I are useful for the treatment of inflammation and autoimmune disease (no data).

IT 815595-31-4P 815595-32-5P 815595-35-8P


815595-36-9P 815595-59-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as inhibitors of p38 MAP kinase)


RN 815595-31-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 815595-32-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 815595-35-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 815595-36-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-59-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



| | | | |
|----|--------------|--------------|--------------|
| IT | 815595-27-8P | 815595-44-9P | 815595-45-0P |
| | 815595-58-5P | 815595-60-9P | 815596-95-3P |
| | 885046-43-5P | 885046-44-6P | 885046-48-0P |
| | 885046-49-1P | 885046-54-8P | 885046-56-0P |
| | 885046-58-2P | 885046-60-6P | 885046-61-7P |
| | 885046-62-8P | 885046-63-9P | 885046-64-0P |
| | 885046-65-1P | 885046-66-2P | 885046-67-3P |
| | 885046-68-4P | 885046-69-5P | 885046-70-8P |
| | 885046-71-9P | 885046-72-0P | 885046-73-1P |
| | 885046-74-2P | 885046-75-3P | 885046-76-4P |
| | 885046-77-5P | 885046-79-7P | 885046-80-0P |
| | 885046-81-1P | 885046-82-2P | 885046-83-3P |
| | 885046-84-4P | 885046-85-5P | 885046-86-6P |
| | 885046-87-7P | 885046-88-8P | 885046-89-9P |
| | 885046-90-2P | 885046-91-3P | 885046-92-4P |
| | 885046-93-5P | 885046-94-6P | 885046-95-7P |
| | 885047-07-4P | 885047-08-5P | 885047-09-6P |
| | 885047-10-9P | 885047-11-0P | 885047-24-5P |
| | 885047-25-6P | 885047-26-7P | 885047-27-8P |
| | 885047-28-9P | 885047-29-0P | 885047-30-3P |
| | 885047-34-7P | 885047-35-8P | 885047-36-9P |
| | 885047-37-0P | 885047-38-1P | 885047-39-2P |
| | 885047-40-5P | 885047-41-6P | 885047-42-7P |
| | 885047-43-8P | 885047-44-9P | 885047-45-0P |
| | 885047-46-1P | 885047-47-2P | 885047-48-3P |
| | 885047-49-4P | 885047-50-7P | 885047-51-8P |
| | 885047-52-9P | 885047-53-0P | 885047-54-1P |
| | 885047-55-2P | 885047-56-3P | 885047-57-4P |


885047-59-6P 885047-60-9P 885047-61-0P
 885047-62-1P 885047-63-2P 885047-64-3P
 885047-65-4P 885047-66-5P 885047-83-6P
 885047-84-7P 885047-85-8P 885047-95-0P
 885048-01-1P 885048-02-2P 885048-06-6P
 885048-12-4P 885048-13-5P 885048-15-7P
 885048-32-8P 885048-34-0P 885048-35-1P
 885048-36-2P 885048-38-4P 885048-41-9P
 885048-43-1P 885048-44-2P 885048-45-3P
 885048-49-7P 885048-52-2P 885048-58-8P
 885048-64-6P 885048-69-1P 885048-71-5P
 885048-76-0P 885048-78-2P 885048-80-6P
 885048-86-2P 885048-87-3P 885048-88-4P
 885048-89-5P 885048-90-8P 885048-91-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as inhibitors of p38 MAP kinase)

RN 815595-27-8 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 815595-44-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-45-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-58-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-60-9 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 815596-95-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-43-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885046-44-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885046-48-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-49-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885046-54-8 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl](4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-56-0 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]phenyl- (CA INDEX NAME)




RN 885046-58-2 CAPLUS

CN Ethanone, 2-(4-chlorophenoxy)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-60-6 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-8-quinolinyl- (CA INDEX NAME)




RN 885046-61-7 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-piperidinyl- (CA INDEX NAME)




RN 885046-62-8 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-methoxy- (CA INDEX NAME)




RN 885046-63-9 CAPLUS

CN Methanone, cyclohexyl[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-64-0 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)




RN 885046-65-1 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-furanyl- (CA INDEX NAME)




RN 885046-66-2 CAPLUS

CN 1-Piperidinecarboxamide, N-cyclohexyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-67-3 CAPLUS

CN 1-Piperidinecarboxamide, N-butyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-68-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 885046-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylethyl)- (CA INDEX NAME)




RN 885046-70-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 885046-71-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methylphenyl)- (CA INDEX NAME)




RN 885046-72-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 885046-73-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-74-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-75-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885046-76-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 885046-77-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(3,5-dimethyl-4-isoxazolyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-79-7 CAPLUS

CN Ethanone, 2-(4-fluorophenyl)-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-80-0 CAPLUS

CN 1-Butanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 885046-81-1 CAPLUS

CN Methanone, (4-fluorophenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-82-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885046-83-3 CAPLUS

CN 1-Piperidinecarboxamide, N-(cyclohexylmethyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-84-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-(4-fluorophenyl)ethyl]-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-85-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[5-methyl-2-(trifluoromethyl)-3-furanyl]- (CA INDEX NAME)




RN 885046-86-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885046-87-7 CAPLUS

CN 1-Propanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885046-88-8 CAPLUS

CN 1-Propanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-3-phenyl- (CA INDEX NAME)




RN 885046-89-9 CAPLUS

CN Ethanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 885046-90-2 CAPLUS


CN 1-Propanone, 2-amino-1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 885046-91-3 CAPLUS

CN Methanone, [4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-(2S)-2-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885046-92-4 CAPLUS


CN 1-Piperidinecarboxamide, N-(3,4-difluorophenyl)-4-[[4-[6-(4-

fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 885046-93-5 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 885046-94-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885046-95-7 CAPLUS


CN 1-Piperidinepentanoic acid, γ -amino-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885047-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(phenylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 885047-08-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-09-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-10-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-methoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-24-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-25-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-26-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-27-8 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3,5-dichlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-28-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(3-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-29-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-30-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-34-7 CAPLUS

CN Methanone, (4-amino-3,5,6-trichloro-2-pyridinyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-35-8 CAPLUS

CN Methanone, (2,6-dimethoxyphenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-36-9 CAPLUS

CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 885047-37-0 CAPLUS

CN Acetamide, N-[2-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]- (CA INDEX NAME)




RN 885047-38-1 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-39-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885047-40-5 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(4-methyl-2-pyrimidinyl)thio]- (CA INDEX NAME)




RN 885047-41-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-42-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-43-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 885047-44-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-45-0 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-46-1 CAPLUS

CN Methanone, [4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl][4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885047-47-2 CAPLUS

CN Methanone, [4-(dimethylamino)phenyl][4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885047-48-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-49-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885047-50-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-51-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885047-52-9 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(5-chloro-2-methoxyphenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-53-0 CAPLUS

CN Acetamide, N-[5-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-4-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 885047-54-1 CAPLUS

CN Benzoic acid, 4-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-55-2 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-56-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-methoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-57-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 885047-59-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-60-9 CAPLUS

CN 1-Piperidinecarboxamide, N-(2-furanylmethyl)-4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885047-61-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(2-methylphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-62-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(2,6-difluorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885047-63-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(3-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-64-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[(4-phenoxyphenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-[[4-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885047-66-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885047-83-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885047-84-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-85-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 885047-95-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-naphthalenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-01-1 CAPLUS

CN Ethanone, 2-[4-(dimethylamino)phenyl]-1-[4-[[4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 885048-02-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-06-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-12-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 885048-13-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-15-7 CAPLUS

CN 2-Pyrimidinamine, 4-(6-[1,1'-biphenyl]-4-ylimidazo[2,1-b]thiazol-5-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-32-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885048-34-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[3-methyl-6-(4-methylphenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-35-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[[4-[6-(4-nitrophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-36-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(6-[1,1'-biphenyl]-4-yl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 885048-38-4 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-41-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 885048-43-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-44-2 CAPLUS

CN Benzoic acid, 4-[[4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885048-45-3 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[[4-[6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 885048-49-7 CAPLUS

CN Acetamide, N-[4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]phenyl]- (CA INDEX NAME)




RN 885048-52-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[2,1-b]thiazol-5-yl]-N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 885048-58-8 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 885048-64-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-69-1 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-71-5 CAPLUS

CN Phenol, 4-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-76-0 CAPLUS

CN 2-Pyrimidinamine, N-[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]-4-[6-(3,4-difluorophenyl)imidazo[2,1-b]thiazol-5-yl]- (CA INDEX NAME)




RN 885048-78-2 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)




RN 885048-80-6 CAPLUS

CN Phenol, 3-[5-[2-[[1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]imidazo[2,1-b]thiazol-6-yl]- (CA INDEX NAME)



RN 885048-86-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 885048-87-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)


10/552,317



● HCl

RN 885048-88-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 885048-89-5 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 885048-90-8 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 885048-91-9 CAPLUS

CN 2-Pyrimidinamine, N-4-piperidinyl-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


IT 935431-17-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinyl imidazooxazoles and imidazothiazoles as inhibitors of p38 MAP kinase)

RN 935431-17-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 33 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:343042 CAPLUS
 DN 144:390934
 TI Preparation of aminopyrimidines as JNK inhibitors
 IN Ratcliffe, Andrew James; Alam, Mahbub; Beevers, Rebekah Elisabeth;
 Davenport, Richard John; Davies, Natasha; Haughan, Alan Findlay; Jones,
 Mark William; Lowe, Christopher; Perry, Benjamin Garfield; Phillips, David
 Jonathan; Pitt, William Ross; Sharpe, Andrew
 PA Celltech R & D Limited, UK
 SO PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006038001 | A1 | 20060413 | WO 2005-GB3827 | 20051004 |
| | W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | GB 2004-22284 | A | 20041006 | | |
| | GB 2005-9642 | A | 20050511 | | |
| OS | CASREACT 144:390934; MARPAT 144:390934 | | | | |
| AB | Title compds. I [A = pyrrole, pyrazole, imidazole or triazole ring; B = benzene, pyridine or pyrimidine ring; M = residue of an azetidine, pyrrolidine or piperidine ring; E = a covalent bond or (un)substituted straight or branched alkylene; Z = H, CHO, CONH ₂ and derivs., CO ₂ H and derivs., (un)substituted Ph, heteroaryl, heterocycloalkyl, etc.; R ₁ , R ₂ = independently H, halo, CN, NO ₂ , OCF ₃ , alkyl, alkoxy, etc.; R ₃ = H, alkyl, SO ₂ H and derivs., etc.; R ₄ = H, alkoxy, oxo, CO ₂ H and derivs., etc.; and their pharmaceutically acceptable salts, solvates or N-oxides] were prepared as JNK inhibitors. Thus, coupling 2,4,5-trichloropyrimidine with [1-(phenylsulfonyl)-1H-indol-3-yl]boronic acid, and amination of the 2-chloropyrimidine intermediate with Et 4-amino-1-piperidinecarboxylate gave aminopyrimidine II•HCO ₂ H. I possessed IC ₅₀ values for inhibition of human JNK1 and/or JNK2 and/or JNK3 enzyme activity of 5 μM or better. I are useful for treating autoimmune and inflammatory disorders, vascular, neurodegenerative, metabolic and ophthalmic disorders, neoplasm and pain. | | | | |
| IT | 882565-17-5P, 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-2-phenylacetamide RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (drug candidate; preparation of aminopyrimidines as JNK inhibitors) | | | | |
| RN | 882565-17-5 CAPLUS | | | | |
| CN | 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- | | | | |

N-methyl- α -phenyl- (CA INDEX NAME)



IT 882566-86-1P 882566-87-2P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as JNK inhibitors)

RN 882566-86-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- α -phenyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882566-87-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- α -phenyl-, (-)- (CA INDEX NAME)

Rotation (-).



IT 882562-76-7P 882562-81-4P,
 N-Ethyl-4-[[5-methyl-4-[1-(phenylsulfonyl)-1H-indol-3-yl]pyrimidin-2-yl]amino]piperidine-1-carboxamide 882562-86-9P, tert-Butyl
 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-93-8P, tert-Butyl
 4-[[4-(1H-benzimidazol-1-yl)-5-chloropyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-97-2P,
 4-(6-Fluoro-1H-indol-3-yl)-2-[(piperidin-4-yl)amino]pyrimidine-5-carbonitrile 882562-98-3P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-03-3P 882563-09-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine 882563-12-4P, 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N,N-dimethylpiperidine-1-carboxamide 882563-41-9P, tert-Butyl
 4-[[5-chloro-4-[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-54-4P
 882563-56-6P, 3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]cyclopentanone 882563-60-2P,
 Methyl (3R)-4-[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-methyl-4-oxobutanoate 882563-80-6P,
 N-[1-[(1,2,3-Benzotriazol-2-yl)ethanoyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-93-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(piperidin-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-97-5P, tert-Butyl
 4-[[4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-99-7P 882564-05-8P
 882564-19-4P 882564-40-1P 882565-18-6P,
 [4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](tetrahydrofuran-3-yl)acetonitrile 882565-19-7P, tert-Butyl
 4-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](cyano)methyl]piperidine-1-carboxylate 882565-33-5P,
 tert-Butyl 4-[[4-(imidazo[1,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl]amino]piperidine-1-carboxylate 882565-39-1P,
 4-[[5-Chloro-4-(1H-indol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-40-4P,
 2-[4-[[5-Chloro-4-(1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminopyrimidines as JNK inhibitors)


RN 882562-76-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, ethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 882562-75-6

CMF C20 H22 Cl N5 O2



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882562-81-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[5-methyl-4-[1-(phenylsulfonyl)-1H-indol-3-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-86-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882562-93-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-benzimidazol-1-yl)-5-chloro-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882562-97-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-(4-piperidinylamino)- (CA INDEX NAME)




RN 882562-98-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-03-3 CAPLUS

CN Glycine, N-[[4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 882563-09-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-4-piperidinyl- (CA INDEX NAME)




RN 882563-12-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 882563-41-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882563-54-4 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 882563-56-6 CAPLUS


CN Cyclopentanone, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 882563-60-2 CAPLUS


CN 1-Piperidinebutanoic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-β-methyl-γ-oxo-, methyl ester, (βR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882563-80-6 CAPLUS

CN Ethanone, 2-(2H-benzotriazol-2-yl)-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-93-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-piperidinyl- (CA INDEX NAME)




RN 882563-97-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882563-99-7 CAPLUS


CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-4-piperidinyl-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 882564-05-8 CAPLUS


CN 2-Pyrimidinamine, 5-chloro-4-imidazo[1,2-a]pyridin-3-yl-N-4-piperidinyl-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 882564-19-4 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -oxo-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 882564-40-1 CAPLUS

CN Formic acid, compd. with 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)ethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-39-8

CMF C20 H23 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882565-18-6 CAPLUS

CN 1-Piperidineacetonitrile, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 882565-19-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]cyanomethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-33-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-imidazo[1,2-a]pyridin-3-yl-5-methyl-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-39-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882565-40-4 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



IT 882562-77-8P, tert-Butyl 4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-82-5P, N-Ethyl-4-[[4-(1H-indol-3-yl)-5-methylpyrimidin-2-yl]amino]piperidine-1-carboxamide 882562-83-6P, Ethyl 4-[[5-cyano-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882562-87-0P, 2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N,N-dimethylacetamide 882562-88-1P, 2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetamide 882562-89-2P, 2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882562-90-5P, N-[2-[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]ethyl]acetamide 882562-91-6P, N-Ethyl-4-[[4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882562-92-7P, 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882562-94-9P, 4-[[4-(1H-Benzimidazol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882562-95-0P, 2-[4-[[4-(1H-Benzimidazol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetamide 882562-98-3P, 4-[[5-Chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-01-1P, 4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-02-2P 882563-04-4P, 4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882563-05-5P, 4-(6-Fluoro-1H-indol-3-yl)-2-[[1-[(1H-imidazol-2-yl)methyl]piperidin-4-yl]amino]pyrimidine-5-carbonitrile 882563-06-6P, N-[[4-[[5-Cyano-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]glycine 882563-07-7P,

4-(6-Fluoro-1H-indol-3-yl)-2-[[1-(propylsulfonyl)piperidin-4-yl]amino]pyrimidine-5-carbonitrile 882563-08-8P,
 4-(6-Fluoro-1H-indol-3-yl)-2-[[1-[(1H-imidazol-4-yl)methyl]piperidin-4-yl]amino]pyrimidine-5-carbonitrile 882563-10-2P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882563-11-3P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-methoxypiperidine-1-carboxamide 882563-13-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(morpholin-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-14-6P,
 N-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]acetamide 882563-15-7P,
 N-(1-Acetylpiperidin-4-yl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-16-8P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-(methoxyacetyl)piperidin-4-yl]pyrimidin-2-amine 882563-17-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydrofuran-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-18-0P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-19-1P,
 5-Chloro-N-[1-(3-furanylcarbonyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-20-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-(1-isonicotinoylpiperidin-4-yl)pyrimidin-2-amine 882563-21-5P, N-[4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]phenyl]acetamide 882563-22-6P, 5-Chloro-N-[1-[4-(dimethylamino)benzoyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-23-7P
 882563-24-8P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-25-9P,
 5-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]imidazolidine-2,4-dione 882563-26-0P,
 N-[1-[(1-Acetylpiperidin-4-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-27-1P,
 [3-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-oxopropyl]urea 882563-28-2P,
 5-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882563-29-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-30-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(3-methylisoxazol-5-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882563-31-7P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-[3-(4-methylpiperazin-1-yl)propyl]piperidine-1-carboxamide 882563-33-9P
 882563-34-0P, 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-methoxy-N-methylpiperidine-1-carboxamide 882563-35-1P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylbutanamide 882563-36-2P,
 2-[4-[[5-Chloro-4-[1-[2-(methylamino)-2-oxoethyl]-1H-indol-3-yl]pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882563-37-3P, Ethyl (3R,4S)-4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-3-methoxypiperidine-1-carboxylate 882563-38-4P, tert-Butyl 4-[[4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-39-5P, N-Ethyl-4-[[5-fluoro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882563-40-8P,
 4-[[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-42-0P,
 4-[[5-Chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]-N,N-dimethylpiperidine-1-carboxamide 882563-43-1P, tert-Butyl

[[4-[[5-chloro-4-[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-yl]amino]piperidin-1-yl]sulfonyl]carbamate
 882563-44-2P, tert-Butyl 4-[[4-(1H-benzimidazol-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882563-45-3P,
 4-[[4-(5-Chloro-1H-benzimidazol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-46-4P,
 4-[[4-(6-Chloro-1H-benzimidazol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882563-48-6P 882563-49-7P
 , 5-Chloro-N-[1-[(1H-imidazol-4-yl)carbonyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-50-0P,
 N-[(S)-2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-1-[(1H-imidazol-4-yl)methyl]-2-oxoethyl]acetamide 882563-51-1P
 , 5-Chloro-N-[1-[(1H-imidazol-2-yl)carbonyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-52-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-2-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882563-53-3P,
 (5R)-5-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882563-55-5P 882563-57-7P
 , (5S)-5-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882563-58-8P,
 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]cyclohexanol 882563-59-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(4-methoxycyclohexyl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-61-3P,
 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-1,3-oxazolidin-2-one 882563-62-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(3-thienyl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-63-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(2-thienyl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-64-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1,3-thiazol-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-65-7P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(2-methyl-1,3-thiazol-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-66-8P,
 6-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-4,5-dihydropyridazin-3(2H)-one 882563-67-9P,
 5-Chloro-N-[1-(cyclopentylcarbonyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-68-0P,
 N-(1-Benzoylpiperidin-4-yl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-69-1P, 5-Chloro-N-[1-(cyclopropylcarbonyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-70-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-71-5P,
 N-[1-[3-(1H-Benzimidazol-2-yl)propanoyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-72-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-(1-propionylpiperidin-4-yl)pyrimidin-2-amine 882563-73-7P, 5-Chloro-N-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-74-8P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1,8-naphthyridin-2-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-75-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(2-methylbenzoyl)piperidin-4-yl]pyrimidin-2-amine 882563-76-0P, 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-4-oxobutanamide 882563-77-1P,
 5-Chloro-N-[1-[(cinnolin-4-yl)carbonyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-78-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-(1-isobutanoylpiperidin-4-yl)pyrimidin-2-amine 882563-79-3P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-(3-

methylbenzoyl)piperidin-4-yl]pyrimidin-2-amine 882563-81-7P,
 3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-5,6-dimethylpyridin-2(1H)-one 882563-82-8P,
 N-[1-[(1H-Benzimidazol-5-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-83-9P,
 N-[1-[(1H-Benzimidazol-2-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882563-84-0P 882563-85-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(2-phenylpropanoyl)piperidin-4-yl]pyrimidin-2-amine 882563-87-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(tetrahydrothiophene-3-ylacetyl)piperidin-4-yl]pyrimidin-2-amine 882563-88-4P,
 3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]cyclopentanol 882563-89-5P,
 (3R)-4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-methyl-4-oxobutanoic acid 882563-90-8P,
 (3R)-4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-methyl-4-oxobutan-1-ol 882563-92-0P 882563-94-2P,
 4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]-N-ethylpiperidine-1-carboxamide 882563-95-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[1-(methylsulfonyl)piperidin-4-yl]carbonyl]piperidin-4-yl]pyrimidin-2-amine 882563-96-4P,
 2-[4-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]piperidin-1-yl]-N-methylacetamide 882564-00-3P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-01-4P,
 (5S)-5-[[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-2-one 882564-03-6P 882564-04-7P
 , 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(tetrahydrofuran-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-06-9P,
 N-[2-[4-[[5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]acetamide 882564-07-0P,
 5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-08-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-2-yl)methyl]sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-10-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-4-yl)methyl]sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-11-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(isopropylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-12-7P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-13-8P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(isopropylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-14-9P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(methylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-15-0P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-4-yl]pyrimidin-2-amine 882564-16-1P,
 5-Chloro-4-(imidazo[1,2-a]pyridin-3-yl)-N-[1-(isopropylsulfonyl)piperidin-4-yl]pyrimidin-2-amine 882564-17-2P, Ethyl
 [4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](oxo)acetate 882564-18-3P, Methyl
 [4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl](oxo)acetate 882564-20-7P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-2-(oxo)acetamide 882564-21-8P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N,N-dimethyl-2-(oxo)acetamide 882564-22-9P,

4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-[2-(morpholin-4-yl)ethyl]piperidine-1-carboxamide 882564-23-0P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882564-24-1P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-[(pyridin-2-yl)methyl]piperidine-1-carboxamide 882564-25-2P
 882564-27-4P 882564-29-6P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(piperidin-4-yl)piperidine-1-carboxamide 882564-30-9P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(piperidin-3-yl)piperidine-1-carboxamide 882564-32-1P 882564-33-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(morpholin-4-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-34-3P 882564-36-5P
 882564-38-7P 882564-41-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-3-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-42-3P,
 3-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-1,1-dimethylurea 882564-43-4P, Morpholine-4-carboxylic acid [2-[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amide 882564-44-5P,
 5-Chloro-N-[1-[(1H-imidazol-1-yl)acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882564-45-6P,
 N-[(3R)-1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-3-yl]acetamide 882564-46-7P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(4-hydroxycyclohexylamino)ethanone 882564-47-8P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[cyclohexyl(2-hydroxyethyl)amino]ethanone 882564-48-9P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxypropylamino)ethanone 882564-49-0P,
 [1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-3-yl]methanol 882564-50-3P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[(1-hydroxymethylcyclopentyl)amino]ethanone 882564-51-4P,
 1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-3-ol 882564-52-5P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(4-hydroxybutylamino)ethanone 882564-53-6P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxy-1-methylethylamino)ethanone 882564-54-7P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[(1-hydroxymethyl-3-methylbutyl)amino]ethanone 882564-55-8P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[[1-(hydroxymethyl)propyl]amino]ethanone 882564-56-9P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxy-1,1-dimethylethylamino)ethanone 882564-57-0P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[(1-hydroxymethyl-2-methylpropyl)amino]ethanone 882564-58-1P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxy-1-phenylethylamino)ethanone 882564-59-2P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxyethylamino)ethanone 882564-60-5P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-[[[1-(hydroxycyclohexyl)methyl]amino]ethanone 882564-62-7P,
 1-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(3-hydroxypropylamino)ethanone 882564-63-8P,
 2-[1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-

yl]-2-oxoethyl]piperidin-2-yl]ethanol 882564-64-9P,
 2-[1-[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-4-yl]ethanol 882564-65-0P,
 1-[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-4-ol 882564-66-1P,
 1-[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidine-4-carboxamide 882564-67-2P,
 1-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(2-hydroxybutylamino)ethanone 882564-68-3P,
 1-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(3-hydroxy-2,2-dimethylpropylamino)ethanone 882564-69-4P
 882564-70-7P, (3R)-1-[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-3-ol 882564-71-8P,
 (3R)-1-[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-3-ol 882564-72-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(1H-indol-3-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882564-73-0P, 5-Chloro-N-[1-[[1,3-dimethylbutyl]amino]acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882564-74-1P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[pyrimidin-4-yl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-75-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyrrolidin-1-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-76-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(morpholin-4-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882564-77-4P, 1-[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-N,N-diethylpiperidine-3-carboxamide
 882564-78-5P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-methyl-2-(morpholin-4-yl)propyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882564-79-6P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[methyl[(1-methyl-1H-imidazol-2-yl)methyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882564-80-9P, 3-[[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]benzenesulfonamide
 882564-81-0P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(pyrrolidin-1-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882564-82-1P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[2-(1-methylpyrrolidin-2-yl)ethyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882564-83-2P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[1,3-thiazol-2-yl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882564-84-3P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[2-(methylamino)propanoyl]piperidin-4-yl]pyrimidin-2-amine 882564-86-5P 882564-87-6P,
 [2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl](methyl)carbamic acid tert-butyl ester 882564-88-7P,
 N-[2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-N-methylacetamide 882564-89-8P 882564-90-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1,2,4-oxadiazol-3-yl)methyl]piperidin-4-yl]pyrimidin-2-amine 882564-91-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyridin-3-yl)methyl]piperidin-4-yl]pyrimidin-2-amine 882564-93-4P 882564-95-6P
 882564-97-8P
 882564-98-9P, 1-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetone 882564-99-0P, Methyl
 2-[4-[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetate 882565-01-7P 882565-02-8P,
 2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(2-fluorophenyl)acetamide 882565-03-9P,
 2-[4-[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[2-


(1H-indol-3-yl)ethyl]acetamide 882565-04-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(pyrimidin-4-yl)acetamide 882565-05-1P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(pyridin-3-yl)acetamide 882565-06-2P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[(pyridin-3-yl)methyl]acetamide 882565-07-3P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[2-(morpholin-4-yl)ethyl]acetamide 882565-08-4P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[2-(piperidin-1-yl)ethyl]acetamide 882565-09-5P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]acetamide 882565-10-8P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-N-[(1-methyl-1H-imidazol-2-yl)methyl]acetamide 882565-11-9P
 , 5-Chloro-4-(1H-indol-3-yl)-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl]pyrimidin-2-amine 882565-12-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(cyclopropylmethyl)acetamide 882565-13-1P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-(1,3-thiazol-2-yl)acetamide 882565-15-3P 882565-16-4P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylpropanamide 882565-20-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-phenylpropionitrile 882565-21-1P 882565-22-2P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(piperidin-4-yl)acetamide 882565-23-3P,
 3-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]dihydrofuran-2(3H)-one 882565-24-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(5-nitro-1,3-thiazol-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-25-5P,
 6-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]nicotinonitrile 882565-26-6P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(pyridin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-27-7P, N-[1-(5-Aminopyridin-2-yl)piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-28-8P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(pyrimidin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-29-9P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-(pyrazin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882565-30-2P,
 2-[4-[[5-Chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882565-31-3P, tert-Butyl
 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882565-32-4P,
 4-[[5-Chloro-4-(6-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-34-6P,
 N-Ethyl-4-[[4-(imidazo[1,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl]amino]piperidine-1-carboxamide 882565-35-7P,
 4-[[5-Chloro-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-36-8P,
 4-[[5-Chloro-4-(imidazo[1,2-a]pyrimidin-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882565-42-6P 882565-44-8P
 882565-45-9P, 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine
 882565-46-0P 882565-47-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methylpiperidin-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882565-48-2P,
 4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-

methyl-4-oxobutanamide 882565-49-3P,
 4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methyl-3-methyl-4-oxobutanamide 882565-50-6P,
 4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N,N-dimethyl-3-methyl-4-oxobutanamide 882565-51-7P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(3-methylbutanoyl)piperidin-4-yl]pyrimidin-2-amine 882565-52-8P 882565-53-9P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882565-54-0P,
 2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-phenylpropanamide 882565-55-1P,
 1-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-1,3,3-trimethylurea 882565-56-2P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(1-methylpiperidin-4-yl)piperidine-1-carboxamide 882565-57-3P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-isopropylpiperidine-1-carboxamide 882565-58-4P,
 N-[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-1-(hydroxymethyl)-2-oxoethyl]acetamide 882565-59-5P
 882565-60-8P, 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(1-methylpiperidin-3-yl)piperidine-1-carboxamide 882565-61-9P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-cyclopropylpiperidine-1-carboxamide 882565-62-0P
 882565-63-1P, N-[1-[2-(Azetidin-1-yl)-2-oxoethyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-64-2P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydrofuran-3-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882565-65-3P,
 1-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidin-3-ol 882565-66-4P,
 3-[[2-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]dihydrofuran-2(3H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as JNK inhibitors)


RN 882562-77-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882562-82-5 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(1H-indol-3-yl)-5-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-83-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-cyano-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 882562-87-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 882562-88-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-89-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882562-90-5 CAPLUS

CN Acetamide, N-[2-[4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]ethyl]- (CA INDEX NAME)



RN 882562-91-6 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 882562-92-7 CAPLUS


CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)

pyrimidinyl)amino]-N-methyl- (CA INDEX NAME)




RN 882562-94-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882562-95-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882562-98-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-01-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-02-2 CAPLUS

CN β -Alanine, N-[[4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 882563-04-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882563-05-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-[[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]amino]- (CA INDEX NAME)




RN 882563-06-6 CAPLUS

CN Glycine, N-[[4-[[5-cyano-4-(6-fluoro-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 882563-07-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-[[1-(propylsulfonyl)-4-piperidinyl]amino]- (CA INDEX NAME)




RN 882563-08-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(6-fluoro-1H-indol-3-yl)-2-[[1-(1H-imidazol-5-ylmethyl)-4-piperidinyl]amino]- (CA INDEX NAME)




RN 882563-10-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882563-11-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methoxy- (CA INDEX NAME)




RN 882563-13-5 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)




RN 882563-14-6 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882563-15-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-16-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-methoxy- (CA INDEX NAME)




RN 882563-17-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 882563-18-0 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 882563-19-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-furanyl- (CA INDEX NAME)




RN 882563-20-4 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)




RN 882563-21-5 CAPLUS

CN Acetamide, N-[4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 882563-22-6 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl][4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 882563-23-7 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-gamma-oxo-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 882563-24-8 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 882563-25-9 CAPLUS

CN 2,4-Imidazolidinedione, 5-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882563-26-0 CAPLUS

CN Ethanone, 1-[4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-27-1 CAPLUS

CN Urea, N-[3-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)




RN 882563-28-2 CAPLUS

CN 2-Pyrrolidinone, 5-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 882563-29-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](5-methyl-2-pyrazinyl)- (CA INDEX NAME)




RN 882563-30-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)



RN 882563-31-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 882563-33-9 CAPLUS

CN Formic acid, compd. with 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(dimethylamino)ethyl]-1-piperidinecarboxamide (2:1) (CA INDEX NAME)

CM 1

CRN 882563-32-8


CMF C22 H28 Cl N7 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882563-34-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methoxy-N-methyl- (CA INDEX NAME)




RN 882563-35-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -ethyl-N-methyl- (CA INDEX NAME)



RN 882563-36-2 CAPLUS


CN 1H-Indole-1-acetamide, 3-[5-chloro-2-[[1-[2-(methylamino)-2-oxoethyl]-4-piperidinyl]amino]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)



RN 882563-37-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-3-methoxy-, ethyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882563-38-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882563-39-5 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[5-fluoro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882563-40-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-42-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 882563-43-1 CAPLUS

CN Carbamic acid, [[4-[[5-chloro-4-[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-pyrimidinyl]amino]-1-piperidinyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 882563-44-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882563-45-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(5-chloro-1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882563-46-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(6-chloro-1H-benzimidazol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882563-48-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1,2,4-triazolo[4,3-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-methyl-, acetate (1:?) (CA INDEX NAME)

CM 1

CRN 882563-47-5


CMF C18 H21 Cl N8 O



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 882563-49-7 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1H-imidazol-5-yl- (CA INDEX NAME)



RN 882563-50-0 CAPLUS


CN Acetamide, N-[(1S)-2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(1H-imidazol-5-ylmethyl)-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882563-51-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1H-imidazol-2-yl- (CA INDEX NAME)



RN 882563-52-2 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(2-pyridinyl)- (CA INDEX NAME)



RN 882563-53-3 CAPLUS

CN 2-Pyrrolidinone, 5-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882563-55-5 CAPLUS

CN 2-Imidazolidinone, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882563-57-7 CAPLUS


CN 2-Pyrrolidinone, 5-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882563-58-8 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](4-hydroxycyclohexyl)- (CA INDEX NAME)




RN 882563-59-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](4-methoxycyclohexyl)- (CA INDEX NAME)




RN 882563-61-3 CAPLUS

CN 2-Oxazolidinone, 4-[[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 882563-62-4 CAPLUS

CN Methanone, [4-[[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-thienyl]- (CA INDEX NAME)




RN 882563-63-5 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-thienyl- (CA INDEX NAME)




RN 882563-64-6 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-thiazolyl- (CA INDEX NAME)




RN 882563-65-7 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](2-methyl-4-thiazolyl)- (CA INDEX NAME)




RN 882563-66-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-4,5-dihydro- (CA INDEX NAME)




RN 882563-67-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]cyclopentyl- (CA INDEX NAME)




RN 882563-68-0 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]phenyl- (CA INDEX NAME)




RN 882563-69-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]cyclopropyl- (CA INDEX NAME)




RN 882563-70-4 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-pyridinyl- (CA INDEX NAME)




RN 882563-71-5 CAPLUS

CN 1-Propanone, 3-(1H-benzimidazol-2-yl)-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-72-6 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-73-7 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2,2-dimethyl- (CA INDEX NAME)




RN 882563-74-8 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-1,8-naphthyridin-2-yl- (CA INDEX NAME)




RN 882563-75-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny](2-methylphenyl)- (CA INDEX NAME)



RN 882563-76-0 CAPLUS


CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-γ-oxo- (CA INDEX NAME)



RN 882563-77-1 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-

piperidinyl]-4-cinnolinyl- (CA INDEX NAME)




RN 882563-78-2 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-methyl- (CA INDEX NAME)




RN 882563-79-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](3-methylphenyl)- (CA INDEX NAME)




RN 882563-81-7 CAPLUS

CN 2(1H)-Pyridinone, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-5,6-dimethyl- (CA INDEX NAME)




RN 882563-82-8 CAPLUS

CN Methanone, 1H-benzimidazol-6-yl[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-83-9 CAPLUS

CN Methanone, 1H-benzimidazol-2-yl[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882563-84-0 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 882563-85-1 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-phenyl- (CA INDEX NAME)




RN 882563-87-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-3-thienyl)- (CA INDEX NAME)



RN 882563-88-4 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](3-hydroxycyclopentyl)- (CA INDEX NAME)



RN 882563-89-5 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- β -methyl- γ -oxo-, (β R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882563-90-8 CAPLUS

CN 1-Butanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-4-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 882563-92-0 CAPLUS


CN Formic acid, compd. with [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl][(2S)-4-hydroxy-2-pyrrolidinyl]methanone (1:1) (CA INDEX NAME)

CM 1

CRN 882563-91-9

CMF C22 H25 Cl N6 O2


Absolute stereochemistry.



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882563-94-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-ethyl- (CA INDEX NAME)




RN 882563-95-3 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl][1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 882563-96-4 CAPLUS
 CN 1-Piperidineacetamide, 4-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl- (CA INDEX NAME)




RN 882564-00-3 CAPLUS
 CN Methanone, [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 882564-01-4 CAPLUS
 CN 2-Pyrrolidinone, 5-[[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]carbonyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 882564-03-6 CAPLUS
 CN Acetamide, N-[2-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-2-oxoethyl]-, acetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 882564-02-5
 CMF C20 H23 N7 O2



CM 2
 CRN 64-19-7
 CMF C2 H4 O2




RN 882564-04-7 CAPLUS
 CN Methanone, [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 882564-06-9 CAPLUS

CN Acetamide, N-[2-[4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 882564-07-0 CAPLUS

CN Methanone, [4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 882564-08-1 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(2-pyridinylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-10-5 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-pyridinylmethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-11-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-12-7 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-13-8 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-14-9 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882564-15-0 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-16-1 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-imidazo[1,2-a]pyridin-3-yl-N-[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 882564-17-2 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-α-oxo-, ethyl ester (CA INDEX NAME)




RN 882564-18-3 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-α-oxo-, methyl ester (CA INDEX NAME)




RN 882564-20-7 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- α -oxo- (CA INDEX NAME)




RN 882564-21-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- α -oxo- (CA INDEX NAME)




RN 882564-22-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 882564-23-0 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-[(4-methyl-1-piperazinyl)carbonyl]-4-piperidiny]- (CA INDEX NAME)




RN 882564-24-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 882564-25-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)




RN 882564-27-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-, compd. with 4-nitrophenol (1:1) (CA INDEX NAME)

CM 1

CRN 882564-26-3


CMF C24 H30 Cl N7 O3 S



CM 2


CRN 100-02-7

CMF C6 H5 N O3




RN 882564-29-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-4-piperidinyl- (CA INDEX NAME)



RN 882564-30-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-3-piperidinyl- (CA INDEX NAME)




RN 882564-32-1 CAPLUS

CN Formic acid, compd. with N-ethyl-4-[[4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 882564-31-0

CMF C20 H24 N6 O



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 882564-33-2 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-morpholinyl)- (CA INDEX NAME)



RN 882564-34-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-methyl-1-piperazinyl)-, hydrochloride (1:?) (CA INDEX NAME)

NAME)



●x HCl


RN 882564-36-5 CAPLUS

CN Formic acid, compd. with 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]-2-(dimethylamino)ethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-35-4

CMF C21 H25 Cl N6 O



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882564-38-7 CAPLUS

CN Formic acid, compd. with 2-amino-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]ethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-37-6


CMF C19 H21 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882564-41-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(3-pyridinylamino)- (CA INDEX NAME)




RN 882564-42-3 CAPLUS

CN Urea, N'-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N,N-dimethyl- (CA INDEX NAME)




RN 882564-43-4 CAPLUS

CN 4-Morpholinecarboxamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 882564-44-5 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidyl]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 882564-45-6 CAPLUS

CN Acetamide, N-[(3R)-1-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidyl]-2-oxoethyl]-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 882564-46-7 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-

piperidinyl]-2-[(4-hydroxycyclohexyl)amino]- (CA INDEX NAME)




RN 882564-47-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[cyclohexyl(2-hydroxyethyl)amino]- (CA INDEX NAME)




RN 882564-48-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxypropyl)amino]- (CA INDEX NAME)




RN 882564-49-0 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[3-(hydroxymethyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 882564-50-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)cyclopentyl]amino]- (CA INDEX NAME)




RN 882564-51-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(3-hydroxy-1-pyrrolidinyl)- (CA INDEX NAME)




RN 882564-52-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(4-hydroxybutyl)amino]- (CA INDEX NAME)




RN 882564-53-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-1-methylethyl)amino]- (CA INDEX NAME)




RN 882564-54-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)




RN 882564-55-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)propyl]amino]- (CA INDEX NAME)




RN 882564-56-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-1,1-dimethylethyl)amino]- (CA INDEX NAME)




RN 882564-57-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)-2-methylpropyl]amino]- (CA INDEX NAME)




RN 882564-58-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-1-phenylethyl)amino]- (CA INDEX NAME)




RN 882564-59-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(2-hydroxyethyl)amino]- (CA INDEX NAME)




RN 882564-60-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(1-hydroxycyclohexyl)methyl]amino]- (CA INDEX NAME)




RN 882564-62-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3-hydroxypropyl)amino]- (CA INDEX NAME)




RN 882564-63-8 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[2-(2-hydroxyethyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 882564-64-9 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[4-(2-hydroxyethyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 882564-65-0 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[(4-hydroxy-1-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 882564-66-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882564-67-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxybutyl)amino]- (CA INDEX NAME)



RN 882564-68-3 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3-hydroxy-2,2-dimethylpropyl)amino]- (CA INDEX NAME)



RN 882564-69-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882564-70-7 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[[3R]-3-

hydroxy-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 882564-71-8 CAPLUS


CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3R)-3-hydroxy-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882564-72-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-(1H-indol-3-yl)ethyl]amino]- (CA INDEX NAME)




RN 882564-73-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(1,3-dimethylbutyl)amino]- (CA INDEX NAME)




RN 882564-74-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(4-pyrimidinylamino)- (CA INDEX NAME)




RN 882564-75-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 882564-76-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)




RN 882564-77-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N,N-diethyl- (CA INDEX NAME)




RN 882564-78-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-methyl-2-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 882564-79-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[methyl[(1-methyl-1H-imidazol-2-yl)methyl]amino]- (CA INDEX NAME)




RN 882564-80-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]- (CA INDEX NAME)




RN 882564-81-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-(1-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)




RN 882564-82-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)




RN 882564-83-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(2-thiazolylamino)- (CA INDEX NAME)



RN 882564-84-3 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methanimino)- (CA INDEX NAME)




RN 882564-86-5 CAPLUS

CN Formic acid, compd. with 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methanimino)-2-phenylethanone (1:1) (CA INDEX NAME)

CM 1

CRN 882564-85-4


CMF C26 H27 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882564-87-6 CAPLUS

CN Carbamic acid, [2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 882564-88-7 CAPLUS


CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N-methyl- (CA INDEX NAME)



RN 882564-89-8 CAPLUS


CN 2H-Pyran-4-carboxamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-

pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]tetrahydro- (CA INDEX NAME)




RN 882564-90-1 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(1,2,4-oxadiazol-3-ylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 882564-91-2 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(3-pyridinylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 882564-93-4 CAPLUS


CN Formic acid, compd. with 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyridinylmethyl)-4-piperidinyl]-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 882564-92-3

CMF C23 H23 Cl N6

10/552,317



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882564-95-6 CAPLUS

CN Formic acid, compd. with 5-chloro-4-(1H-indol-3-yl)-N-[1-(4-pyridinylmethyl)-4-piperidinyl]-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 882564-94-5

CMF C23 H23 Cl N6



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 882564-97-8 CAPLUS

CN Formic acid, compd. with 5-chloro-4-(1H-indol-3-yl)-N-[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 882564-96-7


CMF C22 H23 Cl N6 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882564-98-9 CAPLUS

CN 2-Propanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 882564-99-0 CAPLUS

CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 882565-01-7 CAPLUS


CN 1-Piperidineacetic acid, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/552,317

CM 1

CRN 882565-00-6


CMF C19 H20 Cl N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 882565-02-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(2-fluorophenyl)- (CA INDEX NAME)




RN 882565-03-9 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)




RN 882565-04-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-4-pyrimidinyl- (CA INDEX NAME)




RN 882565-05-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-3-pyridinyl- (CA INDEX NAME)




RN 882565-06-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 882565-07-3 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 882565-08-4 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 882565-09-5 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 882565-10-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-methyl-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 882565-11-9 CAPLUS

CN Ethanone, 2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 882565-12-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 882565-13-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
N-2-thiazolyl- (CA INDEX NAME)




RN 882565-15-3 CAPLUS

CN Formic acid, compd. with 4-[(5-chloro-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-methyl-1-piperidineacetamide (1:1) (CA INDEX NAME)

CM 1

CRN 882565-14-2

CMF C19 H22 Cl N7 O



CM 2


CRN 64-18-6

CMF C H2 O2


O=CH-OH

RN 882565-16-4 CAPLUS


CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N, α -dimethyl- (CA INDEX NAME)



RN 882565-20-0 CAPLUS


CN 1-Piperidineacetonitrile, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -(phenylmethyl)- (CA INDEX NAME)

RN 882565-21-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -(tetrahydro-3-furanyl)-, hydrochloride (1:2) (CA INDEX NAME)


● 2 HCl

RN 882565-22-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -4-piperidinyl- (CA INDEX NAME)


RN 882565-23-3 CAPLUS

CN 2(3H)-Furanone, 3-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]dihydro- (CA INDEX NAME)




RN 882565-24-4 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(5-nitro-2-thiazolyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882565-25-5 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882565-26-6 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882565-27-7 CAPLUS

CN 2-Pyrimidinamine, N-[1-(5-amino-2-pyridinyl)-4-piperidinyl]-5-chloro-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 882565-28-8 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882565-29-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(2-pyrazinyl)-4-piperidinyl]- (CA INDEX NAME)



RN 882565-30-2 CAPLUS


CN 1-Piperidineacetamide, 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 882565-31-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-32-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(6-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882565-34-6 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methyl-2-pyrimidinyl)amino]- (CA INDEX NAME)



RN 882565-35-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-pyrrolo[3,2-c]pyridin-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

10/552,317



RN 882565-36-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(5-chloro-4-imidazo[1,2-a]pyrimidin-3-yl)-2-pyrimidinyl]amino-N-ethyl- (CA INDEX NAME)




RN 882565-42-6 CAPLUS

CN Formic acid, compd. with N-ethyl-4-[[4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-1-piperidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 882565-41-5

CMF C20 H24 N6 O



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 882565-44-8 CAPLUS


CN Formic acid, compd. with 4-[[4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-N-

methyl-1-piperidineacetamide (1:1) (CA INDEX NAME)

CM 1

CRN 882565-43-7


CMF C20 H24 N6 O



CM 2


CRN 64-18-6

CMF C H2 O2



RN 882565-45-9 CAPLUS

CN Methanone, [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 882565-46-0 CAPLUS

CN Formic acid, compd. with [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](4-methyl-1-piperazinyl)methanone (1:1) (CA INDEX NAME)

CM 1

CRN 882565-45-9


CMF C22 H28 N8 O



CM 2


CRN 64-18-6

CMF C H2 O2




RN 882565-47-1 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 882565-48-2 CAPLUS

CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- β -methyl- γ -oxo- (CA INDEX NAME)




RN 882565-49-3 CAPLUS

CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N, β -dimethyl- γ -oxo- (CA INDEX NAME)




RN 882565-50-6 CAPLUS

CN 1-Piperidinebutanamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N,N, β -trimethyl- γ -oxo- (CA INDEX NAME)


RN 882565-51-7 CAPLUS

CN 1-Butanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 882565-52-8 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]tetrahydro-N-methyl- (CA INDEX NAME)




RN 882565-53-9 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](1-methyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 882565-54-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- α -(phenylmethyl)- (CA INDEX NAME)




RN 882565-55-1 CAPLUS

CN Urea, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-N,N',N'-trimethyl- (CA INDEX NAME)




RN 882565-56-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 882565-57-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 882565-58-4 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]- (CA INDEX NAME)




RN 882565-59-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)




RN 882565-60-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-(1-methyl-3-piperidinyl)- (CA INDEX NAME)



RN 882565-61-9 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 882565-62-0 CAPLUS


CN Ethanone, 1-[(2S)-2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-63-1 CAPLUS

CN Ethanone, 1-(1-azetidiny)-2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882565-64-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(tetrahydro-3-furanyl)amino]- (CA INDEX NAME)




RN 882565-65-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](3-hydroxy-1-pyrrolidinyl)- (CA INDEX NAME)



RN 882565-66-4 CAPLUS

CN 2(3H)-Furanone, 3-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]dihydro- (CA INDEX NAME)



IT 882565-67-5P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(tetrahydro-2H-pyran-4-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882565-68-6P, tert-Butyl 3-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]azetidine-1-carboxylate
 882565-69-7P, N-[1-[(Azetidin-3-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-70-0P, tert-Butyl 3-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]pyrrolidine-1-carboxylate
 882565-71-1P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(isopropylamino)acetyl]piperidin-4-yl]pyrimidin-2-amine
 882565-72-2P, tert-Butyl 3-[[2-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]azetidine-1-carboxylate 882565-73-3P,
 4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(tetrahydro-2H-pyran-4-yl)piperidine-1-carboxamide 882565-74-4P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(pyrrolidin-3-yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882565-75-5P 882565-76-6P,
 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]butanoic acid 882565-77-7P,
 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl](propyl)amino]ethanol 882565-78-8P,
 N-[2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]ethyl]acetamide 882565-79-9P,
 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]-1-phenylethanol 882565-80-2P,
 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]cyclohexanol 882565-81-3P,
 4-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl](ethyl)amino]butan-1-ol 882565-82-4P,
 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl](2-methylbutyl)amino]ethanol 882565-83-5P,
 4-[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperazin-2-one 882565-84-6P 882565-85-7P,
 4-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]butan-2-ol 882565-86-8P,
 2-[(tert-Butyl)[2-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]ethanol 882565-87-9P,
 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl](methyl)amino]acetamide 882565-88-0P,
 6-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]hexan-1-ol 882565-89-1P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[[(5-methyl-4H-1,2,4-triazol-3-yl)methyl]amino]acetyl]piperidin-4-yl]pyrimidin-2-amine
 882565-90-4P, 5-Chloro-N-[1-[[[(3,5-dimethyl-1H-pyrazol-4-yl)methyl](methyl)amino]acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-91-5P, [1-[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]pyrrolidin-2-yl]methanol 882565-92-6P,
 2-[[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]amino]-3-methylpentan-1-ol 882565-93-7P,
 1-[2-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]piperidin-3-ol 882565-94-8P,
 N-[1-[(1-Acetylpyrrolidin-3-yl)carbonyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine 882565-95-9P 882565-96-0P
 , 5-Chloro-4-(1H-indol-3-yl)-N-[1-[[methyl(tetrahydro-2H-pyran-4-yl)amino]acetyl]piperidin-4-yl]pyrimidin-2-amine 882565-97-1P,
 N-[1-[(Azetidin-3-yl)amino]acetyl]piperidin-4-yl]-5-chloro-4-(1H-indol-3-

yl)pyrimidin-2-amine 882565-98-2P,
 1-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]azetidin-3-ol 882565-99-3P,
 2-[3-[[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]azetidin-1-yl]-N-methylacetamide 882566-02-1P
 882566-03-2P, N-(Azetidin-3-yl)-4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carboxamide 882566-04-3P,
 tert-Butyl 3-[[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonyl]amino]piperidine-1-carboxylate
 882566-05-4P, 5-Chloro-4-(1H-indol-3-yl)-N-[1-[(1H-tetrazol-5-yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-06-5P,
 5-Chloro-4-(1H-indol-3-yl)-N-[1-(1-oxidopyridin-2-yl)piperidin-4-yl]pyrimidin-2-amine 882566-07-6P,
 5-Chloro-N-[1-[(5,5-dimethylmorpholin-2-yl)acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882566-08-7P,
 5-Chloro-N-[1-[(1H-imidazol-5-yl)acetyl]piperidin-4-yl]-4-(1H-indol-3-yl)pyrimidin-2-amine 882566-18-9P,
 5-Chloro-4-(1-methyl-1H-indol-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine 882566-19-0P, 2-[4-[[5-Chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-20-3P,
 4-[[5-Chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-21-4P,
 5-Chloro-N-[1-[(dimethylamino)acetyl]piperidin-4-yl]-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine 882566-22-5P,
 4-[[5-Chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-(piperidin-4-yl)piperidine-1-carboxamide 882566-23-6P,
 4-[[5-Chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-24-7P 882566-25-8P
 , N-[2-[4-[[5-Chloro-4-(7-cyano-1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-oxoethyl]acetamide 882566-26-9P,
 5-Chloro-4-(1H-indol-1-yl)-N-[1-[(methylamino)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-27-0P,
 5-Chloro-N-[1-[(dimethylamino)acetyl]piperidin-4-yl]-4-(1H-indol-1-yl)pyrimidin-2-amine 882566-28-1P, tert-Butyl
 4-[[4-(4-cyano-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-29-2P, 2-[4-[[5-Chloro-4-(4-cyano-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-30-5P,
 2-[4-[[4-(4-Cyano-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-31-6P 882566-32-7P,
 2-[4-[[5-Chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-33-8P,
 tert-Butyl 4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-34-9P, tert-Butyl
 4-[[5-chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-35-0P,
 N-Methyl-2-[4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]acetamide 882566-36-1P, tert-Butyl
 4-[[4-(4-amino-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-37-2P, tert-Butyl 4-[[4-(4-amino-1H-indol-1-yl)-5-chloropyrimidin-2-yl]amino]piperidine-1-carboxylate 882566-38-3P
 , 4-[[4-(4-Amino-1H-indol-1-yl)-5-chloropyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-39-4P,
 4-[[4-(4-Amino-1H-indol-1-yl)pyrimidin-2-yl]amino]-N-ethylpiperidine-1-carboxamide 882566-40-7P,
 2-[4-[[4-(4-Amino-1H-indol-1-yl)-5-chloropyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide 882566-41-8P,
 2-[4-[[4-(4-Amino-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-

methylacetamide 882566-42-9P, tert-Butyl
 4-[[4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-
 carboxylate 882566-43-0P,
 4-[[5-Chloro-4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]-N-
 ethylpiperidine-1-carboxamide 882566-44-1P,
 2-[4-[[5-Chloro-4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-
 1-yl]-N-methylacetamide 882566-45-2P,
 N-Ethyl-4-[[4-(4-methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidine-1-
 carboxamide 882566-46-3P,
 2-[4-[[4-(4-Methoxy-1H-indol-1-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-
 methylacetamide 882566-47-4P, tert-Butyl
 4-[[5-chloro-4-[4-(dimethylamino)-1H-indol-1-yl]pyrimidin-2-
 yl]amino]piperidine-1-carboxylate 882566-48-5P, tert-Butyl
 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]pyrimidin-2-yl]amino]piperidine-1-
 carboxylate 882566-49-6P,
 4-[[4-[4-(Dimethylamino)-1H-indol-1-yl]pyrimidin-2-yl]amino]-N-
 ethylpiperidine-1-carboxamide 882566-50-9P,
 2-[4-[[4-(Dimethylamino)-1H-indol-1-yl]pyrimidin-2-yl]amino]piperidin-1-
 yl]-N-methylacetamide 882566-51-0P, tert-Butyl
 4-[[4-[4-(aminocarbonyl)-1H-indol-1-yl]pyrimidin-2-yl]amino]piperidine-1-
 carboxylate 882566-52-1P,
 1-[2-[[1-[2-(Methylamino)-2-oxoethyl]piperidin-4-yl]amino]pyrimidin-4-yl]-
 1H-indole-4-carboxamide 882566-53-2P,
 N-Methyl-2-[4-[[4-(1H-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-
 yl]amino]piperidin-1-yl]acetamide 882566-57-6P,
 N-[1-(3-Furanylcarbonyl)piperidin-4-yl]-4-(imidazo[1,2-a]pyridin-3-
 yl)pyrimidin-2-amine 882566-58-7P,
 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-
 N-methyl-2-phenylacetamide 882566-59-8P,
 6-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-
 yl]nicotinonitrile 882566-60-1P,
 4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-N-
 methoxypiperidine-1-carboxamide 882566-61-2P
 882566-62-3P, 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(morpholin-4-
 yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-63-4P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(1-methyl-1H-imidazol-4-
 yl)carbonyl]piperidin-4-yl]pyrimidin-2-amine 882566-64-5P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(3-methylisoxazol-5-
 yl)acetyl]piperidin-4-yl]pyrimidin-2-amine 882566-65-6P,
 4-(Imidazo[1,2-a]pyridin-3-yl)-N-[1-(3-methylbutanoyl)piperidin-4-
 yl]pyrimidin-2-amine 882566-66-7P,
 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-
 2-(piperidin-4-yl)acetamide 882566-67-8P,
 N-[1-[(Dimethylamino)acetyl]piperidin-4-yl]-4-(imidazo[1,2-a]pyridin-3-
 yl)pyrimidin-2-amine 882566-68-9P,
 4-(6-Bromoimidazo[1,2-a]pyridin-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine
 882566-69-0P, 2-[4-[[4-(6-Bromoimidazo[1,2-a]pyridin-3-
 yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide
 882566-70-3P, 2-[4-[[4-(8-Bromoimidazo[1,2-a]pyridin-2-
 yl)pyrimidin-2-yl]amino]piperidin-1-yl]-N-methylacetamide
 882566-71-4P, N-Ethyl-4-[[4-(imidazo[1,2-a]pyridin-3-yl)-5-
 methoxypyrimidin-2-yl]amino]piperidine-1-carboxamide 882566-72-5P
 , 2-[4-[[4-(Imidazo[1,2-a]pyridin-3-yl)-5-methoxypyrimidin-2-
 yl]amino]piperidin-1-yl]-N-methylacetamide 882566-85-0P
 882566-91-8P 882566-92-9P 882566-98-5P
 882566-99-6P 882567-00-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as JNK inhibitors)


RN 882565-67-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 882565-68-6 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882565-69-7 CAPLUS


CN Methanone, 3-azetidiny1[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 882565-70-0 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-

pyrimidinyl]amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882565-71-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(1-methylethyl)amino]- (CA INDEX NAME)



RN 882565-72-2 CAPLUS


CN 1-Azetidinecarboxylic acid, 3-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 882565-73-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-

pyrimidinyl]amino]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 882565-74-4 CAPLUS


CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-3-pyrrolidinyl- (CA INDEX NAME)



RN 882565-75-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-76-6 CAPLUS

CN Butanoic acid, 2-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]- (CA INDEX NAME)




RN 882565-77-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxyethyl)propylamino]- (CA INDEX NAME)




RN 882565-78-8 CAPLUS

CN Acetamide, N-[2-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]amino]ethyl]- (CA INDEX NAME)




RN 882565-79-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxy-2-phenylethyl)amino]- (CA INDEX NAME)




RN 882565-80-2 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxycyclohexyl)amino]- (CA INDEX NAME)




RN 882565-81-3 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[ethyl(4-hydroxybutyl)amino]- (CA INDEX NAME)




RN 882565-82-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(2-hydroxyethyl)(2-methylbutyl)amino]- (CA INDEX NAME)



RN 882565-83-5 CAPLUS


CN 2-Piperazinone, 4-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 882565-84-6 CAPLUS


CN L-Serine, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-85-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(3-hydroxybutyl)amino]- (CA INDEX NAME)




RN 882565-86-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(1,1-dimethylethyl)(2-hydroxyethyl)amino]- (CA INDEX NAME)




RN 882565-87-9 CAPLUS

CN Acetamide, 2-[[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-oxoethyl]methylamino]- (CA INDEX NAME)




RN 882565-88-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[(6-hydroxyhexyl)amino]- (CA INDEX NAME)




RN 882565-89-1 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[3-methyl-1H-1,2,4-triazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 882565-90-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[3,5-dimethyl-1H-pyrazol-4-yl)methyl]methylamino]- (CA INDEX NAME)




RN 882565-91-5 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 882565-92-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[[1-(hydroxymethyl)-2-methylbutyl]amino]- (CA INDEX NAME)




RN 882565-93-7 CAPLUS

CN 4-Piperidinamine, N-[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]-1-[(3-hydroxy-1-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 882565-94-8 CAPLUS


CN Ethanone, 1-[3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 882565-95-9 CAPLUS


CN Ethanone, 1-[(2S)-2-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-4-hydroxy-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882565-96-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 882565-97-1 CAPLUS

CN Ethanone, 2-(3-azetidinylamino)-1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882565-98-2 CAPLUS

CN Methanone, [4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl](3-hydroxy-1-azetidiny)- (CA INDEX NAME)



RN 882565-99-3 CAPLUS

CN 1-Azetidineacetamide, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl- (CA INDEX NAME)




RN 882566-02-1 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl-, (+)- (CA INDEX NAME)


NAME)

Rotation (+).




RN 882566-03-2 CAPLUS

CN 1-Piperidinecarboxamide, N-3-azetidiny-4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-04-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-05-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 882566-06-5 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[1-(1-oxido-2-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 882566-07-6 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(5,5-dimethyl-2-morpholinyl)- (CA INDEX NAME)




RN 882566-08-7 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(1H-imidazol-5-yl)- (CA INDEX NAME)




RN 882566-18-9 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-(1-methyl-1H-indol-3-yl)-N-4-piperidinyl-
(CA INDEX NAME)




RN 882566-19-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-20-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-21-4 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 882566-22-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-4-piperidinyl- (CA INDEX NAME)



RN 882566-23-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 882566-24-7 CAPLUS


CN 1H-Indole-7-carbonitrile, 3-[5-chloro-2-[[1-[(2R)-5-oxo-2-pyrrolidinyl]carbonyl]-4-piperidyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 882566-25-8 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(7-cyano-1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidyl]-2-oxoethyl]- (CA INDEX NAME)




RN 882566-26-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(methylamino)- (CA INDEX NAME)




RN 882566-27-0 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 882566-28-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-cyano-1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-29-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(4-cyano-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-30-5 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-cyano-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-31-6 CAPLUS

CN 1H-Indole-4-carbonitrile, 1-[2-[[1-[2-(dimethylamino)acetyl]-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 882566-32-7 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-33-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-34-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-35-0 CAPLUS

CN 1-Piperidineacetamide, N-methyl-4-[[4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-36-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-amino-1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-37-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-amino-1H-indol-1-yl)-5-chloro-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-38-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(4-amino-1H-indol-1-yl)-5-chloro-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-39-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-(4-amino-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-40-7 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-amino-1H-indol-1-yl)-5-chloro-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-41-8 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-amino-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-42-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-43-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[5-chloro-4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-44-1 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-45-2 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-46-3 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(4-methoxy-1H-indol-1-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-47-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-48-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-49-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 882566-50-9 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-[4-(dimethylamino)-1H-indol-1-yl]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-51-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(aminocarbonyl)-1H-indol-1-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882566-52-1 CAPLUS

CN 1H-Indole-4-carboxamide, 1-[2-[[1-[2-(methylamino)-2-oxoethyl]-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 882566-53-2 CAPLUS

CN 1-Piperidineacetamide, N-methyl-4-[[4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 882566-57-6 CAPLUS

CN Methanone, 3-furanyl[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 882566-58-7 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-methyl-α-phenyl- (CA INDEX NAME)




RN 882566-59-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 882566-60-1 CAPLUS


CN 1-Piperidinecarboxamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-methoxy- (CA INDEX NAME)



RN 882566-61-2 CAPLUS


CN 2-Oxazolidinone, 4-[[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]carbonyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 882566-62-3 CAPLUS

CN Ethanone, 1-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-2-(4-morpholinyl)- (CA INDEX NAME)




RN 882566-63-4 CAPLUS

CN Methanone, [4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl](1-methyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 882566-64-5 CAPLUS

CN Ethanone, 1-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-2-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)





RN 882566-65-6 CAPLUS

CN 1-Butanone, 1-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-1-piperidinyl]-3-methyl- (CA INDEX NAME)




RN 882566-66-7 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- α -4-piperidinyl- (CA INDEX NAME)




RN 882566-67-8 CAPLUS

CN Ethanone, 2-(dimethylamino)-1-[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-piperidiny]- (CA INDEX NAME)




RN 882566-68-9 CAPLUS

CN 2-Pyrimidinamine, 4-(6-bromoimidazo[1,2-a]pyridin-3-yl)-N-4-piperidiny]- (CA INDEX NAME)




RN 882566-69-0 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(6-bromoimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-70-3 CAPLUS

CN 1-Piperidineacetamide, 4-[[4-(8-bromoimidazo[1,2-a]pyridin-2-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 882566-71-4 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methoxy-2-pyrimidinyl)amino]- (CA INDEX NAME)




RN 882566-72-5 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methoxy-2-pyrimidinyl)amino]-N-methyl- (CA INDEX NAME)



RN 882566-85-0 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[(4-pyrazolo[1,5-a]pyridin-3-yl-2-pyrimidinyl)amino]- (CA INDEX NAME)



RN 882566-91-8 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-1,1-dioxido-3-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882566-92-9 CAPLUS

CN Ethanone, 1-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-2-(tetrahydro-1,1-dioxido-3-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 882566-98-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]carbonyl]-N-methyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 882566-99-6 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
α-4-piperidinyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882567-00-2 CAPLUS

CN 1-Piperidineacetamide, 4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-
α-4-piperidinyl-, (-)- (CA INDEX NAME)

Rotation (-).



IT 882566-89-4P 882566-90-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrimidines as JNK inhibitors)

RN 882566-89-4 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 882566-90-7 CAPLUS

CN Acetamide, N-[2-[4-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 34 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:74802 CAPLUS
 DN 144:171004
 TI Preparation of 4-(2- or 3-furyl)pyrimidine derivatives, and pharmaceutical compositions and antitumor agents containing them
 IN Miyazaki, Isao; Murakami, Koji
 PA Taiho Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | JP 2006022073 | A | 20060126 | JP 2004-203695 | 20040709 |
| PRAI | JP 2004-203695 | | 20040709 | | |
| OS | MARPAT 144:171004 | | | | |

AB The derivs. I [X, Y = H, halo, lower alkyl, lower alkoxy, (un)substituted aryl, heteroaryl, NO₂, cyano, trihalomethyl, NR₁R₂, CO₂R₃, S(O)_nR₄, NHCOR₅, CONR₆R₇, COR₈, CH₂OR₉, CH:CHR₁₀, CH:CHCO₂R₁₁, CH:CHCONHR₁₂ [R₁-R₄, R₆, R₇, R₉ = H, lower alkyl, (un)substituted aryl, heteroaryl, (un)substituted aralkyl, heteroaralkyl; NR₆R₇ may be 4-7-membered heteroalicyclic; R₅ = lower alkyl, (un)substituted aryl; R₈ = H, lower alkyl; R₁₀, R₁₂ = (un)substituted aryl, heteroaryl; R₁₁ = H, lower alkyl; n = 0-2]; A = NZN (Z = C₂-10 linear, branched, or cyclic alkylene, wherein 1 or 2 N atoms may form 4-7-membered N-containing heteroalicyclic together with Z); B = CO, SO₂; C = (un)substituted aryl, heteroaryl, (α-lower alkyl)benzyl] or their salts are claimed. Also claimed are pharmaceutical compns. and antitumor agents containing I or their salts. Thus, IC₅₀ of 4-(2-furyl)-2-[1-[4-(2-methoxy-4-methylbenzenesulfonyl)piperazino]]pyrimidine (II), prepared from 4-(2-furyl)-2-piperazinopyrimidine and 2-methoxy-4-methylbenzenesulfonyl chloride, against proliferation of human hepatoma JHH-7 cells was 0.23 μM, vs. 0.99 μM of BAY 43-9006. IC₅₀ of I on proliferation of normal hepatic cell was ≥30 μM, vs. 3.46 μM of BAY 43-9006.

IT 874114-13-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of furylpyrimidine derivs. as antitumor agents)

RN 874114-13-3 CAPLUS
 CN 2-Pyrimidinamine, N-[1-[(2,4-difluorophenyl)sulfonyl]-4-piperidinyl]-4-(2-furanyl)- (CA INDEX NAME)




L17 ANSWER 35 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1314210 CAPLUS
 DN 144:51578
 TI Preparation of mercaptoimidazoles as CCR2 receptor antagonists for the treatment of inflammatory disease
 IN Boeckx, Gustaaf Maria; Van Lommen, Guy Rosalia Eugeen; Doyon, Julien
 Georges Pierre-Olivier; Coesemans, Erwin
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005118574 | A1 | 20051215 | WO 2005-EP52373 | 20050524 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005250157 | A1 | 20051215 | AU 2005-250157 | 20050524 |
| | CA 2565280 | A1 | 20051215 | CA 2005-2565280 | 20050524 |
| | EP 1756089 | A1 | 20070228 | EP 2005-749653 | 20050524 |
| | EP 1756089 | B1 | 20081022 | | |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| | CN 1956976 | A | 20070502 | CN 2005-80016545 | 20050524 |
| | JP 2008500311 | T | 20080110 | JP 2007-513923 | 20050524 |
| | AT 411989 | T | 20081115 | AT 2005-749653 | 20050524 |
| | US 20070244138 | A1 | 20071018 | US 2006-569321 | 20061117 |
| | IN 2006DN06982 | A | 20070713 | IN 2006-DN6982 | 20061122 |
| PRAI | WO 2004-EP50935 | A | 20040526 | | |
| | WO 2005-EP52373 | W | 20050524 | | |

OS CASREACT 144:51578; MARPAT 144:51578

AB The invention relates to compds. I, N-oxides, pharmaceutically acceptable addition salts, quaternary amines, polymorphic forms or stereochem. isomeric forms thereof, wherein R1 = H, (un)substituted alkyl, cycloalkyl or (hetero)aryl; R2 independently = halo, alkyl(oxy/thio), etc.; R3 = H, cyano, etc.; R4 = H or alkyl; n = 1-5; Z = certain cycle ring. The invention also relates to processes for preparing I, their use as CCR2 antagonists and pharmaceutical compns. comprising them. For instance, II was synthesized in multiple steps from 1-(3,4-dichlorophenyl)-1-propanone. The CCR2 antagonistic activities of I were demonstrated by three assays, inhibition of MCP-1-induced Ca-flux in human THP-1 cells, 125I-MCP-1 binding assay and chemotactic response of cells in the presence of MCP-1. Therefore, I and their pharmaceutical compns. are useful for preventing or treating diseases mediated through activation of the CCR2 receptor, such as inflammation.

IT 871343-86-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of mercaptoimidazoles as CCR2 receptor antagonists for the
treatment of inflammatory disease)
RN 871343-86-1 CAPLUS
CN 2H-Imidazole-2-thione, 1-[1-(3,4-dichlorophenyl)propyl]-1,3-dihydro-5-[2-
(4-piperidinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 36 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1289687 CAPLUS

DN 144:51568

TI Preparation of substituted 2-quinolyl-oxazoles and their heterocyclic analogs useful as pde4 inhibitors

IN Kuang, Rongze; Blythin, David; Shih, Neng-Yang; Shue, Ho-Jane; Chen, Xiao; Cao, Jianhua; Gu, Danlin; Huang, Ying; Schwerdt, John H.; Ting, Pauline C.; Wong, Shing-Chun; Xiao, Li

PA Schering Corporation, USA

SO PCT Int. Appl., 233 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | WO 2005116009 | A1 | 20051208 | WO 2005-US17134 | 20050516 |
| | W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005247906 | A1 | 20051208 | AU 2005-247906 | 20050516 |
| | CA 2565599 | A1 | 20051208 | CA 2005-2565599 | 20050516 |
| | US 20060106062 | A1 | 20060518 | US 2005-130359 | 20050516 |
| | EP 1758883 | A1 | 20070307 | EP 2005-750076 | 20050516 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| | CN 1984901 | A | 20070620 | CN 2005-80023666 | 20050516 |
| | BR 2005011295 | A | 20071204 | BR 2005-11295 | 20050516 |
| | JP 2007537300 | T | 20071220 | JP 2007-513471 | 20050516 |
| | TW 286475 | B | 20070911 | TW 2005-94115924 | 20050517 |
| | MX 2006PA13414 | A | 20070123 | MX 2006-PA13414 | 20061117 |
| | KR 2007013306 | A | 20070130 | KR 2006-724186 | 20061117 |
| | IN 2006CN04254 | A | 20070629 | IN 2006-CN4254 | 20061117 |
| | NO 2006005830 | A | 20070216 | NO 2006-5830 | 20061215 |
| PRAI | US 2004-572266P | P | 20040518 | | |
| | WO 2005-US17134 | W | 20050516 | | |
| OS | CASREACT 144:51568; MARPAT 144:51568 | | | | |
| AB | Title compds. I [R1 = H, alkyl, cycloalkyl; R2, R3 and R5 independently = H or halo; R4 = H, halo, alkyl, etc.; A = substituted oxazolyl, imidazole, thiazole or pyrrole], and their pharmaceutically acceptable salts, are prepared and disclosed as pde4 inhibitors. Thus, e.g., II was prepared in a multistep synthesis from 2-trifluoromethyl-8-methoxyquinolin-5-yl carboxylic acid. In PDE4 assays, selected compds. possessed IC50 values ranging from 0.01-1.8 nM. Also claimed are pharmaceutical compns., the use of the compds. as PDE4 inhibitors, and combinations with other actives. | | | | |
| IT | 871009-86-8P | | | | |

10/552,317


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinolyloxazoles and their heterocyclic analogs useful as PDE4 inhibitors)

RN 871009-86-8 CAPLUS

CN Methanone, [5-[(1S)-1-aminoethyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinolinyl]-4-oxazolyl][4-[[4-(2,6-difluorophenyl)-2-pyrimidinyl]amino]-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 37 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1260610 CAPLUS

DN 144:22946

TI Preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases

IN Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Chaffee, Stuart C.; Tempest, Paul A.; Olivieri, Philip R.; Johnson, Rebecca E.; Albrecht, Brian K.; Patel, Vinod F.; Cee, Victor J.; Kim, Joseph L.; Bellon, Steven; Zhu, Xiaotian; Cheng, Yuan; Xi, Ning; Romero, Karina; Nguyen, Hanh Nho; Deak, Holly L.

PA Amgen Inc., USA

SO PCT Int. Appl., 540 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2005113494 | A2 | 20051201 | WO 2005-US16346 | 20050509 |
| | WO 2005113494 | A3 | 20060316 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2005245386 | A1 | 20051201 | AU 2005-245386 | 20050509 |
| | CA 2564355 | A1 | 20051201 | CA 2005-2564355 | 20050509 |
| | US 20060009453 | A1 | 20060112 | US 2005-126000 | 20050509 |
| | EP 1751136 | A2 | 20070214 | EP 2005-779977 | 20050509 |
| | R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | |
| | JP 2007536280 | T | 20071213 | JP 2007-511723 | 20050509 |
| | MX 2006PA12613 | A | 20070131 | MX 2006-PA12613 | 20061031 |
| PRAI | US 2004-569193P | P | 20040507 | | |
| | WO 2005-US16346 | W | 20050509 | | |

OS MARPAT 144:22946

AB The present invention relates to nitrogen-heteroaryl-containing compds. (shown as I; variables defined below; e.g.

4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin-2-yl]amino]-N-[3-[(tetrahydrofuran-2-yl)methoxy]-5-trifluoromethylphenyl]benzamide (shown as II)) and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compds. are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compns., including the compds., and methods of treating disease states related to the activity of protein kinases. For I: A is N or CR10; B is N or CR11; D is N or CR12; E is N or

CH; G is NR13, O, S, C(O), S(O), SO2, CR13R13 or CR13R14; H1 is N or CR5; H2 is N or CR6; H3 is N or CR7; H4 is N or CR5; H5 is N or CR9; R1 is H, halo, haloalkyl, NO2, CN, NR13R13, OR13, SR13 (CHR13)nR13, or R15; alternatively R1 taken together with R10 forms a partially or fully unsatd. 5- or 6-membered ring of C atoms optionally including 1-3 heteroatoms = O, N and S, and the ring (un)substituted; R2 is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; each of R3 and R4, independently, is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, preps. and/or characterization data for >1200 examples of I and intermediates are included. For example, II was prepared in 2 steps starting with condensation of


4-(2-chloropyridin-3-yl)pyrimidine (preparation given) with 3-amino-4-fluorobenzoic acid in Et3N-TFA to give 4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin-2-yl]amino]benzoic acid, which was condensed with [3-[(tetrahydrofuran-2-yl)methoxy]-5-trifluoromethylphenyl]amine using EDC and DMAP in DMF.

IT 870233-05-9P, N-[3-Methyl-4-[[3-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-3-(trifluoromethyl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases)

RN 870233-05-9 CAPLUS

CN Benzamide, N-[3-methyl-4-[[3-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



L17 ANSWER 38 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1193341 CAPLUS

DN 143:460148

TI Preparation of 4-[2-(cycloalkylamino)pyrimidin-4-yl]-3-phenylimidazolin-2-one derivatives as p38 MAP-kinase inhibitors for the treatment of inflammatory diseases

IN Kubo, Akira; Nakane, Tetsu; Nakajima, Tatsuo; Murakami, Takanori; Miyoshi, Hidetaka; Ogasawara, Akihito

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005105790 | A1 | 20051110 | WO 2005-JP8564 | 20050428 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005238390 | A1 | 20051110 | AU 2005-238390 | 20050428 |
| | CA 2563042 | A1 | 20051110 | CA 2005-2563042 | 20050428 |
| | EP 1740578 | A1 | 20070110 | EP 2005-738662 | 20050428 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| | BR 2005010335 | A | 20071023 | BR 2005-10335 | 20050428 |
| | JP 2007535476 | T | 20071206 | JP 2006-519531 | 20050428 |
| | NO 2006004175 | A | 20061213 | NO 2006-4175 | 20060915 |
| | CN 101146797 | A | 20080319 | CN 2005-80012938 | 20061024 |
| | US 20070185326 | A1 | 20070809 | US 2006-587498 | 20061026 |
| | MX 2006PA12512 | A | 20070208 | MX 2006-PA12512 | 20061027 |
| | KR 2006135965 | A | 20061229 | KR 2006-724928 | 20061127 |
| | KR 793479 | B1 | 20080114 | | |
| PRAI | JP 2004-133204 | A | 20040428 | | |
| | US 2004-566089P | P | 20040429 | | |
| | JP 2005-7832 | A | 20050114 | | |
| | WO 2005-JP8564 | W | 20050428 | | |

OS CASREACT 143:460148; MARPAT 143:460148

AB The invention provides novel heterocyclic compds. I [wherein: R1 is a halogen, nitro, alkyl, etc.; p is 1 or 2; A is 2-oxo-4-imidazolin-3,4-diyl, etc.; X is CH or N; Z is O, NR2; R2 is H, alkyl, etc.; B is cycloalkyl or monocyclic saturated heterocyclic group; Y is single bond, CO, SO2; and E is an aryl or heterocyclic group; or a pharmaceutically acceptable salt thereof], which are useful as p38 MAP kinase inhibitors. Approx. 135 compds. I were prepared, as well as some intermediates. For instance, reaction of sulfoxide II with the corresponding trans-isomeric cyclohexylamine derivative at 90° in dioxane for 5 days gave invention compound III, isolated as the

monohydrochloride. In an in-vivo test for inhibition of LPS-induced TNF- α production in rats, invention compound IV.HCl gave 100% inhibition at 5 mg/kg orally.


IT 1044974-04-0 1044974-05-1 1044974-06-2
 1044974-07-3 1044974-08-4 1044974-09-5
 1044974-10-8 1044974-11-9 1044974-12-0
 1044974-13-1 1044974-14-2 1044974-15-3
 1044974-16-4 1044975-15-6 1044975-16-7
 1044975-17-8 1044975-18-9 1044975-19-0
 1044975-20-3 1044975-21-4 1044975-22-5
 1044975-23-6 1044975-24-7 1044975-25-8
 1044975-26-9 1044975-27-0 1044975-28-1
 1044996-99-7 1044997-00-3 1044997-01-4
 1044997-02-5 1044997-03-6 1044997-04-7
 1044997-05-8 1044997-06-9 1044997-07-0
 1044997-08-1 1044997-09-2 1044997-10-5
 1044997-11-6 1044997-12-7 1044997-13-8
 1044997-14-9 1044997-15-0 1044997-16-1
 1044997-17-2 1044997-18-3 1044997-19-4
 1044997-20-7 1044997-21-8 1044998-19-7
 1044998-20-0 1044998-21-1 1044998-22-2
 1044998-23-3 1044998-24-4 1044998-25-5
 1048020-53-6 1048022-13-4

RL: PRPH (Prophetic)

(Preparation of 4-[2-(cycloalkylamino)pyrimidin-4-yl]-3-phenylimidazolin-2-one derivatives as p38 MAP-kinase inhibitors for the treatment of inflammatory diseases)


RN 1044974-04-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044974-05-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044974-06-2 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(1-pyrrolidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044974-07-3 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(4-morpholinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044974-08-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyridinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1044974-09-5 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrazinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044974-10-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

10/552,317




RN 1044974-11-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044974-12-0 CAPLUS
CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

10/552,317




RN 1044974-13-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-4-[2-[[1-(2-thiazolyl)-4-piperidiny]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1044974-14-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044974-15-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1-pyrrolidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044974-16-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(4-morpholinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-15-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyridinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-16-7 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrazinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1044975-17-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044975-18-9 CAPLUS
CN 2H-Imidazol-2-one, 4-[2-[[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-19-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1044975-20-3 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-4-[2-[[1-(2-thiazolyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1044975-21-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


10/552,317



RN 1044975-22-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044975-23-6 CAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(4-morpholinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044975-24-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrazinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044975-25-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyridinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044975-26-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044975-27-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044975-28-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044996-99-7 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(4-ethyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-
(CA INDEX NAME)




RN 1044997-00-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044997-01-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-([1,1'-bipiperidin]-4-ylamino)-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-02-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrimidinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-03-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-04-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-[(1-methyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-05-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyridinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-06-9 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-pyrazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-07-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-oxazolyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-08-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(4-methyl-1-piperazinyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-09-2 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(4-ethyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-10-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(2-oxo-1-pyrrolidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-11-6 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-([1,1'-bipiperidin]-4-ylamino)-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1044997-12-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrimidinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-13-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-14-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-15-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyridinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-16-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-pyrazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-17-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-oxazolyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-18-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(4-methyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-19-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(4-ethyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-20-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(2-oxo-1-pyrrolidinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044997-21-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044998-19-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrimidinylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044998-20-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044998-21-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyridinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1044998-22-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044998-23-3 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(2-pyrazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1044998-24-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044998-25-5 CAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(4-methyl-1-piperazinyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1048020-53-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(1H-pyrazol-5-yl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1048022-13-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1H-pyrazol-3-yl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




IT 869220-92-8P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(thien-2-ylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-34-1P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(1,3,5-trimethylpyrazol-4-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-35-2P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(1,2-dimethylimidazol-5-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-36-3P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-37-4P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(phenylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-38-5P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(naphthalen-2-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-39-6P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(pyridin-2-yl)carbonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869222-25-3P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(thien-2-ylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of [(cycloalkylamino)pyrimidinyl]phenylimidazolinone derivs. as p38 MAP kinase inhibitors for the treatment of inflammatory diseases)

RN 869220-92-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-thienylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 869221-34-1 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-35-2 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 869221-36-3 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 869221-37-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(phenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869221-38-5 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-naphthalenylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869221-39-6 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-pyridinylcarbonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 869222-25-3 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(2-thienylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 775575-82-1, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-(piperidin-4-ylamino)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of
 [(cycloalkylamino)pyrimidinyl]phenylimidazolinone derivs. as p38 MAP
 kinase inhibitors for the treatment of inflammatory diseases)
 RN 775575-82-1 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 39 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1154546 CAPLUS

DN 143:422365

TI Preparation of diarylpyridazines and -pyrimidines as inhibitors of serine/threonine kinase (Akt kinase) activity.

PA Merck & Co., Inc., USA; Bilodeau, Mark T.; Chua, Peter C.; Cosford, Nicholas D. P.; Hoffman, Jacob M.; Nagasawa, Johnny Yasuo

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005100344 | A1 | 20051027 | WO 2005-US11687 | 20050405 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005233584 | A1 | 20051027 | AU 2005-233584 | 20050405 |
| | CA 2561311 | A1 | 20051027 | CA 2005-2561311 | 20050405 |
| | EP 1737843 | A1 | 20070103 | EP 2005-734336 | 20050405 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| | CN 1942465 | A | 20070404 | CN 2005-80011976 | 20050405 |
| | JP 2007532558 | T | 20071115 | JP 2007-507479 | 20050405 |
| | US 20080280889 | A1 | 20081113 | US 2006-547367 | 20060928 |
| | US 2006DN06436 | A | 20070831 | IN 2006-DN6436 | 20061101 |
| PRAI | US 2004-561167P | P | 20040409 | | |
| | WO 2005-US11687 | W | 20050405 | | |

OS CASREACT 143:422365; MARPAT 143:422365

AB Title compds. [I; X = N, Y = CH, or X = CH, Y = N; n = 0-4; p = 0-5; R1, R2 = H, (substituted) alkyl, alkoxy, alkylcarbonyl, alkoxy carbonyl, alkynyl oxycarbonyl, aryl, aryloxy, arylcarbonyl, aryloxy carbonyl, CO2H, cyano, halo, OH, amino, aminocarbonyl, O, perfluoroalkyl, perfluoroalkoxy, etc.], were prepared. Thus, title compound (II) was prepared in 3 steps from 4-phenyl-3,6-dichloropyridazine, dimethylamine, 4-formylphenylboronic acid, and 2-(3-piperidine-4-yl-1H-pyrazol-5-yl)pyridine. Several I inhibited Akt1, Akt2, and/or Akt3 with IC50 ≤50 μM.

IT 868280-18-6P 868280-38-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyridazines and pyrimidines as inhibitors of serine/threonine kinase)

RN 868280-18-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-2-pyrimidinylamino]-,

ethyl ester (CA INDEX NAME)




RN 868280-38-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-phenyl-4-[[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-2-pyrimidinyl]amino]-, ethyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 868280-18-6

CMF C37 H41 N9 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/552,317



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 40 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1103779 CAPLUS

DN 143:387011

TI Preparation of azaindoles as inhibitors of JAK and other protein kinases

IN Salituro, Francesco; Farmer, Luc; Bethiel, Randy; Harrington, Edmund; Green, Jeremy; Court, John; Come, Jon; Lauffer, David; Aronov, Alex; Binch, Hayley; Boyall, Dean; Charrier, Jean-Damien; Everitt, Simon; Fraysse, Damien; Mortimore, Michael; Pierard, Francoise; Robinson, Daniel

PA Vertex Pharmaceuticals Incorporated, USA; et al.

SO PCT Int. Appl., 432 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005095400 | A1 | 20051013 | WO 2005-US10846 | 20050330 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005228904 | A1 | 20051013 | AU 2005-228904 | 20050330 |
| | CA 2560454 | A1 | 20051013 | CA 2005-2560454 | 20050330 |
| | EP 1730146 | A1 | 20061213 | EP 2005-756052 | 20050330 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| | US 20070043063 | A1 | 20070222 | US 2005-93821 | 20050330 |
| | CN 1938303 | A | 20070328 | CN 2005-80010348 | 20050330 |
| | BR 2005009369 | A | 20070911 | BR 2005-9369 | 20050330 |
| | JP 2007531760 | T | 20071108 | JP 2007-506535 | 20050330 |
| | MX 2006PA11327 | A | 20061215 | MX 2006-PA11327 | 20061002 |
| | IN 2006KN02852 | A | 20070608 | IN 2006-KN2852 | 20061003 |
| | NO 2006004852 | A | 20061024 | NO 2006-4852 | 20061024 |
| | KR 2007027542 | A | 20070309 | KR 2006-722762 | 20061030 |
| | JP 2008156370 | A | 20080710 | JP 2008-60340 | 20080310 |
| PRAI | US 2004-557503P | P | 20040330 | | |
| | US 2004-625599P | P | 20041105 | | |
| | JP 2007-506535 | A3 | 20050330 | | |
| | WO 2005-US10846 | W | 20050330 | | |
| OS | CASREACT 143:387011; MARPAT 143:387011 | | | | |
| AB | The title compds. I [R1 = TR', Si(R') ₃ ; R2-R4 = halo, CN, NO ₂ , etc.; X1-X3 = N, CH (wherein the hydrogen atom of CH is optionally replaced by R5); x = 1-4; R5 = halo, CN, NO ₂ , etc.; T = a bond, alkylidene, etc.; R' = H, alkyl, (hetero)cyclyl, etc.; with provisos] which are inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting with 7-azaindole, was given. The compds. I were tested against JAK2, JAK3, ROCK and Aurora kinases (data given). The invention also provides pharmaceutical compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders. | | | | |

IT 866545-69-9P 866545-70-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of azaindoles as inhibitors of JAK and other protein kinases)
 RN 866545-69-9 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(phenylmethyl)-4-piperidinyl]-4-(1H-pyrrolo[2,3-
 b]pyridin-3-yl)- (CA INDEX NAME)



RN 866545-70-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-
 pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 41 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1103772 CAPLUS

DN 143:386909

TI Substituted thiophene derivatives as anti-cancer agents, and their preparation, pharmaceutical compositions, and use as inhibitors of PKB/Akt, PKA, and CDC7.

IN Lin, Xiaodong; Rico, Alice; Zhou, Yasheen; Jefferson, Ann B.; Walter, Annette

PA Chiron Corporation, USA; Wang, Xiaojing Michael

SO PCT Int. Appl., 245 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005095386 | A1 | 20051013 | WO 2005-US10690 | 20050330 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005228899 | A1 | 20051013 | AU 2005-228899 | 20050330 |
| | CA 2561977 | A1 | 20051013 | CA 2005-2561977 | 20050330 |
| | US 20050256121 | A1 | 20051117 | US 2005-95993 | 20050330 |
| | EP 1732919 | A1 | 20061220 | EP 2005-760186 | 20050330 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| | CN 1989131 | A | 20070627 | CN 2005-80010575 | 20050330 |
| | BR 2005008230 | A | 20070717 | BR 2005-8230 | 20050330 |
| | JP 2007531757 | T | 20071108 | JP 2007-506511 | 20050330 |
| | MX 2006PA10520 | A | 20070326 | MX 2006-PA10520 | 20060914 |
| | IN 2006KN02980 | A | 20070608 | IN 2006-KN2980 | 20061016 |
| | US 20080255120 | A1 | 20081016 | US 2008-129367 | 20080529 |
| PRAI | US 2004-558342P | P | 20040330 | | |
| | US 2005-95993 | A3 | 20050330 | | |
| | WO 2005-US10690 | W | 20050330 | | |

OS CASREACT 143:386909; MARPAT 143:386909

AB The invention relates to new substituted five-membered compds. I and their pharmaceutically acceptable salts, esters or prodrugs, compns. of the new compds. together with pharmaceutically acceptable carriers, and uses. In compds. I, A is N-containing heteroaryl with 5-6 ring atoms and 1-4 ring N atoms; n is 0-1; R is H, OH, (un)substituted (cyclo)alkyl, SO₂R⁷ (R⁷ is C₁-C₅ alkyl or substituted alkyl), alkoxy, CO₂H or esters, NO₂, (un)substituted (hetero)aryl or heterocyclyl, acylamino, or acyl; R₁ is (independently) halo, cyano, NO₂, OH, SH, (un)substituted: NH₂, alkoxy, (hetero)aryloxy, alkylthio, CONH₂, acylamino, (hetero)aryl, heterocyclyl, or alkyl; m is 0-2; R₂ and R₄ are independently H, (un)substituted: cycloalkyl, heterocyclyl, (hetero)aryl, alk(en/yn)yl, alkoxy, OH, (di)(alkyl)amino; with the proviso that one R₂ or R₄ is H under some

circumstances; R3 is H, alkyl, and (un)substituted (C1-5 alkylene)p-Z; Z is (un)substituted alkyl, alkylamino, (un)substituted alkoxy, cycloalkyl, (un)substituted heterocyclyl or (hetero)aryl; p is 0-1; Q is (un)substituted or thio-analogous CONH, CH2NH, NHCO, NHCO2, NHCONH, OCONH, CO2, CH:CH, C.tplbond.C, SO2NH, or SONH; where QR3 and R4 may form an (un)substituted heterocyclic ring; W is O, S, SO, or SO2; with provisos, and including pharmaceutically acceptable salts, esters and/or prodrugs. Over 370 compds. I were prepared, and these compds. are claimed individually. The compds. are inhibitors of Akt, PKA, and CDC7 protein kinases (no data), and are thus useful in the treatment of cancer. For example, 5-acetyl-2-thiophenecarboxylic acid was activated with CDI and amidated with 4-fluorophenethylamine to give the corresponding amide. The acetyl group of the amide was converted to a vinyllogous enamine using DMF di-Me acetal, and this was condensed with methylguanidine HCl to give invention compound II.


IT 866522-78-3P, N-[2-(2,4-Dichlorophenyl)ethyl]-5-[2-(pyridin-4-ylamino)pyrimidin-4-yl]thiophene-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted thiophene derivs. as PKB/Akt, PKA, and CDC7 inhibitors for treatment of cancer)

RN 866522-78-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 42 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:902688 CAPLUS

DN 143:248403

TI Preparation of 2-aminopyrimidinones for inhibiting hYAK3 proteins

IN Hasegawa, Masaichi; Takada, Mio; Washio, Yoshiaki

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2005076854 | A2 | 20050825 | WO 2005-US2972 | 20050203 |
| | WO 2005076854 | A3 | 20051222 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1713793 | A2 | 20061025 | EP 2005-712420 | 20050203 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS | | | |
| | JP 2007520558 | T | 20070726 | JP 2006-552188 | 20050203 |
| | US 20070117818 | A1 | 20070524 | US 2006-588527 | 20060804 |
| PRAI | US 2004-542090P | P | 20040204 | | |
| | WO 2005-US2972 | W | 20050203 | | |
| OS | CASREACT 143:248403; MARPAT 143:248403 | | | | |
| AB | The title compds. I [R1 = quinolinyl, benzodioxolanyl, benzimidazolyl, etc.; R2 = pyridyl, benzimidazolyl, indazolyl, etc.], useful for inhibiting hYAK3 proteins, were prepared E.g., a multi-step synthesis of I [R1 = quinolin-6-yl; R2 = (CH2)2NH2], starting from 2,4,6-trichloropyrimidine and 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)quinoline, was given. The compds. I were tested for their ability to inhibit the hYAK3 kinase (specific data were given for representative compds. I). The pharmaceutical composition comprising the compound I and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins by administering an ED of compound I were disclosed. | | | | |
| IT | 863327-70-2P 863328-15-8P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of 2-aminopyrimidinones for inhibiting hYAK3 proteins) | | | | |
| RN | 863327-70-2 CAPLUS | | | | |
| CN | 2-Thiophenecarboxamide, N-[6-[1,6-dihydro-6-oxo-2-(4-pyridinylamino)-4-pyrimidinyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME) | | | | |

10/552,317



RN 863328-15-8 CAPLUS

CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



L17 ANSWER 43 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:451383 CAPLUS
 DN 142:482041
 TI A preparation of bicyclic pyrazolone derivatives, useful as cytokine inhibitors
 IN Clark, Michael Philip; Laughlin, Steven Karl; Golebiowski, Adam; Brugel, Todd Andrew; Sabat, Mark
 PA The Procter & Gamble Company, USA
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|------------------|----------|
| PI | WO 2005047287 | A2 | 20050526 | WO 2004-US37264 | 20041109 |
| | WO 2005047287 | A3 | 20050728 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2004289691 | A1 | 20050526 | AU 2004-289691 | 20041109 |
| | CA 2545781 | A1 | 20050526 | CA 2004-2545781 | 20041109 |
| | EP 1682551 | A2 | 20060726 | EP 2004-810572 | 20041109 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS | | | |
| | CN 1878772 | A | 20061213 | CN 2004-80032839 | 20041109 |
| | JP 2007510739 | T | 20070426 | JP 2006-539725 | 20041109 |
| | BR 2004016358 | A | 20070508 | BR 2004-16358 | 20041109 |
| | SG 147476 | A1 | 20081128 | SG 2008-8004 | 20041109 |
| | KR 2006086391 | A | 20060731 | KR 2006-708849 | 20060508 |
| | KR 835152 | B1 | 20080609 | | |
| | IN 2006DN02569 | A | 20070810 | IN 2006-DN2569 | 20060508 |
| | MX 2006PA05209 | A | 20060720 | MX 2006-PA5209 | 20060509 |
| | NO 2006002639 | A | 20060608 | NO 2006-2639 | 20060608 |
| PRAI | US 2003-518886P | P | 20031110 | | |
| | WO 2004-US37264 | W | 20041109 | | |

OS CASREACT 142:482041; MARPAT 142:482041

AB The invention relates to a preparation of 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-one derivs. of formula I [wherein: R is O(CH₂)₀₋₅-alkyl, NH₂, or is O(CH₂)₀₋₅-aryl, etc.; R₁ is (hetero)aryl; L is (CH₂)₀₋₂, (CH₂)₀₋₂-NH-(CH₂)₀₋₂, or (CH₂)₀₋₂-O-(CH₂)₀₋₂, etc.; R₂ is H, (CH₂)₀₋₅-O-(CH₂)₀₋₅H, (CH₂)₀₋₅-NH₂, or (CH₂)₀₋₅-CO₂H, etc.; Z is O, S, NH, or N(alkyl), etc.] which inhibit the extracellular release of inflammatory cytokines. For instance, pyrazolone derivative II [R₃ = NHCH(Me)CH₂OMe] was prepared via heterocyclization of ketoester III with pyrazolidine dihydrochloride, S-oxidation of the obtained pyrazolopyrazole derivative II (R₃ = SMe), and subsequent amination of the obtained methanesulfonylpyrimidine derivative II (R₃ = SO₂Me) by

(S)-1-methoxy-2-propylamine (the yield of the heterocyclization step was 10%). The preferred invention compds. exhibited activities (IC50) at a level below 1 μ M.


IT 1044958-03-3 1044958-06-6 1044958-11-3
 1044958-16-8 1044958-19-1 1044958-24-8
 1044958-50-0 1044958-57-7 1044958-61-3
 1044958-67-9 1044958-69-1 1044958-96-4

RL: PRPH (Prophetic)

(A preparation of bicyclic pyrazolone derivatives, useful as cytokine inhibitors)

RN 1044958-03-3 CAPLUS


CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 6,7-dihydro-2-(2-methylphenoxy)-3-[2-(4-piperidinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)



the hetero ring is not "aromatic"


RN 1044958-06-6 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 6,7-dihydro-2-(2-methylphenoxy)-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-11-3 CAPLUS


CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(2-chlorophenoxy)-6,7-dihydro-3-[2-(4-piperidinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-16-8 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(4-fluorophenoxy)-6,7-dihydro-3-[2-(4-piperidinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)



RN 1044958-19-1 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(4-fluorophenoxy)-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-24-8 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(2-chlorophenoxy)-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-
 (CA INDEX NAME)




RN 1044958-50-0 CAPLUS
 CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 6,7-dihydro-2-[(2-methylphenyl)methyl]-3-[2-(4-piperidinylamino)-4-
 pyrimidinyl]- (CA INDEX NAME)


10/552,317




RN 1044958-57-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044958-61-3 CAPLUS
CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
2-[(2-chlorophenyl)methyl]-6,7-dihydro-3-[2-(4-pyridinylamino)-4-
pyrimidinyl]- (CA INDEX NAME)




RN 1044958-67-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044958-69-1 CAPLUS
CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,

2-[(4-fluorophenyl)methyl]-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1044958-96-4 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
6,7-dihydro-2-[(2-methylphenyl)methyl]-3-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



L17 ANSWER 44 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:395300 CAPLUS
 DN 142:430277
 TI Novel imidazole derivatives, their preparation and use as anticancer agents
 IN Honold, Konrad; Scheiblich, Stefan; Von Hirschheydt, Thomas; Voss, Edgar
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2005040154 | A1 | 20050506 | WO 2004-EP11598 | 20041015 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20050113342 | A1 | 20050526 | US 2004-961907 | 20041012 |
| US 7169781 | B2 | 20070130 | | |
| AU 2004283845 | A1 | 20050506 | AU 2004-283845 | 20041015 |
| CA 2538134 | A1 | 20050506 | CA 2004-2538134 | 20041015 |
| EP 1678163 | A1 | 20060712 | EP 2004-765966 | 20041015 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1867563 | A | 20061122 | CN 2004-80030583 | 20041015 |
| BR 2004015525 | A | 20061226 | BR 2004-15525 | 20041015 |
| JP 2007508344 | T | 20070405 | JP 2006-534696 | 20041015 |
| MX 2006PA03698 | A | 20060605 | MX 2006-PA3698 | 20060331 |
| KR 2006063985 | A | 20060612 | KR 2006-707335 | 20060417 |
| KR 796971 | B1 | 20080122 | | |
| IN 2006CN01307 | A | 20070629 | IN 2006-CN1307 | 20060417 |
| PRAI EP 2003-23677 | A | 20031017 | | |
| WO 2004-EP11598 | W | 20041015 | | |

OS CASREACT 142:430277; MARPAT 142:430277

AB The invention relates a group of novel imidazole derivs. I, which are inhibitors of tyrosine kinases. In compds. I, K and L are independently selected from H, halo, alkyl, OH, and alkoxy; X is H, OH, alkoxy, mercapto, alkylthio, etc.; Y is (un)substituted aryl or heteroaryl; Z is halo, OH, alkoxy, allyloxy, alkyl, methylthio, etc.; and n is 1 or 2. The invention also relates to the preparation of I, pharmaceutical compns. containing

one or more compds. I as active ingredients, as well as to the use of the compns. for the treatment of disorders mediated by c-met or src tyrosine kinases, such as cancer. II, formed by the substitution of the Weinreb-amide of 3-chlorobenzoyl chloride with lithiated 4-methyl-2-(methylthio)pyrimidine, was converted to the α -keto oxime with nitrite. The oxime underwent cyclization with III (prepared by silylation of 3,5-dichlorobenzyl alc. followed by formylation and

desilylation) in the presence of NH₄OAc to form N-hydroxyimidazole IV. IV was reduced to give the corresponding NH-imidazole and then oxidized to convert the methylthio group into a methylsulfonyl group, which then underwent substitution with 4-[2-(diethylamino)ethoxy]aniline to give imidazole V. The compds. of the invention are inhibitors of src and C-met tyrosine kinases, and compound V has IC₅₀ values of 0.5 nM and 4 nM, resp.


IT 850919-12-9P, 2-(2,6-Dichlorophenyl)-4-(4-chlorophenyl)-5-[2-(4-pyridinylamino)pyrimidin-4-yl]-imidazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazole derivs. and their use as anticancer agents)

RN 850919-12-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)-1H-imidazol-5-yl]-N-4-pyridinyl- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 45 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:300435 CAPLUS

DN 142:373859

TI Preparation of pyrimidine and pyridine derivatives useful as HMG-CoA reductase inhibitors

IN Ahmad, Saleem; Robl, Jeffrey A.; Ngu, Khehyong

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2005030758 | A1 | 20050407 | WO 2004-US31212 | 20040922 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 20050085497 | A1 | 20050421 | US 2004-946055 | 20040921 |
| | US 7371759 | B2 | 20080513 | | |
| | EP 1667997 | A1 | 20060614 | EP 2004-784885 | 20040922 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| PRAI | US 2003-505893P | P | 20030925 | | |
| | WO 2004-US31212 | W | 20040922 | | |
| OS | CASREACT 142:373859; MARPAT 142:373859 | | | | |
| AB | Title compds. I [X = N, CR5; R1-2 = H, alkyl, alkoxyalkyl, etc.; R3 = (hetero)aryl, cycloalkyl, etc.; R4 = H, (cyclo)alkyl, haloalkyl, etc.; R5 = H, alkyl; Z = hydroxyalkyl, etc.] are prepared For instance, II is prepared in 5 steps from a substituted pyrimidine, 2-methyl-2H-[1,2,4]triazol-3-ylamine, and a prior art homochiral dihydroxy acetone derivative I are HMG-CoA reductase inhibitors and are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis [no data]. | | | | |
| IT | 849469-93-8P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidine and pyridine derivs. useful as HMG-CoA reductase inhibitors) | | | | |
| RN | 849469-93-8 CAPLUS | | | | |
| CN | 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-(4-pyridinylamino)-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME) | | | | |


Absolute stereochemistry.

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 46 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:130195 CAPLUS
 DN 142:373790
 TI One-pot synthesis of polysubstituted pyrimidines
 AU Kiselyov, Alexander S.
 CS Chemical Diversity, Small Molecule Drug Discovery, San Diego, CA, 92121, USA
 SO Tetrahedron Letters (2005), 46(10), 1663-1665
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 142:373790
 AB A series of polysubstituted pyrimidines, e.g., I, were synthesized from in situ generated α,β -unsatd. imines and the corresponding amidine or guanidine derivs. in a convenient one-pot procedure. The pyrimidines were obtained in good yields.
 IT 849589-54-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of polysubstituted pyrimidines via addition of alkylphosphates to arylcarbonitriles followed by olefination with arylaldehydes and heterocyclization with amidines or guanidines)
 RN 849589-54-4 CAPLUS
 CN 2-Pyrimidinamine, 4-phenyl-6-(3-pyridinyl)-N-4-pyridinyl- (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 47 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:71173 CAPLUS

DN 142:176866

TI Preparation of biaryl piperazinyl-pyridine analogues as capsaicin receptor modulators

IN Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Chenard, Bertrand L.; De Lombaert, Stephane; Hodgetts, Kevin J.; Hutchison, Alan; Yoon, Taeyoung; Zheng, Xiaozhang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 381 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|------------------|----------|
| PI | WO 2005007648 | A2 | 20050127 | WO 2004-US23064 | 20040716 |
| | WO 2005007648 | A3 | 20050324 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2004257289 | A1 | 20050127 | AU 2004-257289 | 20040716 |
| | CA 2531619 | A1 | 20050127 | CA 2004-2531619 | 20040716 |
| | EP 1644358 | A2 | 20060412 | EP 2004-778532 | 20040716 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | |
| | CN 1823057 | A | 20060823 | CN 2004-80020350 | 20040716 |
| | US 20070027155 | A1 | 20070201 | US 2004-893799 | 20040716 |
| | JP 2007534624 | T | 20071129 | JP 2006-520390 | 20040716 |
| PRAI | US 2003-488564P | P | 20030716 | | |
| | US 2003-516135P | P | 20031031 | | |
| | WO 2004-US23064 | W | 20040716 | | |

OS CASREACT 142:176866; MARPAT 142:176866

AB The title compds. I [Ar2 = (un)substituted Ph, 6-membered aromatic heterocycle; X, Y, Z = CRx, N (at least one of X, Y and Z = N); K, J, F = N, CH or carbon substituted with R1; Rx = H, alkyl, NH2, CN, mono or dialkylamino; R1 = halo, OH, NH2, CN, etc.; R3 = H, halo, phenylalkyl, cycloalkylalkyl, etc.; R4 = H, alkyl, haloalkyl, oxo], useful for treating conditions related to capsaicin receptor activation, were prepared E.g., a 2-step synthesis of II, starting from 2,4,6-trichloropyrimidine and morpholine, was given. The compds. I were evaluated for agonist and antagonist capsaicin receptor activity (data given). Pharmaceutical compns. and methods for using compds. I to treat disorders related to capsaicin receptor activation (pain, asthma, etc.), are provided, as are methods for using such ligands, for receptor localization studies.


IT 833468-31-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor modulators)

RN 833468-31-8 CAPLUS

CN 2-Pyrimidinamine, 4-(3-chloro-4-fluorophenyl)-N-methyl-N-(1-methyl-4-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (CA INDEX NAME)



L17 ANSWER 48 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:1127326 CAPLUS
 DN 142:74593
 TI Preparation of pyrimidinyl imidazothiazoles and imidazooxazoles as inhibitors of p38
 IN Ashwell, Mark; Ali, Syed; Liu, Jifeng; Liu, Yanbin; Lohse, Peter; Mekonnen, Belew; Selliah, Robert; Tandon, Manish; Wrona, Woj
 PA Arqule, Inc., USA
 SO PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|------------------|----------|
| PI | WO 2004110990 | A2 | 20041223 | WO 2004-US15368 | 20040514 |
| | WO 2004110990 | A3 | 20050324 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2004247626 | A1 | 20041223 | AU 2004-247626 | 20040514 |
| | CA 2526285 | A1 | 20041223 | CA 2004-2526285 | 20040514 |
| | EP 1633758 | A2 | 20060315 | EP 2004-752390 | 20040514 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | |
| | CN 1823072 | A | 20060823 | CN 2004-80019855 | 20040514 |
| | JP 2006528983 | T | 20061228 | JP 2006-533130 | 20040514 |
| | MX 2005PA12377 | A | 20060525 | MX 2005-PA12377 | 20051115 |
| | IN 2005DN05250 | A | 20071130 | IN 2005-DN5250 | 20051116 |
| | US 20070270418 | A1 | 20071122 | US 2007-556161 | 20070419 |
| PRAI | US 2003-470735P | P | 20030515 | | |
| | US 2003-512298P | P | 20031017 | | |
| | WO 2004-US15368 | W | 20040514 | | |

not prior
no 102(e) date

OS MARPAT 142:74593
 AB In general, the present invention relates to compds. I [X = O, S(O)m; Y = OR4, NR4R5; m = 0-2; n = 1-2; R1 = H, CN, CO2H, halo, etc.; Ar = aryl; R3 = H, halo, NH2, etc.; R4, R5 = H, alkyl, aryl, etc.; or NR4R5 = heterocyclic ring; with the provisos] capable of inhibiting p38, methods for inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity. E.g., a multi-step synthesis of II, starting from cyanamide and 2-hydroxyacetaldehyde, was given. The compds. I were tested for their biol. activity in various tests. Thus, it was found that compds. I inhibit ATF2 phosphorylation by p38 MAP kinase in vitro (specific data were given for over 300 compds. I). Also, the compds. I inhibit the release of TNF α , IL-1 β or both in in vitro assay (data given). The compds. I were tested in the collagen-induced model of arthritis in rats and showed dose-dependent inhibition of clin. and hostopatol. parameters of arthritis, including inflammation and bone damage (data

given for representative compds. I). The pharmaceutical composition comprising the compound I is disclosed.


IT 956026-85-0 1066555-66-5

RL: PRPH (Prophetic)

(Preparation of pyrimidinyl imidazothiazoles and imidazooxazoles as inhibitors of p38)


RN 956026-85-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1066555-66-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 815594-66-2P 815595-25-6P 815595-26-7P
 815595-27-8P 815595-29-0P 815595-31-4P
 815595-32-5P 815595-33-6P 815595-34-7P
 815595-35-8P 815595-36-9P 815595-44-9P
 815595-45-0P 815595-49-4P 815595-53-0P
 815595-54-1P 815595-56-3P 815595-57-4P
 815595-58-5P 815595-59-6P 815595-60-9P
 815595-61-0P 815595-62-1P 815595-63-2P
 815595-64-3P 815595-65-4P 815595-66-5P
 815595-67-6P 815596-58-8P 815596-73-7P
 815596-92-0P 815596-93-1P 815596-94-2P
 815596-95-3P 815596-96-4P 815597-01-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinyl imidazothiazoles and imidazooxazoles as inhibitors of p38)

RN 815594-66-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-

5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 815595-25-6 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-26-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 815595-27-8 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 815595-29-0 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 815595-31-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-32-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

NAME)




RN 815595-33-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-34-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-35-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-36-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 815595-44-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 815595-45-0 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 815595-49-4 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-53-0 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-54-1 CAPLUS

CN Ethanone, 1-[4-[[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-56-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



RN 815595-57-4 CAPLUS


CN Ethanone, 1-[4-[[4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 815595-58-5 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 815595-59-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 815595-60-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]-8-methyl-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.




RN 815595-61-0 CAPLUS
 CN 2-Pyrimidinamine, N-4-piperidinyl-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)



RN 815595-62-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)




RN 815595-63-2 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(methylsulfonyl)-4-piperidinyl]-4-[6-[3-(trifluoromethyl)phenyl]imidazo[2,1-b]oxazol-5-yl]- (CA INDEX NAME)




RN 815595-64-3 CAPLUS

CN Ethanone, 1-[4-[[4-[6-(2,4-difluorophenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 815595-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chlorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-66-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-chloro-4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 815595-67-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-methyl-N-[4-[6-(2-methylphenyl)imidazo[2,1-b]oxazol-5-yl]-2-pyrimidinyl]- (CA INDEX NAME)




RN 815596-58-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 815596-73-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 815596-92-0 CAPLUS

CN Methanone, (4-fluorophenyl)[4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-1-piperidinyloxybutanoate] (CA INDEX NAME)




RN 815596-93-1 CAPLUS

CN Ethanone, 1-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]-4-piperidinyloxybutanoate] (CA INDEX NAME)




RN 815596-94-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(4-fluorophenyl)methyl]-4-piperidinyloxybutanoate] (CA INDEX NAME)




RN 815596-95-3 CAPLUS

CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 815596-96-4 CAPLUS


CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 815597-01-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl]-N-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)


10/552,317



L17 ANSWER 49 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:1059317 CAPLUS
 DN 142:23305
 TI Preparation of trisubstituted heteroaromatic compounds as calcium sensing
 receptor modulators
 IN Yang, Wu; Dickson, John K.; Cooper, Christopher B.; Dodd, Dharmpal S.;
 Ruan, Zheming; Schnur, Dora M.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2004106296 | A2 | 20041209 | WO 2004-US16713 | 20040527 |
| | WO 2004106296 | A3 | 20051222 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 20050004151 | A1 | 20050106 | US 2004-854484 | 20040526 |
| | US 7459460 | B2 | 20081202 | | |
| PRAI | US 2003-473904P | P | 20030528 | | |
| OS | CASREACT 142:23305; MARPAT 142:23305 | | | | |
| AB | Title compds. I [X = C, N; A, B = CH, N and A and B cannot both be CH; R1 = ArL; R2 = H, alkyl or R1 and R2 can be joined to form a cycloheteroalkyl ring; Ar = (hetero)aryl; L = linking group; R3, R4, R6 = H, alkyl, cycloalkyl, etc.; R4 = alkyl, cycloalkyl, alkenyl, alkynyl, etc.; R7 = alkyl, cycloalkyl, etc.; R8 = H, alkyl or R7 and R8 can be joined together to form a 4-7 membered cycloheteroalkyl ring] are prepared For instance, II is prepared in 5 steps from pyrazole-1-carboxyimidine and benzylmethylamine. I are calcium-sensing receptor modulators; they are useful for the treatment of diseases associated with abnormal bone or mineral homeostasis. | | | | |
| IT | 802915-97-5P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of trisubstituted heteroarom. compds. as calcium sensing receptor modulators) | | | | |
| RN | 802915-97-5 CAPLUS | | | | |
| CN | 1-Piperidinecarboxylic acid, 4-[[5-[[[(2-phenoxyethyl)amino]carbonyl]-4-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME) | | | | |

10/552,317



L17 ANSWER 50 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:878380 CAPLUS
 DN 141:379931
 TI Preparation of aminopyrimidines as IKK inhibitors for treating autoimmune diseases and inflammations
 IN Bollbuck, Birgit; Denholm, Alastair; Eder, Joerg; Hersperger, Rene; Janser, Philipp; Revesz, Laszlo; Schlapbach, Achim; Waelchli, Rudolf
 PA Novartis Ag, Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 217 pp.
 CODEN: PIXXD2 Applicant's
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2004089913 | A1 | 20041021 | WO 2004-EP3819 | 20040408 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004228352 | A1 | 20041021 | AU 2004-228352 | 20040408 |
| | AU 2004228352 | B2 | 20080306 | | |
| | CA 2521340 | A1 | 20041021 | CA 2004-2521340 | 20040408 |
| | EP 1615898 | A1 | 20060118 | EP 2004-726485 | 20040408 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | BR 2004009314 | A | 20060425 | BR 2004-9314 | 20040408 |
| | CN 1802357 | A | 20060712 | CN 2004-80016050 | 20040408 |
| | JP 2006522768 | T | 20061005 | JP 2006-505087 | 20040408 |
| | US 20070043048 | A1 | 20070222 | US 2005-552317 | 20051007 |
| | IN 2005CN02563 | A | 20070831 | IN 2005-CN2563 | 20051007 |
| PRAI | GB 2003-8466 | A | 20030411 | | |
| | WO 2004-EP3819 | W | 20040408 | | |

OS MARPAT 141:379931

AB Title compds. I [wherein R1 = H, (un)substituted lower alkyl, aryl, heterocycloalkyl, etc.; R2 = (un)substituted aryl, wherein aryl is not 4-(4-fluorophenyl)-1(1-methylpiperidin-4-yl)imidazole; each R3, R4 = independently H, CN, halo, OH, lower alkoxy, (un)substituted lower alkyl; X = CR6R7; Y = CR8R9; Z = CR10R11; W = CR12R13; each R6 to R13 = independently H, (un)substituted lower alkyl, lower alkoxy, CH2O-NH2, etc.; wherein at least one of R6 to R13 is not equal to H; any pair of R6 to R13 are joined together to form an (un)substituted C1 to C4 bridge in which one or more of the bridge atoms is optionally replaced by O, S, NH and derivs.; their pharmaceutically acceptable salts, esters or prodrugs] were prepared as inhibitors of IKK protein kinase (IKK) and production of tumor necrosis factor- α (TNF- α). For e.g., a 3-step synthesis of II was given. I showed IC50 values range of 20 to 1,000 nM in the IKK kinase activity assay. I, at 30 mg/kg p.o., i.v. or s.c., inhibited TNF- α production to the extent of up to about 50% or more in LPS stimulated mice. I are useful as immunosuppressants and antiinflammatory

agents.

IT 778643-81-5P, [4-[5-(3-Amino-3-methylbut-1-ynyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine
 778644-21-6P, 1-[5'-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl][2,2']bithiophenyl-5-yl]ethanone
 778644-27-2P, 1-[4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]ethanone O-methyloxime
 778644-31-8P, 4-[5-[5-Bromo-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid methyl ester
 778644-36-3P, [4-[5-[[2-(Piperidin-1-yl)ethyl]amino]methyl]thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-44-3P,
 N-[[5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]methyl]methanesulfonamide 778644-54-5P,
 [4-[5-(1-Aminocyclohexylethynyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-62-5P,
 3-[[[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]propionitrile 778644-71-6P,
 [4-[5-(2-Aminoethyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-72-7P,
 [4-(4,5,6,7-Tetrahydrobenzo[b]thiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-79-4P,
 1-[4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]ethanone 778644-81-8P,
 [4-(5-Chlorothiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-82-9P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid methyl ester
 778644-88-5P, 1-[5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]ethanone
 778644-90-9P, [5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methanol 778644-92-1P,
 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-1-ol 778644-95-4P,
 3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]benzonitrile 778645-08-2P,
 [4-[5-(Aminomethyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-09-3P,
 [4-[5-(4-Aminomethylphenyl)thiophen-2-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-16-2P,
 3-[3-Methyl-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionic acid methyl ester 778645-20-8P,
 1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-3-one 778645-21-9P,
 1-Phenyl-3-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-one 778645-25-3P,
 [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl] (1-benzylpiperidin-4-yl)amine 778645-26-4P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl] (piperidin-4-yl)amine 778645-27-5P,
 3-[4-[[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]piperidin-1-yl]propionitrile 778645-28-6P,
 [4-(6-Methoxybenzo[b]thiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-29-7P,
 2-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophen-6-ol 778645-32-2P,
 [4-(6-(Oxiranylmethoxy)benzo[b]thiophen-2-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-34-4P,
 [4-(6-Methoxybenzo[b]thiophen-2-yl)-5-methylpyrimidin-2-yl] (2,2,6,6-


tetramethylpiperidin-4-yl)amine 778645-61-7P,
 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propionic acid methyl ester 778645-65-1P,
 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propan-1-ol 778645-68-4P,
 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butyronitrile 778645-70-8P,
 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butan-2-one 778645-84-4P,
 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-3-carbonitrile 778645-86-6P,
 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-4-carbonitrile 778645-95-7P,
 [4-(6-Methoxy-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-97-9P, [4-(7-Methoxy-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-16-5P,
 [4-(7-Nitro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-30-3P, (E)-4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]-2-methylbut-3-en-2-ol 778646-31-4P, (E)-3-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]acrylonitrile 778646-32-5P,
 (E)-4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-methylbut-3-en-2-ol 778646-33-6P,
 (E)-3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]acrylonitrile 778646-34-7P,
 [4-[6-[(E)-2-(Imidazol-1-yl)ethenyl]-1H-indol-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-35-8P,
 (E)-3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]acrylonitrile 778646-36-9P,
 (E)-N,N-Dimethyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-propenamide 778647-25-9P,
 [3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778643-81-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-methyl-1-butyn-1-yl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-21-6 CAPLUS

CN Ethanone, 1-[5'-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]- (CA INDEX NAME)




RN 778644-27-2 CAPLUS

CN Ethanone, 1-[4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]phenyl]-, O-methyloxime (CA INDEX NAME)




RN 778644-31-8 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[5-bromo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778644-36-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[[2-(1-piperidinyl)ethyl]amino]methyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-44-3 CAPLUS

CN Methanesulfonamide, N-[[5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]methyl]- (CA INDEX NAME)




RN 778644-54-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(1-aminocyclohexyl)ethynyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-62-5 CAPLUS

CN Propanenitrile, 3-[[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]amino]- (CA INDEX NAME)




RN 778644-71-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-aminoethyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-72-7 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-79-4 CAPLUS

CN Ethanone, 1-[4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]phenyl]- (CA INDEX NAME)




RN 778644-81-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-chloro-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-82-9 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778644-88-5 CAPLUS

CN Ethanone, 1-[5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]- (CA INDEX NAME)




RN 778644-90-9 CAPLUS

CN 2-Thiophenemethanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-92-1 CAPLUS

CN 2-Thiophenebutanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-95-4 CAPLUS

CN Benzonitrile, 3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778645-08-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(aminomethyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-09-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(aminomethyl)phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-16-2 CAPLUS

CN 2-Thiophenepropanoic acid, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778645-20-8 CAPLUS

CN 3-Pentanone, 1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778645-21-9 CAPLUS

CN 1-Propanone, 1-phenyl-3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778645-25-3 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-[1-(phenylmethyl)-4-piperidinyl]-
(CA INDEX NAME)




RN 778645-26-4 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-4-piperidinyl- (CA INDEX NAME)




RN 778645-27-5 CAPLUS

CN 1-Piperidinepropanenitrile, 4-[(4-benzo[b]thien-2-yl-2-pyrimidinyl)amino]-
(CA INDEX NAME)




RN 778645-28-6 CAPLUS

CN 2-Pyrimidinamine, 4-(6-methoxybenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-29-7 CAPLUS

CN Benzo[b]thiophene-6-ol, 2-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-32-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-oxiranylmethoxy)benzo[b]thien-2-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-34-4 CAPLUS

CN 2-Pyrimidinamine, 4-(6-methoxybenzo[b]thien-2-yl)-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-61-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778645-65-1 CAPLUS

CN Benzenepropanol, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-68-4 CAPLUS

CN Benzenebutanenitrile, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-70-8 CAPLUS

CN 2-Butanone, 4-[4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 778645-84-4 CAPLUS

CN 1H-Indole-3-carbonitrile, 1-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-86-6 CAPLUS

CN 1H-Indole-4-carbonitrile, 1-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-95-7 CAPLUS

CN 2-Pyrimidinamine, 4-(6-methoxy-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778645-97-9 CAPLUS


CN 2-Pyrimidinamine, 4-(7-methoxy-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778646-16-5 CAPLUS

CN 2-Pyrimidinamine, 4-(7-nitro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)


10/552,317



RN 778646-30-3 CAPLUS

CN 3-Buten-2-ol, 4-[5-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-6-yl]-2-methyl-, (3E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-31-4 CAPLUS

CN 2-Propenenitrile, 3-[5-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-6-yl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-32-5 CAPLUS

CN 3-Buten-2-ol, 4-[5-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-2-methyl-, (3E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-33-6 CAPLUS

CN 2-Propenenitrile, 3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-6-yl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-34-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-[(1E)-2-(1H-imidazol-1-yl)ethenyl]-1H-indol-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778646-35-8 CAPLUS


CN 2-Propenenitrile, 3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 778646-36-9 CAPLUS
 CN 2-Propenamide, N,N-dimethyl-3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 778647-25-9 CAPLUS
 CN 1H-Indol-7-amine, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



IT 778643-77-9P, 2-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-2-ol 778643-78-0P, 4-[5-[5-Methoxy-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-2-methylbutan-2-ol 778643-79-1P, [4-[5-(4-Methoxybutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine hydrochloride 778643-80-4P, (E)-4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]but-3-en-2-ol 778643-82-6P, (E)-2-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-1-but-3-en-2-ol 778643-83-7P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pyrrolidin-2-one 778643-84-8P, 4-[5-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-1-ol 778643-85-9P, 1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-2-ol 778643-86-0P, 2,2-Dimethyl-N-methyl-3-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionamide 778643-87-1P, 2-Methyl-4-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]pyrrol-1-yl]butan-2-ol 778643-88-2P, 2-[2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]cyclopropyl]propan-2-ol 778643-89-3P, 2-[(1R,2R)-2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]cyclopropyl]propan-2-ol 778643-90-6P, 2-Ethoxy-2-methyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-one 778643-91-7P, [4-[5-(3-Methoxypropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-92-8P, 2'-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]bicyclopropyl-1-ol 778643-93-9P, 4-[3-Methoxy-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-2-methylbutan-2-ol 778643-94-0P, [4-[5-(2-Amino-2-methylpropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-95-1P, 2,2-Difluoro-3-methyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butane-1,3-diol 778643-96-2P, 2,3,3-Trimethyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-2-ol 778643-97-3P, [4-(5-Benzyloxythiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-98-4P, [4-[5-(Butyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778643-99-5P, [4-(5-Propoxythiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-00-1P, [4-[5-(2-Methoxyethoxy)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-01-2P, [4-[5-(Pyridin-4-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-02-3P, 1-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-

yl]thiophen-2-yl]piperidin-4-ol 778644-03-4P,
 [4-[5-(Pyridin-3-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-04-5P,
 [4-[5-(Pyridin-2-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-05-6P,
 [4-[5-(Piperazin-4-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-06-7P,
 4-[5-[2-[(8-Azabicyclo[3.2.1]oct-3-yl)exo-amino]pyrimidin-4-yl]thiophen-2-yl]-1-methylpiperidin-4-ol 778644-07-8P,
 8-Azabicyclo[3.2.1]oct-3-yl[4-[5-(piperazin-1-yl)thiophen-2-yl]pyrimidin-2-yl]exo-amine 778644-08-9P,
 [4-[5-((E)-3-Amino-3-methylbut-1-enyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-09-0P,
 [4-[5-(3-Amino-3-methylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-10-3P,
 2-Methyl-4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]-3-butyn-2-ol 778644-11-4P,
 [4-[5-(3-Methylpiperazin-1-yl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-12-5P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-sulfonamide 778644-13-6P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid N-((S)-1-carbamoyl-2-phenylethyl)amide 778644-14-7P, (S)-3-Phenyl-2-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]amino]propionic acid methyl ester 778644-15-8P,
 (R)-3-Phenyl-2-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]amino]propionic acid methyl ester 778644-16-9P, 2-Benzyl-1-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]piperidin-4-one 778644-17-0P, 1-[[[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]piperidine-4-carboxylic acid isopropylamide 778644-18-1P,
 2-(Biphenyl-4-yl)-2-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]amino]acetic acid methyl ester 778644-19-2P, (2S,4R)-4-Hydroxy-1-[[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thien-2-yl]carbonyl]pyrrolidine-2-carboxylic acid benzyl ester 778644-20-5P, [4-([2,2']Bithiophenyl-5-yl)-5-methylpyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-22-7P
 778644-23-8P, [5-Bromo-4-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-24-9P, N-[2-[5-[5-Bromo-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]acetamide 778644-25-0P,
 [4-[5-(2-Aminoethyl)thiophen-2-yl]-5-bromopyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-26-1P,
 [5-Bromo-4-[5-(2-dimethylaminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-28-3P,
 [4-[5-[4-((Z)-1-Methyl-1-propenyl)phenyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-29-4P,
 [4-[5-[4-(1-Aminoethyl)phenyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-30-7P,
 [5-Bromo-4-(5-chlorothiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-32-9P,
 4-[5-[5-Bromo-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-1-ol 778644-33-0P,
 [4-[5'-(1-Aminoethyl)[2,2']bithiophenyl-5-yl]pyrimidin-2-yl](2,2,6,6-

tetramethylpiperidin-4-yl)amine 778644-34-1P,
 [4-[5-(3-Aminomethylphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-35-2P,
 [4-[5-[4-[(Dimethylamino)methyl]phenyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-37-4P,
 [4-[5-[Methyl[2-(piperidin-1-yl)ethyl]amino]methyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-38-5P,
 2-Methyl-5-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-2-ol 778644-39-6P,
 [4-[5-(2-Isopropylaminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-40-9P,
 N-[2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]methanesulfonamide 778644-41-0P,
 [2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]urea 778644-42-1P,
 [5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methylurea 778644-43-2P,
 N-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methylmethanesulfonamide 778644-45-4P,
 [4-[5'-[(Dimethylamino)methyl]-[2,2']bithiophenyl-5-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-46-5P,
 [[5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]methyl]urea 778644-47-6P,
 2-Methoxy-N-[[5'-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]methyl]acetamide 778644-48-7P,
 3-[3-Methyl-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionamide 778644-49-8P,
 [4-[5-(3-Amino-3-ethylpentyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-50-1P,
 [4-[5-(2-Methylsulfinylethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-51-2P,
 [4-[5-(3-Methylsulfonylpropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-52-3P,
 [4-[5-(4-Methylsulfonylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-53-4P,
 1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-3-ol 778644-55-6P,
 [4-[5-[2-(1-Aminocyclohexyl)ethyl]thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-56-7P,
 Phenyl[[4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyryl]amino]acetic acid methyl ester 778644-57-8P,
 [4-[5-(5-Phenylpentyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-58-9P,
 [N-Benzyl[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]acetic acid ethyl ester 778644-59-0P
 778644-60-3P, 1-Phenyl-3-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-ol 778644-61-4P,
 3-Ethyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-3-ol 778644-63-6P,
 3-[Benzyl-[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]propionitrile 778644-64-7P,
 3-[Methyl-[[5-[2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]amino]propionitrile 778644-65-8P,
 N-(2-Cyanoethyl)-N-[[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methyl]acetamide 778644-66-9P,
 1-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethanone 778644-67-0P,

[4-[5-(4-Chlorophenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-68-1P,
 3-Methyl-5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carbonitrile 778644-69-2P,
 [4-([2,2']Bithiophenyl-5-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-70-5P 778644-73-8P,
 4-Chloro-2-[(E)-2-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethenyl]benzonitrile 778644-74-9P, 2-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-4,5,6,7-tetrahydrobenzo[b]thiophen-4-ol 778644-75-0P, (2,2,6,6-Tetramethylpiperidin-4-yl)[4-(thieno[3,2-c]pyridin-2-yl)pyrimidin-2-yl]amine 778644-76-1P, (4-Chlorophenyl)[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methanol 778644-77-2P, N-[2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]acetamide 778644-78-3P, [4-[5-(2-Dimethylaminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-80-7P, 3-Methyl-5-[2-(2,2,6,6-tetramethylpiperidin-4-ylamino)pyrimidin-4-yl]thiophene-2-carboxylic acid methyl ester 778644-83-0P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid 778644-84-1P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid benzylamide 778644-85-2P, [4-(5-Nitrothiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-86-3P, [4-[5-(4-Methoxyphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-87-4P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenol 778644-89-6P, [4-[5-(2-Methoxyphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-91-0P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid (2-aminoethyl)amide 778644-93-2P, [4-[5-(3-Methoxyphenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778644-94-3P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]benzenesulfonamide 778644-96-5P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]benzoic acid methyl ester 778644-97-6P, [4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]methanol 778644-98-7P, [3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]methanol 778644-99-8P, N-[3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]acetamide 778645-00-4P, [4-[5-(3-Aminophenyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-01-5P, 1-[3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]phenyl]ethanone 778645-02-6P, 5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-sulfonamide 778645-03-7P, [4-[5-(1-Aminoethyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-04-8P, 3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-ol 778645-05-9P, 3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionic acid methyl ester 778645-06-0P,

[4-[5-(4-Aminobutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-07-1P,
 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carbonitrile 778645-10-6P,
 [5'-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl][2,2']bithiophenyl-5-yl]methanol 778645-11-7P,
 2-Methyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-1-ol 778645-12-8P,
 3-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propionamide 778645-13-9P,
 [4-[5-(3-Aminopropyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-14-0P,
 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butan-2-ol 778645-15-1P,
 [4-(5'-Aminomethyl-[2,2']bithiophenyl-5-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-17-3P, Acetic acid
 2-methyl-2-nitro-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propyl ester 778645-18-4P,
 6-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]hexanenitrile 778645-19-5P,
 [4-[5-(6-Aminohexyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-22-0P,
 4-[[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]piperidine-1-carboxylic acid ethyl ester 778645-23-1P,
 4-[[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]-2,2,6,6-tetramethylpiperidin-1-ol 778645-24-2P,
 [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](1,2,2,6,6-pentamethylpiperidin-4-yl)amine 778645-30-0P, [4-(6-Ethoxybenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-31-1P, [4-(6-Allyloxybenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-33-3P,
 1-Isopropylamino-3-[[2-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophen-6-yl]oxy]propan-2-ol 778645-35-5P, 1-Isopropylamino-3-[[2-[5-methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophen-6-yl]oxy]propan-2-ol 778645-36-6P,
 [1-(3-Aminopropyl)piperidin-4-yl][4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]amine 778645-37-7P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6-trimethylpiperidin-4-yl)amine 778645-38-8P,
 [4-(3-Methylbenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-39-9P,
 [4-(5-Methylbenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-40-2P,
 [4-(7-Methoxybenzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-41-3P,
 [4-(Benzo[b]thiophen-5-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-42-4P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-43-5P,
 2-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzo[b]thiophene-7-carboxylic acid (2-diethylaminoethyl)amide 778645-44-6P, 8-Azabicyclo[3.2.1]oct-3-yl[4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]endo-amine 778645-45-7P,
 (2R,4R)-4-[[4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl]amino]piperidine-2-carboxylic acid methyl ester 778645-47-9P,
 [4-(Benzo[b]thiophen-2-yl)-5-methylpyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-48-0P,
 [4-[4-(Pyridin-4-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-

yl)amine 778645-49-1P, 1-Methyl-4-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]piperidin-4-ol 778645-50-4P, [4-[4-(Pyridin-3-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-51-5P, [4-[4-(Pyridin-2-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-52-6P, [4-[4-(4-Methylpiperazin-1-yl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-53-7P, [4-[6-(3-Amino-3-methylbutyl)pyridin-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-54-8P, [4-(4-Methylsulfanylphenyl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-55-9P, [4-(Naphthalen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-57-1P, (2,2,6,6-Tetramethylpiperidin-4-yl)[4-(4-vinylphenyl)pyrimidin-2-yl]amine 778645-58-2P, 4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzenesulfonamide 778645-59-3P, N-(2-Hydroxyethyl)-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]benzenesulfonamide 778645-60-6P, [4-[4-(3-Amino-3-methylbutyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-62-8P, 2-Methyl-4-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butan-2-ol 778645-63-9P, 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propionamide 778645-64-0P, [4-[4-(2-Aminoethyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-66-2P, [4-[4-(3-Aminopropyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-67-3P, [4-[4-(3-Methoxypropyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-69-5P, [4-[4-(4-Aminobutyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-71-9P, 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butan-2-ol 778645-72-0P, [4-[4-(3-Aminobutyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-73-1P, 2-Methyl-4-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]butyronitrile 778645-74-2P, [4-[4-(2-Aminopropyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-75-3P, 2-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenoxy]methyl]benzonitrile 778645-76-4P, [4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenoxy]acetonitrile 778645-77-5P, [4-[4-[2-(Imidazol-1-yl)ethoxy]phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-78-6P, 4-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenoxy]butyronitrile 778645-79-7P, [4-[4-(Pyridin-4-ylmethoxy)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-80-0P, [4-(Indol-1-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-81-1P, [4-(4-Methoxyindol-1-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-82-2P, 1-[1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-3-yl]ethanone 778645-83-3P, [4-(5-Methoxyindol-1-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-85-5P, 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-3-carboxamide 778645-87-7P, 1-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-4-carboxamide 778645-88-8P, [4-(1-Methylindol-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-


yl)amine 778645-89-9P, [4-(1H-Indol-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-90-2P,
 [4-(1H-Indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-91-3P, [4-(1-Methylindol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-92-4P,
 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-5-carbonitrile 778645-93-5P,
 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-6-carbonitrile 778645-94-6P,
 [4-(5H-[1,3]Dioxolo[4,5-f]indol-7-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778645-96-8P,
 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-ol hydrobromide 778645-98-0P,
 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-ol 778645-99-1P, [4-[6-(2-Aminopropyl)-1H-indol-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-00-7P,
 [6-Methoxy-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]indol-1-yl]acetonitrile 778646-01-8P,
 [4-(7-Fluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-02-9P, [4-(6-Fluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-03-0P,
 [4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-04-1P,
 [4-(7-Chloro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-05-2P, [4-(6-Chloro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-06-3P,
 (2,2,6,6-Tetramethylpiperidin-4-yl)[4-(6-trifluoromethyl-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-07-4P,
 [4-(7-Methyl-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-08-5P, 2-Methyl-4-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]butan-2-ol 778646-09-6P,
 [4-(6,7-Difluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-10-9P,
 2-Methyl-4-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]butan-2-ol 778646-11-0P,
 [4-(5,7-Difluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-12-1P,
 [4-[6-[(Morpholin-4-yl)sulfonyl]-1H-indol-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-13-2P,
 [4-(5-Fluoro-7-methyl-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-14-3P,
 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-6-sulfonic acid dimethylamide 778646-15-4P,
 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-7-carbonitrile 778646-17-6P,
 (Morpholin-4-yl)[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]methanone 778646-18-7P,
 3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indole-7-sulfonic acid methylamide 778646-19-8P,
 (5-Azaspiro[3.5]non-8-yl)[4-(7-chloro-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-20-1P, [4-(7-Chloro-1H-indol-3-yl)pyrimidin-2-yl](2,2-dimethylpiperidin-4-yl)amine 778646-21-2P,
 [4-(7-Fluoro-1H-indol-3-yl)pyrimidin-2-yl](2,2-dimethylpiperidin-4-yl)amine 778646-22-3P, (1-Azaspiro[5.5]undecan-4-yl)[4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-23-4P,
 (trans-2,6-Dimethylpiperidin-4-yl)[4-(1H-indol-3-yl)pyrimidin-2-yl]amine 778646-24-5P, [4-(7-Chloro-1H-indol-3-yl)pyrimidin-2-yl](trans-2,6-

dimethylpiperidin-4-yl)amine 778646-25-6P,
 (trans-2,6-Dimethylpiperidin-4-yl) [4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amine 778646-26-7P, [4-(5-Fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-27-8P,
 [4-(6-Chloro-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-28-9P,
 [4-(7-Chloro-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-29-0P,
 [4-(6-Chloro-7-fluoro-1H-indol-3-yl)pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-37-0P,
 (E)-2-Methyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]acrylonitrile 778646-38-1P,
 4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]-2-methylbutan-2-ol 778646-39-2P,
 3-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]propionitrile 778646-40-5P,
 3-[7-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]propionitrile 778646-41-6P,
 4-[5-Fluoro-3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-methylbutan-2-ol 778646-42-7P,
 3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-6-yl]propionitrile 778646-43-8P,
 [4-[6-[2-(Imidazol-1-yl)ethyl]-1H-indol-3-yl]pyrimidin-2-yl] (2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-44-9P,
 3-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]propionitrile 778646-45-0P,
 N,N-Dimethyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]propionamide 778646-46-1P,
 2-Methyl-3-[3-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]propionitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778643-77-9 CAPLUS

CN 2-Thiophenepropanol, α,α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-78-0 CAPLUS

CN 2-Thiophenepropanol, 5-[5-methoxy-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- α,α -dimethyl- (CA INDEX NAME)



RN 778643-79-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-methoxybutyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 778643-80-4 CAPLUS

CN 3-Buten-2-ol, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]-, (3E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 778643-82-6 CAPLUS


CN 3-Buten-2-ol, 2-methyl-4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 778643-83-7 CAPLUS

CN 2-Pyrrolidinone, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-84-8 CAPLUS

CN 2-Thiophenebutanol, 5-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-85-9 CAPLUS

CN 2-Thiopheneethanol, alpha-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-86-0 CAPLUS

CN 2-Thiophenepropanamide, N, α , α -trimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-87-1 CAPLUS

CN 1H-Pyrrole-1-propanol, α , α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778643-88-2 CAPLUS


CN Cyclopropanemethanol, α , α -dimethyl-2-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]- (CA INDEX NAME)



RN 778643-89-3 CAPLUS


CN Cyclopropanemethanol, α , α -dimethyl-2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 778643-90-6 CAPLUS

CN 1-Propanone, 2-ethoxy-2-methyl-1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-91-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-methoxypropyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-92-8 CAPLUS

CN [1,1'-Bicyclopropyl]-1-ol, 2'-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-93-9 CAPLUS

CN 2-Thiophenepropanol, 3-methoxy- α,α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-94-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-amino-2-methylpropyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-95-1 CAPLUS

CN 1,3-Butanediol, 2,2-difluoro-3-methyl-1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778643-96-2 CAPLUS

CN 2-Thiophenepropanol, $\alpha,\alpha,\beta,\beta$ -tetramethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778643-97-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(phenylmethoxy)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-98-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-butyl-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778643-99-5 CAPLUS

CN 2-Pyrimidinamine, 4-(5-propoxy-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-00-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-methoxyethoxy)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-01-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-pyridinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-02-3 CAPLUS

CN 4-Piperidinol, 1-methyl-4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-03-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-pyridinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-04-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-pyridinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-05-6 CAPLUS


CN 2-Pyrimidinamine, 4-[5-(1-piperazinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-06-7 CAPLUS

CN 4-Piperidinol, 4-[5-[2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-4-pyrimidinyl]-2-thienyl]-1-methyl- (CA INDEX NAME)


Relative stereochemistry.



RN 778644-07-8 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-[5-(1-piperazinyl)-2-thienyl]-2-pyrimidinyl]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.




RN 778644-08-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-methyl-1-buten-1-yl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-09-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-methylbutyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-10-3 CAPLUS

CN 3-Butyn-2-ol, 2-methyl-4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-11-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-methyl-1-piperazinyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny]- (CA INDEX NAME)



RN 778644-12-5 CAPLUS


CN 2-Thiophenesulfonamide, 5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778644-13-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 778644-14-7 CAPLUS

CN L-Phenylalanine, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]-2-thienyl]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 778644-15-8 CAPLUS


CN D-Phenylalanine, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]-2-thienyl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 778644-16-9 CAPLUS

CN 4-Piperidinone, 2-(phenylmethyl)-1-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]- (CA INDEX NAME)




RN 778644-17-0 CAPLUS

CN 4-Piperidinecarboxamide, N-(1-methylethyl)-1-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]- (CA INDEX NAME)



RN 778644-18-1 CAPLUS


CN [1,1'-Biphenyl]-4-acetic acid, α -[[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 778644-19-2 CAPLUS


CN L-Proline, 4-hydroxy-1-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]carbonyl]-, phenylmethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 778644-20-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2,2'-bithiophen]-5-yl-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-22-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5'-(1-aminoethyl)[2,2'-bithiophen]-5-yl]-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-23-8 CAPLUS

CN 2-Pyrimidinamine, 5-bromo-4-(4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-24-9 CAPLUS

CN Acetamide, N-[2-[5-[5-bromo-2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)




RN 778644-25-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-aminoethyl)-2-thienyl]-5-bromo-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)



RN 778644-26-1 CAPLUS


CN 2-Pyrimidinamine, 5-bromo-4-[5-[2-(dimethylamino)ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)



RN 778644-28-3 CAPLUS


CN 2-Pyrimidinamine, 4-[5-[4-[(1Z)-1-methyl-1-propen-1-yl]phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 778644-29-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(1-aminoethyl)phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-30-7 CAPLUS

CN 2-Pyrimidinamine, 5-bromo-4-(5-chloro-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-32-9 CAPLUS

CN 2-Thiophenebutanol, 5-[5-bromo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-33-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5'-(1-aminoethyl)[2,2'-bithiophen]-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-34-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[3-(aminomethyl)phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-35-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-[(dimethylamino)methyl]phenyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-37-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[methyl[2-(1-piperidinyl)ethyl]amino]methyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-38-5 CAPLUS

CN 2-Thiophenebutanol, α, α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778644-39-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-[(1-methylethyl)amino]ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-40-9 CAPLUS

CN Methanesulfonamide, N-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)




RN 778644-41-0 CAPLUS

CN Urea, N-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)




RN 778644-42-1 CAPLUS

CN Urea, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]- (CA INDEX NAME)




RN 778644-43-2 CAPLUS

CN Methanesulfonamide, N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]- (CA INDEX NAME)




RN 778644-45-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5'-[(dimethylamino)methyl][2,2'-bithiophen]-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-46-5 CAPLUS

CN Urea, N-[[5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]methyl]- (CA INDEX NAME)




RN 778644-47-6 CAPLUS

CN Acetamide, 2-methoxy-N-[[5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]methyl]- (CA INDEX NAME)




RN 778644-48-7 CAPLUS

CN 2-Thiophenepropanamide, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-49-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-amino-3-ethylpentyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-50-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(methylsulfinylethyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-51-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[3-(methylthio)propyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-52-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(methylsulfonyl)butyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-53-4 CAPLUS

CN 2-Thiophenepropanol, α -ethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-55-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(1-aminocyclohexyl)ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-56-7 CAPLUS

CN Benzeneacetic acid, α -[[1-oxo-4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]butyl]amino]-, methyl ester (CA INDEX NAME)




RN 778644-57-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(5-phenylpentyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-58-9 CAPLUS

CN Glycine, N-(phenylmethyl)-N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 778644-59-0 CAPLUS


CN 2-Propanol, 2-methyl-1-[(phenylmethyl)[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]amino]- (CA INDEX NAME)



RN 778644-60-3 CAPLUS


CN 2-Thiophenepropanol, α -phenyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)

RN 778644-61-4 CAPLUS

CN 2-Thiophenepropanol, α,α -diethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778644-63-6 CAPLUS

CN Propanenitrile, 3-[(phenylmethyl)[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]amino]- (CA INDEX NAME)




RN 778644-64-7 CAPLUS

CN Propanenitrile, 3-[methyl[[5-[2-[(1,2,2,6,6-pentamethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]amino]- (CA INDEX NAME)




RN 778644-65-8 CAPLUS

CN Acetamide, N-(2-cyanoethyl)-N-[[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]methyl]- (CA INDEX NAME)




RN 778644-66-9 CAPLUS

CN Ethanone, 1-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-67-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-68-1 CAPLUS

CN 2-Thiophenecarbonitrile, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-69-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2,2'-bithiophen]-5-yl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-70-5 CAPLUS


CN 2-Pyrimidinamine, 4-[5-(1-methylethenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778644-73-8 CAPLUS


CN Benzonitrile, 4-chloro-2-[(1E)-2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 778644-74-9 CAPLUS

CN Benzo[b]thiophene-4-ol, 4,5,6,7-tetrahydro-2-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-75-0 CAPLUS

CN 2-Pyrimidinamine, N-(2,2,6,6-tetramethyl-4-piperidinyl)-4-thieno[3,2-c]pyridin-2-yl- (CA INDEX NAME)




RN 778644-76-1 CAPLUS

CN 2-Thiophenemethanol, α -(4-chlorophenyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-77-2 CAPLUS

CN Acetamide, N-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)




RN 778644-78-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(dimethylamino)ethyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-80-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778644-83-0 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-84-1 CAPLUS

CN 2-Thiophenecarboxamide, N-(phenylmethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-85-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-nitro-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-86-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-methoxyphenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778644-87-4 CAPLUS

CN Phenol, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-89-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2-methoxyphenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-91-0 CAPLUS

CN 2-Thiophenecarboxamide, N-(2-aminoethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778644-93-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-methoxyphenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778644-94-3 CAPLUS

CN Benzenesulfonamide, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-96-5 CAPLUS

CN Benzoic acid, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, methyl ester (CA INDEX NAME)




RN 778644-97-6 CAPLUS

CN Benzenemethanol, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-98-7 CAPLUS

CN Benzenemethanol, 3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778644-99-8 CAPLUS

CN Acetamide, N-[3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]phenyl]- (CA INDEX NAME)




RN 778645-00-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-aminophenyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-01-5 CAPLUS

CN Ethanone, 1-[3-[5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]phenyl]- (CA INDEX NAME)




RN 778645-02-6 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-03-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(1-aminoethyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-04-8 CAPLUS

CN 2-Thiophenepropanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-05-9 CAPLUS

CN 2-Thiophenepropanoic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 778645-06-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-aminobutyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-07-1 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-10-6 CAPLUS

CN [2,2'-Bithiophene]-5-methanol, 5'-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-11-7 CAPLUS

CN 2-Thiophenemethanol, α -(1-methylethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-12-8 CAPLUS

CN 2-Thiophenepropanamide, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-13-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(3-aminopropyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-14-0 CAPLUS


CN 2-Thiophenepropanol, α -methyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)

RN 778645-15-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5'-(aminomethyl)[2,2'-bithiophen]-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-17-3 CAPLUS

CN 2-Thiophenemethanol, α -(1-methyl-1-nitroethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 2-acetate (CA INDEX NAME)


RN 778645-18-4 CAPLUS

CN 2-Thiophenehexanenitrile, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-19-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(6-aminohexyl)-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-22-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(4-benzo[b]thien-2-yl-2-pyrimidinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 778645-23-1 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(1-hydroxy-2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-24-2 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(1,2,2,6,6-pentamethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-30-0 CAPLUS

CN 2-Pyrimidinamine, 4-(6-ethoxybenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-31-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-propen-1-yloxy)benzo[b]thien-2-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-33-3 CAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[[2-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]benzo[b]thien-6-yl]oxy]- (CA INDEX NAME)




RN 778645-35-5 CAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[[2-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]benzo[b]thien-6-yl]oxy]- (CA INDEX NAME)




RN 778645-36-6 CAPLUS

CN 2-Pyrimidinamine, N-[1-(3-aminopropyl)-4-piperidinyl]-4-benzo[b]thien-2-yl-
(CA INDEX NAME)




RN 778645-37-7 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(2,2,6-trimethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 778645-38-8 CAPLUS

CN 2-Pyrimidinamine, 4-(3-methylbenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 778645-39-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methylbenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 778645-40-2 CAPLUS

CN 2-Pyrimidinamine, 4-(7-methoxybenzo[b]thien-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-41-3 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-5-yl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-42-4 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778645-43-5 CAPLUS


CN Benzo[b]thiophene-7-carboxamide, N-[2-(diethylamino)ethyl]-2-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778645-44-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-(4-benzo[b]thien-2-yl-2-pyrimidinyl)-, (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 778645-45-7 CAPLUS


CN 2-Piperidinecarboxylic acid, 4-[(4-benzo[b]thien-2-yl-2-pyrimidinyl)amino]-, methyl ester, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 778645-47-9 CAPLUS

CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-5-methyl-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-48-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-pyridinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-49-1 CAPLUS

CN 4-Piperidinol, 1-methyl-4-[4-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778645-50-4 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(3-pyridinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)



RN 778645-51-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(2-pyridinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-

piperidinyl)- (CA INDEX NAME)




RN 778645-52-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-methyl-1-piperazinyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-53-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-amino-3-methylbutyl)-3-pyridinyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-54-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(methylthio)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-55-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-naphthalenyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-57-1 CAPLUS

CN 2-Pyrimidinamine, 4-(4-ethenylphenyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-58-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-59-3 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-60-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-amino-3-methylbutyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-62-8 CAPLUS

CN Benzenepropanol, α,α -dimethyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778645-63-9 CAPLUS

CN Benzenepropanamide, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-64-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(2-aminoethyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-66-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-aminopropyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-67-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-methoxypropyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-69-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-aminobutyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-71-9 CAPLUS

CN Benzenepropanol, α -methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-72-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-aminobutyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-73-1 CAPLUS

CN Benzenebutanenitrile, α -methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-74-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(2-aminopropyl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-75-3 CAPLUS

CN Benzonitrile, 2-[[4-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]phenoxy]methyl]- (CA INDEX NAME)




RN 778645-76-4 CAPLUS

CN Acetonitrile, 2-[4-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]phenoxy]- (CA INDEX NAME)




RN 778645-77-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-78-6 CAPLUS

CN Butanenitrile, 4-[4-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]phenoxy]- (CA INDEX NAME)




RN 778645-79-7 CAPLUS

CN 2-Pyrimidinamine, 4-[4-[2-(4-pyridinylmethoxy)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-80-0 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-1-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-81-1 CAPLUS

CN 2-Pyrimidinamine, 4-(4-methoxy-1H-indol-1-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-82-2 CAPLUS

CN Ethanone, 1-[1-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 778645-83-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methoxy-1H-indol-1-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-85-5 CAPLUS

CN 1H-Indole-3-carboxamide, 1-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-87-7 CAPLUS

CN 1H-Indole-4-carboxamide, 1-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-88-8 CAPLUS

CN 2-Pyrimidinamine, 4-(1-methyl-1H-indol-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-89-9 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 778645-90-2 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 778645-91-3 CAPLUS

CN 2-Pyrimidinamine, 4-(1-methyl-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778645-92-4 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-93-5 CAPLUS

CN 1H-Indole-6-carbonitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-94-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5H-1,3-dioxolo[4,5-f]indol-7-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778645-96-8 CAPLUS


CN 1H-Indol-6-ol, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, hydrobromide (1:?) (CA INDEX NAME)




● x HBr

RN 778645-98-0 CAPLUS

CN 1H-Indol-7-ol, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778645-99-1 CAPLUS

CN 1H-Indole-6-ethanamine, α -methyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


RN 778646-00-7 CAPLUS

CN 1H-Indole-1-acetonitrile, 6-methoxy-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-01-8 CAPLUS

CN 2-Pyrimidinamine, 4-(7-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-02-9 CAPLUS

CN 2-Pyrimidinamine, 4-(6-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-03-0 CAPLUS

CN 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-04-1 CAPLUS

CN 2-Pyrimidinamine, 4-(7-chloro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-05-2 CAPLUS

CN 2-Pyrimidinamine, 4-(6-chloro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-06-3 CAPLUS

CN 2-Pyrimidinamine, N-(2,2,6,6-tetramethyl-4-piperidinyl)-4-[6-(trifluoromethyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 778646-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-(7-methyl-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-08-5 CAPLUS

CN 1H-Indole-6-propanol, α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-09-6 CAPLUS

CN 2-Pyrimidinamine, 4-(6,7-difluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-10-9 CAPLUS

CN 1H-Indole-7-propanol, α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5,7-difluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-12-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-morpholinylsulfonyl)-1H-indol-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-13-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-fluoro-7-methyl-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-14-3 CAPLUS

CN 1H-Indole-6-sulfonamide, N,N-dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-15-4 CAPLUS

CN 1H-Indole-7-carbonitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-17-6 CAPLUS

CN Methanone, 4-morpholinyl[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 778646-18-7 CAPLUS

CN 1H-Indole-7-sulfonamide, N-methyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-19-8 CAPLUS

CN 5-Azaspiro[3.5]nonan-8-amine, N-[4-(7-chloro-1H-indol-3-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 778646-20-1 CAPLUS


CN 2-Pyrimidinamine, 4-(7-chloro-1H-indol-3-yl)-N-(2,2-dimethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778646-21-2 CAPLUS
 CN 2-Pyrimidinamine, N-(2,2-dimethyl-4-piperidiny1)-4-(7-fluoro-1H-indol-3-yl)- (CA INDEX NAME)




RN 778646-22-3 CAPLUS
 CN 1-Azaspiro[5.5]undecan-4-amine, N-[4-(7-fluoro-1H-indol-3-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 778646-23-4 CAPLUS
 CN 2-Pyrimidinamine, N-[(2R,6R)-2,6-dimethyl-4-piperidiny1]-4-(1H-indol-3-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 778646-24-5 CAPLUS
 CN 2-Pyrimidinamine, 4-(7-chloro-1H-indol-3-yl)-N-[(2R,6R)-2,6-dimethyl-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 778646-25-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(2R,6R)-2,6-dimethyl-4-piperidinyl]-4-(7-fluoro-1H-indol-3-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 778646-26-7 CAPLUS
 CN 2-Pyrimidinamine, 4-(5-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-27-8 CAPLUS

CN 2-Pyrimidinamine, 4-(6-chloro-5-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-28-9 CAPLUS

CN 2-Pyrimidinamine, 4-(7-chloro-5-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778646-29-0 CAPLUS


CN 2-Pyrimidinamine, 4-(6-chloro-7-fluoro-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 778646-37-0 CAPLUS


CN 2-Propenenitrile, 2-methyl-3-[3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 778646-38-1 CAPLUS

CN 1H-Indole-6-propanol, 5-fluoro- α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-39-2 CAPLUS

CN 1H-Indole-6-propanenitrile, 5-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-40-5 CAPLUS

CN 1H-Indole-6-propanenitrile, 7-fluoro-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-41-6 CAPLUS

CN 1H-Indole-7-propanol, 5-fluoro- α,α -dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-42-7 CAPLUS

CN 1H-Indole-6-propanenitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-43-8 CAPLUS

CN 2-Pyrimidinamine, 4-[6-[2-(1H-imidazol-1-yl)ethyl]-1H-indol-3-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-44-9 CAPLUS

CN 1H-Indole-7-propanenitrile, 3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-45-0 CAPLUS

CN 1H-Indole-7-propanamide, N,N-dimethyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778646-46-1 CAPLUS

CN 1H-Indole-7-propanenitrile, α -methyl-3-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)


IT 778646-65-4P, 2-Methyl-1-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]propan-2-ol 778646-69-8P, 2,3,3-Trimethyl-5-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]pentan-2-ol 778646-71-2P, 2-[(1S,2S)-2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]cyclopropyl]propan-2-ol 778646-74-5P, [4-[5-(2-Dimethylaminoethoxy)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine dihydrochloride 778646-82-5P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid phenethylamide 778646-83-6P, [4-(1H-Indol-3-yl)piperidin-1-yl][5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]methanone 778646-88-1P, 1-[2-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]ethyl]cyclobutanol 778646-90-5P, (5-Azaspiro[3.5]nonan-8-yl)[4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]amine 778646-93-8P, [4-(Benzo[b]thiophen-2-yl)pyrimidin-2-yl](trans-2,6-

dimethylpiperidin-4-yl)amine 778647-26-0P,
 N-[3-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]acetamide 778647-27-1P,
 [4-(7-Bromo-1H-indol-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-28-2P, [4-(1H-Pyrrolo[3,2-h]quinolin-3-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine
 780767-19-3P, 8-Azabicyclo[3.2.1]oct-3-yl[4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl]-exo-amine 780767-20-6P 780767-21-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778646-65-4 CAPLUS

CN 2-Thiopheneethanol, α,α -dimethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778646-69-8 CAPLUS


CN 2-Thiophenebutanol, $\alpha,\alpha,\beta,\beta$ -tetramethyl-5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778646-71-2 CAPLUS


CN Cyclopropanemethanol, α,α -dimethyl-2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 778646-74-5 CAPLUS


CN 2-Pyrimidinamine, 4-[5-[2-(dimethylamino)ethoxy]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidiny)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 778646-82-5 CAPLUS

CN 2-Thiophenecarboxamide, N-(2-phenylethyl)-5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-83-6 CAPLUS

CN Methanone, [4-(1H-indol-3-yl)-1-piperidiny][5-[2-[(2,2,6,6-tetramethyl-4-piperidiny)amino]-4-pyrimidinyl]-2-thienyl]- (CA INDEX NAME)




RN 778646-88-1 CAPLUS

CN Cyclobutanol, 1-[2-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]ethyl]- (CA INDEX NAME)



RN 778646-90-5 CAPLUS


CN 5-Azaspiro[3.5]nonan-8-amine, N-(4-benzo[b]thien-2-yl-2-pyrimidinyl)- (CA INDEX NAME)



RN 778646-93-8 CAPLUS


CN 2-Pyrimidinamine, 4-benzo[b]thien-2-yl-N-[(2R,6R)-2,6-dimethyl-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 778647-26-0 CAPLUS

CN Acetamide, N-[3-[2-[(2,2,6,6-tetramethyl-4-piperidiny]amino]-4-pyrimidinyl]-1H-indol-7-yl]- (CA INDEX NAME)




RN 778647-27-1 CAPLUS

CN 2-Pyrimidinamine, 4-(7-bromo-1H-indol-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)



RN 778647-28-2 CAPLUS


CN 2-Pyrimidinamine, 4-(1H-pyrrolo[3,2-h]quinolin-3-yl)-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)



RN 780767-19-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-(4-benzo[b]thien-2-yl-2-pyrimidinyl)-, (3-exo)- (CA INDEX NAME)


Relative stereochemistry.



RN 780767-20-6 CAPLUS

CN 2-Pyrimidinamine, N-[(2R,6S)-2,6-dimethyl-4-piperidiny]-4-(7-fluoro-1H-indol-3-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 780767-21-7 CAPLUS

CN 2-Pyrimidinamine, N-[(2R,6S)-2,6-dimethyl-4-piperidiny]-4-(7-fluoro-1H-indol-3-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 778645-56-0P, [4-(4-Bromophenyl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate, IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)

RN 778645-56-0 CAPLUS

CN 2-Pyrimidinamine, 4-(4-bromophenyl)-N-(2,2,6,6-tetramethyl-4-piperidiny)-

(CA INDEX NAME)




IT 778646-58-5P, [4-(5-Bromothiophen-2-yl)pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-64-3P, 4-[5-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyric acid methyl ester 778646-76-7P, 4-[5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]piperazine-1-carboxylic acid ethyl ester 778646-78-9P, (8-Azabicyclo[3.2.1]oct-3-yl)[4-[5-[4-(ethoxycarbonyl)piperazin-1-yl]thiophen-2-yl]pyrimidin-2-yl]exo-amine 778646-80-3P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid ethyl ester 778646-81-4P, 5-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophene-2-carboxylic acid 778646-84-7P, 1-[5'-[5-Methyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]-[2,2']bithiophenyl-5-yl]ethanone O-methyloxime 778646-85-8P, Toluene-4-sulfonic acid 4-[5-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]thiophen-2-yl]butyl ester 778646-86-9P, [4-[5-(4-Methylsulfanylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778646-87-0P, [4-[5-(4-Methylsulfinylbutyl)thiophen-2-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-01-1P, [4-[6-(3-Amino-3-methylbut-1-ynyl)pyridin-3-yl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-02-2P, (4-Phenylpyrimidin-2-yl)(2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-03-3P, [4-[4-(3-Amino-3-methylbut-1-ynyl)phenyl]pyrimidin-2-yl](2,2,6,6-tetramethylpiperidin-4-yl)amine 778647-04-4P, 3-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propionic acid 778647-05-5P, Toluene-4-sulfonic acid 3-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propyl ester 778647-07-7P, Toluene-4-sulfonic acid 1-methyl-3-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propyl ester 778647-09-9P, 1-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propan-2-one 778647-10-2P, 1-[4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]propan-2-ol 778647-11-3P, Toluene-4-sulfonic acid 1-methyl-2-[4-[2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenyl]ethyl ester 778647-13-5P, 4-[2-[(2,2,6,6-Tetramethylpiperidin-4-yl)amino]pyrimidin-4-yl]phenol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)


RN 778646-58-5 CAPLUS

CN 2-Pyrimidinamine, 4-(5-bromo-2-thienyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-64-3 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 778646-76-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-thienyl]-, ethyl ester (CA INDEX NAME)



RN 778646-78-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-4-pyrimidinyl]-2-thienyl]-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 778646-80-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, ethyl ester (CA INDEX NAME)




RN 778646-81-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778646-84-7 CAPLUS

CN Ethanone, 1-[5'-[5-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl][2,2'-bithiophen]-5-yl]-, O-methyloxime (CA INDEX NAME)




RN 778646-85-8 CAPLUS

CN 2-Thiophenebutanol, 5-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 2-(4-methylbenzenesulfonate) (CA INDEX NAME)




RN 778646-86-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(methylthio)butyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778646-87-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[4-(methylsulfinyl)butyl]-2-thienyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778647-01-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-amino-3-methyl-1-butyn-1-yl)-3-pyridinyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778647-02-2 CAPLUS

CN 2-Pyrimidinamine, 4-phenyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778647-03-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3-amino-3-methyl-1-butyn-1-yl)phenyl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




RN 778647-04-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778647-05-5 CAPLUS

CN Benzenepropanol, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)




RN 778647-07-7 CAPLUS

CN Benzenepropanol, α -methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)




RN 778647-09-9 CAPLUS

CN 2-Propanone, 1-[4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 778647-10-2 CAPLUS

CN Benzeneethanol, α -methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778647-11-3 CAPLUS

CN Benzeneethanol, α -methyl-4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)



RN 778647-13-5 CAPLUS

CN Phenol, 4-[2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



IT 778646-77-8, 5-Bromo-2-[[8-azabicyclo[3.2.1]oct-3-yl)exo-amino]pyrimidin-4-yl]thiophene


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminopyrimidines as inhibitors of TNF- α production for treating autoimmune diseases and inflammations)

RN 778646-77-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[4-(5-bromo-2-thienyl)-2-pyrimidinyl]-
, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 51 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:857595 CAPLUS

DN 141:350190

TI Preparation of thiazoles as inhibitors of protein kinases

IN Brechley, Guy; Farmer, Luc J.; Harrington, Edmund Martin; Knegetel, Ronald; O'Donnell, Michael; Salituro, Francesco G.; Studley, John R.; Wang, Jian

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2004087699 | A2 | 20041014 | WO 2004-US9166 | 20040325 |
| | WO 2004087699 | A3 | 20041209 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2004225977 | A1 | 20041014 | AU 2004-225977 | 20040325 |
| | CA 2523126 | A1 | 20041014 | CA 2004-2523126 | 20040325 |
| | US 20050004150 | A1 | 20050106 | US 2004-809946 | 20040325 |
| | US 7276502 | B2 | 20071002 | | |
| | EP 1605946 | A2 | 20051221 | EP 2004-758338 | 20040325 |
| | EP 1605946 | B1 | 20080528 | | |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | |
| | JP 2006522125 | T | 20060928 | JP 2006-509290 | 20040325 |
| | AT 396731 | T | 20080615 | AT 2004-758338 | 20040325 |
| PRAI | US 2003-457468P | P | 20030325 | | |
| | WO 2004-US9166 | W | 20040325 | | |

OS MARPAT 141:350190

AB The title compds. [I; R1, R2 = R, halo, CN, NO2, etc.; R = H, (un)substituted alkyl; Ar1 = (un)substituted aryl, heteroaryl, etc.; R3, R4 = ZR7; or R3 and R4 are taken together to form (un)substituted (un)saturated 3-8 membered ring having 0-3 heteroatoms; Z = a bond, alkylidene, etc.; R7 = halo, CN, NO2, etc.], useful of inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting from benzothiazole, was given. The compds. I were tested against SYK and ZAP-70 kinases (data given for representative compds. I). The invention also provides pharmaceutically acceptable compns. comprising said compds. I and methods of using the compns. in the treatment of various disease, conditions, or disorders.


IT 774229-12-8P 774229-32-2P 774229-55-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazoles as inhibitors of protein kinases)


RN 774229-12-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 774229-32-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-4-piperidinyl- (CA INDEX NAME)



RN 774229-55-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-4-pyridinyl- (CA INDEX NAME)



L17 ANSWER 52 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:857175 CAPLUS
 DN 141:350167
 TI Preparation of imidazolin-2-one derivatives as p38 MAP kinase inhibitors
 IN Kubo, Akira; Imashiro, Ritsuo; Sakurai, Hiroaki; Miyoshi, Hidetaka;
 Ogasawara, Akihito; Hiramatsu, Hajime; Nakajima, Tatsuo; Nakane, Tetsu
 PA Japan
 SO U.S. Pat. Appl. Publ., 76 pp., Cont.-in-part of Appl. No. PCT/JP02/10937.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 20040204426 | A1 | 20041014 | US 2004-827294 | 20040420 |
| | WO 2003035638 | A1 | 20030501 | WO 2002-JP10937 | 20021022 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004201666 | A1 | 20040513 | AU 2004-201666 | 20040421 |
| | WO 2004094404 | A1 | 20041104 | WO 2004-JP5716 | 20040421 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | JP 2004339210 | A | 20041202 | JP 2004-125060 | 20040421 |
| | EP 1628968 | A1 | 20060301 | EP 2004-728708 | 20040421 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | JP 2001-324029 | A | 20011022 | | |
| | JP 2002-263680 | A | 20020910 | | |
| | WO 2002-JP10937 | A2 | 20021022 | | |
| | JP 2003-116076 | A | 20030421 | | |
| | AU 2002-363108 | A3 | 20021022 | | |
| | WO 2004-JP5716 | W | 20040421 | | |
| OS | MARPAT 141:350167 | | | | |
| AB | The title compds. I [wherein G1 = (un)substituted alkyl or B-W; B = (un)substituted Ph, naphthyl, aromatic heterocyclyl, or cycloalkyl; W = a single bond or (un)substituted alkylene; Q1 and Q2 = independently H, halo, alkyl; n = 0-4; R1 = H, (un)substituted (cyclo)alkyl, Ph, or heterocyclyl; Z1-Z4 = independently CH or N with exclusions; G2 = H, NR3R4, OR5, SR5, COR6, CHR7R8, or heterocyclyl; R3-R8 = independently H, alkenyl, alkynyl, OH, alkoxy, alkoxyoxalyl, alkylsulfonyl, (un)substituted | | | | |

alkyl, amino, alkanoyl, carbamoyl, cycloalkyl, Ph, heterocyclyl(carbonyl), PhCO, or heterocyclyl-CO] and pharmaceutically acceptable salts were prepared as p38 mitogen activation proteins (MAP) kinase inhibitors. Thus, reacting 2,2-diethoxy-2-(pyridin-4-yl)ethylamine (preparation given) with 4-fluorophenyl isocyanate afforded the imidazolinone II. The representative compds. I significantly reduced the production of $\text{TNF-}\alpha$ in mice in vivo.


IT 521090-46-0P 521090-47-1P 521090-48-2P
521090-50-6P 521090-51-7P 521090-60-8P
521091-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MAP kinase inhibitor; preparation of imidazolinones as p38 MAP kinase inhibitors)

RN 521090-46-0 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 521090-47-1 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-[[1-(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (CA INDEX NAME)




RN 521090-48-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 521090-50-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 521090-51-7 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 521090-60-8 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 521091-47-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


| | | | |
|----|--------------|--------------|--------------|
| IT | 1070144-05-6 | 1070144-08-9 | 1070144-10-3 |
| | 1070144-11-4 | 1070144-13-6 | 1070144-15-8 |
| | 1070144-18-1 | 1070144-24-9 | 1070144-25-0 |
| | 1070144-29-4 | 1070144-30-7 | 1070144-35-2 |
| | 1070144-36-3 | 1070144-40-9 | 1070144-41-0 |
| | 1070144-42-1 | 1070144-48-7 | 1070144-53-4 |
| | 1070144-56-7 | 1070144-57-8 | 1070144-59-0 |
| | 1070144-62-5 | 1070144-65-8 | 1070144-68-1 |
| | 1070144-71-6 | 1070144-73-8 | 1070144-76-1 |
| | 1070144-78-3 | 1070144-79-4 | 1070144-81-8 |

RL: PRPH (Prophetic)

(Preparation of imidazolin-2-one derivatives as p38 MAP kinase inhibitors)


RN 1070144-05-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1070144-08-9 CAPLUS


CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1070144-10-3 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/552,317



RN 1070144-11-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1070144-13-6 CAPLUS
CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 1070144-15-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 1070144-18-1 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylpropyl)- (CA INDEX NAME)




RN 1070144-24-9 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[1-(methanesulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(4-fluorophenyl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-25-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-1-(4-(trifluoromethyl)phenyl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-29-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 1070144-30-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)



RN 1070144-35-2 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 1070144-36-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


10/552,317



RN 1070144-40-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1070144-41-0 CAPLUS
CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(1-methylpropyl)- (CA INDEX NAME)




RN 1070144-42-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(1-methylpropyl)-
(CA INDEX NAME)




RN 1070144-48-7 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-
(CA INDEX NAME)




RN 1070144-53-4 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1070144-56-7 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-57-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-59-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 1070144-62-5 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-3-furanyl)- (CA INDEX NAME)



RN 1070144-65-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1070144-68-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1070144-71-6 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-3-(3-chlorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1070144-73-8 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1070144-76-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


10/552,317



RN 1070144-78-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1070144-79-4 CAPLUS
CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[4-methyl-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-3-furanyl)- (CA INDEX NAME)



RN 1070144-81-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylpropyl)-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



IT 774579-33-8P 774579-49-6P 774579-50-9P
 774579-76-9P 774579-77-0P 774579-78-1P
 774579-79-2P 774579-80-5P 774579-81-6P
 774579-82-7P 774579-83-8P 774579-84-9P
 774579-85-0P 774579-86-1P 774579-87-2P
 774579-88-3P 774579-89-4P 774579-90-7P
 774579-91-8P 774579-92-9P 774579-93-0P
 774579-96-3P 774579-99-6P 774580-00-6P
 774580-01-7P 774580-03-9P 774580-04-0P
 774580-05-1P 774580-06-2P 774580-07-3P
 774580-08-4P 774580-09-5P 774580-10-8P
 774580-11-9P 774580-16-4P 774580-17-5P
 774580-18-6P 774580-19-7P 774580-23-3P
 774580-24-4P 774580-25-5P 774580-48-2P
 774580-49-3P 774580-50-6P 774580-59-5P
 774580-60-8P 774580-61-9P 774580-71-1P
 774580-72-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of imidazolinones as p38 MAP kinase inhibitors)

RN 774579-33-8 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 774579-49-6 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-50-9 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-76-9 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-77-0 CAPLUS
 CN 2H-Imidazol-2-one, 1-(1-acetyl-4-piperidiny)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-78-1 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidiny]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-79-2 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(methanesulfonyl)-4-piperidiny]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-80-5 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-81-6 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-82-7 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(butylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-83-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 2-methylpropyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-84-9 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[1-(1-oxobutyl)-4-piperidiny]amino]-4-pyrimidinyl]-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 774579-85-0 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidiny]amino)-4-pyrimidinyl]-1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-86-1 CAPLUS
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 774579-87-2 CAPLUS
 CN 2H-Imidazol-2-one, 1-ethyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-88-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-89-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774579-90-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774579-91-8 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774579-92-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774579-93-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-96-3 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774579-99-6 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-00-6 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-01-7 CAPLUS
 CN 2H-Imidazol-2-one, 1-(cyclopropylmethyl)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methanesulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-03-9 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-04-0 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-05-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-06-2 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(1-oxopropyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-07-3 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-08-4 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[(1-acetyl-4-piperidinyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-09-5 CAPLUS
 CN 2H-Imidazol-2-one, 4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(methoxymethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-10-8 CAPLUS
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)


10/552,317



● HCl

RN 774580-11-9 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-16-4 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

RN 774580-17-5 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclobutyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-18-6 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-19-7 CAPLUS


CN 1-Piperidinesulfonamide, 4-[[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-23-3 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(methoxymethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-24-4 CAPLUS
 CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-25-5 CAPLUS
 CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(3-hydroxy-3-methylbutyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-48-2 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclopentyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-49-3 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-50-6 CAPLUS
 CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 774580-59-5 CAPLUS
 CN 2H-Imidazol-2-one, 1-cyclohexyl-4-[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-60-8 CAPLUS
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 774580-61-9 CAPLUS
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(methanesulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 774580-71-1 CAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[1-(methanesulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 774580-72-2 CAPLUS
 CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[1-(methanesulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/552,317



● HCl

L17 ANSWER 53 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:372883 CAPLUS
 DN 140:375182
 TI Preparation of 3-(pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
 IN Clark, Michael Philip; Laufersweiler, Matthew John; De, Biswanath; Janusz, Michael John
 PA The Procter & Gamble Company, USA
 SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 246,214.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 20040087639 | A1 | 20040506 | US 2003-689388 | 20031020 |
| | US 7087615 | B2 | 20060808 | | |
| | US 20030134867 | A1 | 20030717 | US 2002-246214 | 20020918 |
| | US 6730668 | B2 | 20040504 | | |
| | CN 1681819 | A | 20051012 | CN 2003-821850 | 20030318 |
| | CN 1315834 | C | 20070516 | | |
| | ZA 2005001590 | A | 20060222 | ZA 2005-1590 | 20050223 |
| | KR 2007051374 | A | 20070517 | KR 2007-710029 | 20070502 |
| | KR 842191 | B1 | 20080630 | | |
| | KR 2007087684 | A | 20070828 | KR 2007-716926 | 20070723 |
| PRAI | US 2001-323625P | P | 20010920 | | |
| | US 2002-246214 | A2 | 20020918 | | |
| | WO 2003-US8477 | W | 20030318 | | |
| | KR 2005-704666 | A3 | 20050318 | | |
| | KR 2007-710029 | A3 | 20070502 | | |

OS MARPAT 140:375182

AB The present invention relates to compds. which are capable of preventing the extracellular release of inflammatory cytokines, said compds., including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, have the formula (I) [R = O(CH₂)_kR₃, (un)substituted NH₂ (wherein k = 0-5; R₃ = (un)substituted alkyl, hydrocarbonyl, heterocyclyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl); R₁ = (un)substituted (hetero)aryl; R₂ = H, (CH₂)_jO(CH₂)_nR₈, (CH₂)_jNR_{9a}R_{9b}, (CH₂)_jCO₂R₁₀, (CH₂)_jOCO₂R₁₀, (CH₂)_jCON(R₁₀)₂, (CH₂)_jOCON(R₁₀)₂; or two R₂ units can be taken together to form a CO unit (wherein R₈, R_{9a}, R_{9b}, R₁₀ = H, alkyl; or R_{9a} and R_{9b} are taken together to form carbocyclic or heterocyclic ring; j, n = 0-5); Z = O, S, NR₁₁, NOR₁₁ (R₁₁ = H, alkyl)]. Interleukin-1 (IL-1) and tumor necrosis factor- α (TNF- α) are among the important biol. substances known collectively as cytokines and understood to mediate the inflammatory response associated with the immunol. recognition of infectious agents. These pro-inflammatory cytokines are suggested as an important mediators in many disease states or syndromes, inter alia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease (IBS), septic shock, cardiopulmonary dysfunction, acute respiratory disease, cachexia, and therefore responsible for the progression and manifestation of human disease states. The compds. I can provide pain relief, and reduce psoriasis in humans or higher mammal (data provided for one of the compds. I). Thus, 6.0 g Me 4-fluorophenylacetate was added to a cold (-78°) solution of lithium diisopropylamide (2M, 21.4 mL) in THF and stirred at -78° for 1 h at -78°, followed by adding dropwise a solution of 6.0 g 2-methylsulfanylpurimidine-4-carboxaldehyde (preparation


given) in 30 mL THF and the resulting mixture was stirred for 45 min at -78° to give, after workup and silica gel chromatog., 8.7 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-3-hydroxypropionic acid Me ester (II) (76 %). To a suspension of CrO₃ in CH₂Cl₂ (300 mL) was added pyridine and stirred vigorously for 1 h at room temperature, followed by adding a solution of the crude II prepared above in 50 mL CH₂Cl₂ dropwise, and the reaction mixture was stirred at room temperature for 16 h to give, after workup and silica gel chromatog., 3.7 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-3-oxopropionic acid Me ester (III) (43% yield) as a yellow solid. To a solution of 7.8 g pyrazolidine in 100 mL pyridine was added 11.5 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-3-oxopropionic acid Me ester and heated to 90° for 16 h to give, after silica gel chromatog., 3.9 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one (37%) which (1.3 g) was dissolved in a 1:1 mixture of THF and MeOH (56 mL), treated dropwise with 9.34 g Oxone in 42 mL H₂O, and stirred at room temperature for 1 h to give 2-(4-fluorophenyl)-3-(2-methanesulfonylpurimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one. The pharmaceutical compns. comprising the compound I are claimed.

IT 503072-98-8P, 2-(4-Fluorophenyl)-3-[2-[[1-(propanesulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (pyrimidinyl)dihydro-5H-pyrazolo[1,2-a]pyrazolones which provide analgesia)

RN 503072-98-8 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(4-fluorophenyl)-6,7-dihydro-3-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 54 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:162457 CAPLUS
 DN 140:199322
 TI Preparation of 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for the
 prevention of extracellular release of inflammatory cytokines
 IN Clark, Michael Philip; Laufersweiler, Matthew John; Golebiowski, Adam;
 Sabat, Mark; Brugel, Todd Andrew
 PA The Procter & Gamble Company, USA
 SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 246,214.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 20040038971 | A1 | 20040226 | US 2003-390216 | 20030317 |
| | US 6849627 | B2 | 20050201 | | |
| | US 20030134867 | A1 | 20030717 | US 2002-246214 | 20020918 |
| | US 6730668 | B2 | 20040504 | | |
| | CN 1681819 | A | 20051012 | CN 2003-821850 | 20030318 |
| | CN 1315834 | C | 20070516 | | |
| | ZA 2005001590 | A | 20060222 | ZA 2005-1590 | 20050223 |
| | KR 2007051374 | A | 20070517 | KR 2007-710029 | 20070502 |
| | KR 842191 | B1 | 20080630 | | |
| | KR 2007087684 | A | 20070828 | KR 2007-716926 | 20070723 |
| PRAI | US 2001-323625P | P | 20010920 | | |
| | US 2002-246214 | A2 | 20020918 | | |
| | WO 2003-US8477 | W | 20030318 | | |
| | KR 2005-704666 | A3 | 20050318 | | |
| | KR 2007-710029 | A3 | 20070502 | | |

OS MARPAT 140:199322

AB Title compds. I [R1 = (un)substituted aryl, heteroaryl; R2 = H, (CH2)_jO(CH2)_nR8, (CH2)_jCO2R10, etc.; R8, R10 = H, alkyl; j, n = 0-5; Z = O, S, NR11, etc.; R11 = H, alkyl; R3 = (un)substituted aryl, heteroaryl] and their pharmaceutically acceptable salts were prepared For example, condensation of sulfone II, e.g., prepared from pyruvic aldehyde di-Me acetal in 4-steps, and (S)-methylbenzylamine afforded pyrazolopyrazolone III. In cell based interleukin-1, cyclooxygenase-2 and tumor necrosis factor assays, compds. I exhibited IC50 values below 1.0 μM (sic).


IT 503072-98-8 1055722-42-3

RL: PRPH (Prophetic)

(Preparation of 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for the prevention of extracellular release of inflammatory cytokines)


RN 503072-98-8 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
 2-(4-fluorophenyl)-6,7-dihydro-3-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1055722-42-3 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 660857-85-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolo[1,2-a]pyrazolones for the prevention of extracellular release of inflammatory cytokines)

RN 660857-85-2 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
2-(4-fluorophenyl)-6,7-dihydro-3-[2-(4-pyridinylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 55 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:143155 CAPLUS
 DN 140:199339
 TI Preparation of 6-aminopurines and related compounds as selective
 phosphodiesterase-4 inhibitors for treatment of psychosis and inflammation
 IN Liu, Ruiping; Hopper, Allen T.; Tehim, Ashok; Hess, Hans-Jurgen E.; Rong,
 Yajing
 PA Memory Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004014913 | A2 | 20040219 | WO 2003-US24914 | 20030808 |
| | WO 2004014913 | A3 | 20040729 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |
| | CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |
| | GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, | | | | |
| | LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, | | | | |
| | PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, | | | | |
| | TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, | | | | |
| | KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, | | | | |
| | FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, | | | | |
| | BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2494028 | A1 | 20040219 | CA 2003-2494028 | 20030808 |
| | AU 2003264017 | A1 | 20040225 | AU 2003-264017 | 20030808 |
| | EP 1529049 | A2 | 20050511 | EP 2003-785075 | 20030808 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |
| | IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1688580 | A | 20051026 | CN 2003-823977 | 20030808 |
| | JP 2005538134 | T | 20051215 | JP 2004-527913 | 20030808 |
| | US 20070093510 | A1 | 20070426 | US 2003-636979 | 20030808 |
| | US 7332486 | B2 | 20080219 | | |
| | US 20080139583 | A1 | 20080612 | US 2008-26198 | 20080205 |
| PRAI | US 2002-401765P | P | 20020808 | | |
| | US 2003-636979 | A1 | 20030808 | | |
| | WO 2003-US24914 | W | 20030808 | | |

OS MARPAT 140:199339

AB Title compds. I [X = NHR1; R1 = H, (un)substituted alkyl, cycloalkyl,
 etc.; R2 = (un)substituted aryl, heteroaryl, heteroarylalkyl, etc.,] and
 their pharmaceutically acceptable salts were prepared For example,
 electrophilic substitution of aminocyclopropane with compound I [X = Cl; R2
 = 2-fluorobenzyl], e.g., prepared from 5-aminoimidazole-4-carboxamide
 hydrochloride in 3-steps, followed by acid work-up furnished compound I [R1
 = cyclopropyl; R2 = 2-fluorobenzyl] methanesulfonate in 80.3% overall
 yield. In human PDE-4 inhibition assays, compds. I showed indicative
 (sic.) inhibition of PDE-4 activity (no data provided). Compds. I are
 claimed useful for the treatment of psychosis, Alzheimer's disease,
 allergy, inflammation, etc.

IT 660867-32-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 6-aminopurines and related compds. as selective PDE-4

inhibitors for treatment of psychosis and inflammation)

RN 660867-32-3 CAPLUS

CN 9H-Purin-6-amine, N-cyclopropyl-9-[2-(4-pyridinylamino)-4-pyrimidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



L17 ANSWER 56 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:991504 CAPLUS

DN 140:42177

TI Preparation of pyrazoles as p38 α kinase, TNF and/or cyclooxygenase-2 inhibitors

IN Benson, Alan G.; Fraher, Thomas Phillip; Hepperle, Michael E.; Jerome, Kevin D.; Naing, Win; Selness, Shaun Raj; Walker, John K.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 341 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003104223 | A1 | 20031218 | WO 2003-US17906 | 20030605 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2488402 | A1 | 20031218 | CA 2003-2488402 | 20030605 |
| | AU 2003237446 | A1 | 20031222 | AU 2003-237446 | 20030605 |
| | US 20040082551 | A1 | 20040429 | US 2003-456933 | 20030605 |
| | BR 2003011619 | A | 20050308 | BR 2003-11619 | 20030605 |
| | EP 1511743 | A1 | 20050309 | EP 2003-736898 | 20030605 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005538958 | T | 20051222 | JP 2004-511293 | 20030605 |
| | MX 2004PA11638 | A | 20050307 | MX 2004-PA11638 | 20041123 |
| PRAI | US 2002-386415P | P | 20020605 | | |
| | WO 2003-US17906 | W | 20030605 | | |

OS MARPAT 140:42177

AB This invention is directed generally to pyrazoles (shown as I; variables defined below; most examples of I are 4-pyrimidinylpyrazoles, e.g. II) that, inter alia, inhibit p38 α kinase (data included), TNF (no data), and/or cyclooxygenase-2 (no data) activity. The pyrazoles further include tautomers of such compds., as well as salts of such compds. and tautomers. This invention also is directed to compns. of such pyrazoles, intermediates for the syntheses of such pyrazoles, methods for making such pyrazoles, and methods for treating (including preventing) conditions (particularly pathol. conditions) associated with p38 kinase, TNF, and/or cyclooxygenase-2 activity. For I: L1 = a bond, O, S, S(O), S(O)2, N(Ra), C(O), C(O)N(Ra), N(Ra)C(O), C(O)O, OC(O), OC(O)O, C(H):C(H), C.tplbond.C, N:N, N(Ra)N(Ra), N(Ra)C(O)N(Ra), C(S)N(Ra), N(Ra)C(S), CH2, OCH2, CH2O, SCH2, and CH2S; and L2 = O, S, S(O), S(O)2, N(Ra), C(O), C(O)N(Ra), N(Ra)C(O), C(O)O, OC(O), OC(O)O, C(H):C(H), C.tplbond.C, N:N, N(Ra)N(Ra), N(Ra)C(O)N(Ra), C(S)N(Ra), N(Ra)C(S), CH2, OCH2, CH2O, SCH2, and CH2S. X1 = N and C bonded to H, except that X1 is C bonded to H if any of X2, X3, X5, or X6 is NH or O; and X2 = CH2, NH, and O, except that X2 is CH2 if X3 is O or NH; and X3 = CH2, NH, and O, except that X3 is CH2 if X2 is O or NH; and X4 = N and C bonded to H; and X5 = CH2 and NH, except that X5 is

CH₂ if X₃ is O or X₆ is NH; and X₆ = CH₂ and NH, except that X₆ is CH₂ if X₂ is O or X₅ is NH. R₁ = H, hydroxyalkyl, carboxyalkyl, aminoalkyl, aminocarbonylalkyl, and aminocarbonylaminoalkyl; R_{3A} and R_{3B} = halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, and alkoxyalkyl; and R_{3c} = H, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, and alkoxyalkyl; R₄ = pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyriny, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, and the sulfone of thiomorpholinyl; R₅ = H, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxy carbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, and heterocyclylalkyl; addnl. details are given in the claims. Although the methods of preparation are not claimed, 28 example preps. and characterization data for an addnl. 114 examples of I are included. For example, II was prepared from 4-[3-(4-chlorophenyl)-4-(pyrimidin-4-yl)-1H-pyrazol-5-yl]cyclohexanone and ((R)-(+)- α -methylbenzyl)amine followed by sodium triacetoxymethylborohydride.


IT 635726-14-6P 635726-15-7P 635726-16-8P
635726-17-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazoles as p38 α kinase, TNF and/or cyclooxygenase-2 inhibitors)


RN 635726-14-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-(4-chlorophenyl)-4-[2-[[1-(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 635726-15-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 635726-16-8 CAPLUS


CN Ethanone, 1-[4-[5-(4-chlorophenyl)-4-[2-[[1-(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-1-piperidinyl]-2-hydroxy- (CA INDEX NAME)



RN 635726-17-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-5-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)

10/552,317



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 57 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:376852 CAPLUS

DN 138:385443

TI Preparation of amino imidazolyl pyrimidinecarboxaldehyde thiosemicarbazones, pyridine analogs and related compounds as inhibitors of I κ B kinases

IN Hawley, Ronald Charles; Labadie, Sharada Shenvi; Sjogren, Eric Brian; Talamas, Francisco Xavier

PA F. Hoffmann-La Roche AG, Switz.

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003040131 | A1 | 20030515 | WO 2002-EP12164 | 20021031 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2465711 | A1 | 20030515 | CA 2002-2465711 | 20021031 |
| | AU 2002350657 | A1 | 20030519 | AU 2002-350657 | 20021031 |
| | EP 1444223 | A1 | 20040811 | EP 2002-785344 | 20021031 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | BR 2002013899 | A | 20040831 | BR 2002-13899 | 20021031 |
| | CN 1582284 | A | 20050216 | CN 2002-822194 | 20021031 |
| | JP 2005511608 | T | 20050428 | JP 2003-542177 | 20021031 |
| | RU 2308455 | C2 | 20071020 | RU 2004-117545 | 20021031 |
| | US 20030144303 | A1 | 20030731 | US 2002-288968 | 20021106 |
| | US 6846828 | B2 | 20050125 | | |
| | MX 2004PA04166 | A | 20040708 | MX 2004-PA4166 | 20040430 |
| | US 20050107403 | A1 | 20050519 | US 2004-967430 | 20041018 |
| | US 7157580 | B2 | 20070102 | | |
| PRAI | US 2001-338312P | P | 20011107 | | |
| | WO 2002-EP12164 | W | 20021031 | | |
| | US 2002-288968 | A3 | 20021106 | | |

OS MARPAT 138:385443

AB The present invention relates to aminopyrimidine and aminopyridine derivs. (shown as I; variables defined below; e.g. 2-butylamino-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone (1)) and methods for their preparation The compds. are useful as inhibitors of I κ B kinases and, therefore, may be used for the treatment of inflammatory, metabolic or malignant conditions (e.g. rheumatoid arthritis, inflammatory bowel disease, psoriasis, cancer, diabetes and septic shock). IC₅₀ values for inhibition of IKK β enzyme activity are reported for 3 examples of I; e.g. 0.314 μ M for 1. Eleven example preps. of intermediates and I and characterization data for .apprx.150 I are included. For example, 2-isopropylamino-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde

2-methylthiosemicarbazone was prepared in 7 steps starting from Et diethoxyacetate, thiourea and benzyl bromide giving 2-benzylsulfanyl-6-diethoxymethylpyrimidin-4-ol as the 1st intermediate (50%); this intermediate was sequentially converted to the chloride (74%), pyrimidine imidazole, sulfone (31% for 2 steps), amino pyrimidine acetal (66%), aldehyde (64%) and finally the aldehyde thiosemicarbazone (71%). For I: one of either V or X is N and the other is CRa, or both V and X are CRa (Ra = H, (C1-C6)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C6)alkyl); Y is O, S or NR (R is H, CN, NO₂, (C1-C10)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (C3-C10)alkenyl or (C2-C10)alkynyl). Z is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or N(R₂)(R₃); R₁ is H, (C1-C10)alkyl, (C3-C10)alkenyl, (C2-C10)alkynyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C1-C10)heteroalkyl, heterocyclyl, heterocyclyl (C1-C6)alkyl, aryl, aryl(C1-C4)alkyl, aryl(C1-C4) heteroalkyl, heteroaryl(C1-C4)alkyl, heteroaryl(C1-C4)heteroalkyl, C(O)R₁₁ or (C1-C6)alkylene-C(O)R₁₁; R₄ is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C2-C6)alkenyl or (C2-C6)alkynyl; A is H, (C1-C10)alkyl, (C3-C10)alkenyl, (C2-C10)alkynyl, halo (C1-C6) alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C1-C10)heteroalkyl, heterocyclyl, heterocyclyl(C1-C6) alkyl, heterosubstituted (C3-C7)cycloalkyl, aryl, aryl(C1-C4)alkyl, aryl(C1-C4)heteroalkyl, heteroaryl, heteroaryl(C1-C4)alkyl, heteroaryl(C1-C4)heteroalkyl or RaRbNC(:X) (Ra and Rb = H, (C1-C4)alkyl or aryl). X is O or S; B is a (un)substituted five- or six-membered aromatic ring containing at least 1 N and 0-3 addnl.

heteroatoms,

wherein the B ring substituents = halogen, CF₃, CF₃O, (C1-C6)alkyl, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, cyano, nitro, sulfonamido, acyl, acylamino and carboxamido; U is -NR₅-, -O- or -S-; addnl. details are given in the claims.


- IT 525559-27-7P, 2-((1-(Methylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-(3-hydroxy-3-methylbutyl)thiosemicarbazone 525559-33-5P,
 2-((1-(Methylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-(tetrahydropyran-4-ylmethyl)thiosemicarbazone 525559-42-6P,
 2-((1-Benzylpiperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone 525559-64-2P,
 2-((1-(Ethoxycarbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525559-69-7P, 2-((1-Acetyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525559-74-4P, 2-((1-(Methylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-00-3P,
 2-((1-((Dimethylamino)carbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-07-0P, 2-((1-((Dimethylamino)sulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-08-1P,
 2-((1-(Ethylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-11-6P, 2-((1-(Isopropylsulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-12-7P,
 2-((1-(2-Acethylethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-

yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-13-8P, 2-((1-(Aminocarbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-16-1P,
 2-((1-(Acetylmethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-19-4P, 2-((1-(Aminocarbothioyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-20-7P,
 2-((1-((Methylamino)carbothioyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-21-8P, 2-((1-((Dimethylamino)carbothioyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-22-9P,
 2-((1-(Aminosulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-25-2P, 2-((1-((Methylamino)carbonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-29-6P,
 2-((1-(2-(Methylsulfonyl)ethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-30-9P, 2-((1-(Cyanomethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-methylthiosemicarbazone
 525560-35-4P, 2-((1-(2-Cyanoethyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde
 2-methylthiosemicarbazone 525560-43-4P,
 2-((1-(Aminosulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-((tetrahydropyran-4-yl)methyl)thiosemicarbazone 525560-44-5P,
 2-((1-(Aminosulfonyl)piperidin-4-yl)amino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde 2-butylthiosemicarbazone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of amino imidazolyl pyrimidinecarboxaldehyde thiosemicarbazones, pyridine analogs and related compds. as inhibitors of IkB kinases)


RN 525559-27-7 CAPLUS

CN Hydrazinecarbothioamide, 1-(3-hydroxy-3-methylbutyl)-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525559-33-5 CAPLUS

CN Hydrazinecarbothioamide, 2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 525559-42-6 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525559-64-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 525559-69-7 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[(1-acetyl-4-piperidinyl)amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525559-74-4 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-00-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 525560-07-0 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-[(dimethylamino)sulfonyl]-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-08-1 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(ethylsulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-11-6 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[2-[[1-[(1-methylethyl)sulfonyl]-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-12-7 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(3-oxobutyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-13-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 525560-16-1 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(2-oxopropyl)-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-19-4 CAPLUS

CN 1-Piperidinecarbothioamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 525560-20-7 CAPLUS

CN 1-Piperidinecarbothioamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 525560-21-8 CAPLUS

CN 1-Piperidinecarbothioamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 525560-22-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(aminosulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-25-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[[2-(aminothioxomethyl)-2-methylhydrazinylidene]methyl]-6-(1-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 525560-29-6 CAPLUS

CN Hydrazinecarbothioamide, 1-methyl-2-[[6-(1-methyl-1H-imidazol-5-yl)-2-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]amino]-4-pyrimidinyl]methylene]- (CA INDEX NAME)




RN 525560-30-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(cyanomethyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-35-4 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(2-cyanoethyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-methyl- (CA INDEX NAME)




RN 525560-43-4 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(aminosulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)



RN 525560-44-5 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[[1-(aminosulfonyl)-4-piperidinyl]amino]-6-(1-methyl-1H-imidazol-5-yl)-4-pyrimidinyl]methylene]-1-butyl- (CA INDEX NAME)



IT 525559-28-8, 2-(1-Methanesulfonylpiperidin-4-ylamino)-6-(1-methyl-1H-imidazol-5-yl)pyrimidine-4-carboxaldehyde


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of amino imidazolyl pyrimidinecarboxaldehyde thiosemicarbazones, pyridine analogs and related compds. as inhibitors of IκB kinases)

RN 525559-28-8 CAPLUS

CN 4-Pyrimidinecarboxaldehyde, 6-(1-methyl-1H-imidazol-5-yl)-2-[[1-(methanesulfonyl)-4-piperidinyl]amino]- (CA INDEX NAME)

10/552,317



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 58 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:335096 CAPLUS

DN 138:353990

TI Preparation of 4-imidazolin-2-one derivatives as MAP kinase inhibitors

IN Kubo, Akira; Imashiro, Ritsuo; Sakurai, Hiroaki; Miyoshi, Hidetaka;
Ogasawara, Akihito; Hiramatsu, Hajime

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003035638 | A1 | 20030501 | WO 2002-JP10937 | 20021022 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2461100 | A1 | 20030501 | CA 2002-2461100 | 20021022 |
| | AU 2002363108 | A1 | 20030506 | AU 2002-363108 | 20021022 |
| | EP 1439174 | A1 | 20040721 | EP 2002-802049 | 20021022 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | BR 2002013465 | A | 20041109 | BR 2002-13465 | 20021022 |
| | CN 1571781 | A | 20050126 | CN 2002-820837 | 20021022 |
| | CN 100402521 | C | 20080716 | | |
| | HU 2004001949 | A2 | 20050128 | HU 2004-1949 | 20021022 |
| | US 20040204426 | A1 | 20041014 | US 2004-827294 | 20040420 |
| | MX 2004PA03729 | A | 20040723 | MX 2004-PA3729 | 20040421 |
| | KR 742058 | B1 | 20070723 | KR 2004-705911 | 20040421 |
| | NO 2004002010 | A | 20040709 | NO 2004-2010 | 20040514 |
| PRAI | JP 2001-324029 | A | 20011022 | | |
| | JP 2002-263680 | A | 20020910 | | |
| | WO 2002-JP10937 | W | 20021022 | | |
| | JP 2003-116076 | A | 20030421 | | |
| OS | MARPAT 138:353990 | | | | |
| AB | The title compds. I [wherein G1 = (un)substituted alkyl or B-W; B = (un)substituted Ph, Naphthyl, aromatic heterocyclyl, or cycloalkyl; W = a single bond or (un)substituted alkylene; Q1 and Q2 = independently H, halo, or alkyl; n = 0-4; R1 = H, (un)substituted (cyclo)alkyl, Ph, or heterocyclyl; Z1-Z4 = independently CH or N with exclusions; G2 = H, NR3R4, OR5, SR5, COR6, CHR7R8, or heterocyclyl; R3-R8 = independently H, alkenyl, alkynyl, OH, alkoxy, alkoxyoxalyl, alkylsulfonyl, (un)substituted alkyl, amino, alkanoyl, carbamoyl, cycloalkyl, Ph, heterocyclyl(carbonyl), PhCO, or heterocyclyl-CO] and pharmaceutically acceptable salts are prepared as mitogen activation proteins (MAP) kinase inhibitors. For example, the compound II•HCl was prepared in a multi-step synthesis. II•HCl showed 69% inhibitory activity against TNF- α in rat in the amount of 1 mg/kg after 90 min. | | | | |
| IT | 521090-46-0P 521090-47-1P 521090-48-2P | | | | |

521090-50-6P 521090-51-7P 521090-60-8P


521091-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(MAP kinase inhibitor; preparation of imidazolinone derivs. as MAP kinase
inhibitors)

RN 521090-46-0 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methyl-4-
piperidiny]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 521090-47-1 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-[[1-
(phenylmethyl)-4-piperidiny]amino]-4-pyrimidinyl]-1H-imidazol-1-
yl]methyl]- (CA INDEX NAME)




RN 521090-48-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 521090-50-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 521090-51-7 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 521090-60-8 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 521091-47-4 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RE.CNT 99 THERE ARE 99 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 59 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:326011 CAPLUS
 DN 139:230704
 TI 2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors
 AU Manley, Peter J.; Balitza, Adrienne E.; Bilodeau, Mark T.; Coll, Kathleen E.; Hartman, George D.; McFall, Rosemary C.; Rickert, Keith W.; Rodman, Leonard D.; Thomas, Kenneth A.
 CS Departments of Medicinal Chemistry and Cancer Research, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(10), 1673-1677
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 139:230704
 AB 2,4-Disubstituted pyrimidines were synthesized as a novel class of KDR kinase inhibitors. Evaluation of the SAR of the screening lead compound I (R = H) (KDR IC₅₀=105 nM, Cell IC₅₀=8% inhibition at 500 nM) led to the potent 3,5-dimethylaniline derivative I (R = Me) (KDR IC₅₀=6 nM, cell IC₅₀=19 nM).
 IT 496795-25-6P 496795-34-7P 496795-35-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 2,4-disubstituted pyrimidines as a novel class of KDR kinase inhibitors)
 RN 496795-25-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)




RN 496795-34-7 CAPLUS
 CN 2-Pyrimidinamine, N-(2-methyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RN 496795-35-8 CAPLUS

10/552,317

CN 2-Pyrimidinamine, N-(2,6-dimethyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 60 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:242338 CAPLUS
 DN 138:271694
 TI Preparation of 3-(pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for control of inflammatory cytokines
 IN Clark, Michael Phillip; Laufersweiler, Matthew John; Djung, Jane Far-Jine; Natchus, Michael George; De, Biswanath
 PA The Procter & Gamble Company, USA
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2003024971 | A1 | 20030327 | WO 2002-US30135 | 20020920 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6566357 | B1 | 20030520 | US 2002-246499 | 20020918 |
| | US 20030105084 | A1 | 20030605 | US 2002-245927 | 20020918 |
| | US 6821971 | B2 | 20041123 | | |
| | CA 2461073 | A1 | 20030327 | CA 2002-2461073 | 20020920 |
| | AU 2002327690 | A1 | 20030401 | AU 2002-327690 | 20020920 |
| | AU 2002327690 | B2 | 20060720 | | |
| | EP 1427728 | A1 | 20040616 | EP 2002-763693 | 20020920 |
| | EP 1427728 | B1 | 20070307 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | BR 2002012716 | A | 20040803 | BR 2002-12716 | 20020920 |
| | CN 1555375 | A | 20041215 | CN 2002-818228 | 20020920 |
| | CN 1257905 | C | 20060531 | | |
| | CN 1555379 | A | 20041215 | CN 2002-818229 | 20020920 |
| | CN 1250551 | C | 20060412 | | |
| | CN 1556811 | A | 20041222 | CN 2002-818380 | 20020920 |
| | CN 1249066 | C | 20060405 | | |
| | JP 2005504082 | T | 20050210 | JP 2003-528818 | 20020920 |
| | PT 1427727 | T | 20050630 | PT 2002-763692 | 20020920 |
| | ES 2237691 | T3 | 20050801 | ES 2002-763692 | 20020920 |
| | HU 2005000752 | A2 | 20060130 | HU 2005-752 | 20020920 |
| | AT 332901 | T | 20060815 | AT 2002-799017 | 20020920 |
| | AT 356126 | T | 20070315 | AT 2002-763693 | 20020920 |
| | ES 2268154 | T3 | 20070316 | ES 2002-799017 | 20020920 |
| | RU 2299885 | C2 | 20070527 | RU 2004-111803 | 20020920 |
| | NZ 531063 | A | 20070831 | NZ 2002-531063 | 20020920 |
| | ES 2282459 | T3 | 20071016 | ES 2002-763693 | 20020920 |
| | ZA 2004001260 | A | 20040830 | ZA 2004-1260 | 20040217 |
| | ZA 2004001402 | A | 20040827 | ZA 2004-1402 | 20040220 |
| | ZA 2004001403 | A | 20040830 | ZA 2004-1403 | 20040220 |
| | MX 2004PA02574 | A | 20040618 | MX 2004-PA2574 | 20040318 |

| | | | | |
|----------------------|----|----------|----------------|----------|
| NO 2004001605 | A | 20040621 | NO 2004-1605 | 20040420 |
| HK 1071565 | A1 | 20070126 | HK 2005-104374 | 20050524 |
| PRAI US 2001-323625P | P | 20010920 | | |
| WO 2002-US30135 | W | 20020920 | | |

OS MARPAT 138:271694

AB The present invention relates to compds. which are capable of preventing the extracellular release of inflammatory cytokines, said compds., including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, have the formula (I) [R = O(CH₂)_kR₃, (un)substituted NH₂; wherein k = an integer of 0-5; R₃ = each (un)substituted C1-C4 alkyl, hydrocarbonyl, heterocyclyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl; R₁ = each (un)substituted aryl or heteroaryl; R₂ = H, (CH₂)_jO(CH₂)_nR₈, (CH₂)_jNR_{9a}R_{9b}, (CH₂)_jCO₂R₁₀, (CH₂)_jOCO₂R₁₀, (CH₂)_jCON(R₁₀)₂, (CH₂)_jOCOCON(R₁₀)₂; or two R₂ units can be taken together to form a CO unit; wherein R₈, R_{9a}, R_{9b}, R₁₀ = H, C1-4 alkyl; or R_{9a} and R_{9b} are taken together to form a C3-7 carbocyclic or heterocyclic ring; j, n = an integer of 0-5; Z = O, S, NR₁₁, NOR₁₁; wherein R₁₁ = H, C1-4 alkyl]. Interleukin-1 (IL-1) and tumor necrosis factor- α (TNF- α) are among the important biol. substances known collectively as cytokines and understood to mediate the inflammatory response associated with the immunol. recognition of infectious agents. These pro-inflammatory cytokines are suggested as an important mediators in many disease states or syndromes, inter alia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease (IBS), septic shock, cardiopulmonary dysfunction, acute respiratory disease, cachexia, and therefore responsible for the progression and manifestation of human disease states. The compds. I can block, abate, control, mitigate, or prevent the release of cytokines from cells which produce them (no data). Thus, 6.0 g Me 4-fluorophenylacetate was added to a cold (-78°) solution of lithium diisopropylamide (2 M, 21.4 mL) in THF and stirred at -78° for 1 h at -78°, followed by adding dropwise a solution of 6.0 g 2-methylsulfanylpurimidine-4-carboxaldehyde (preparation given) in 30 mL THF and the resulting mixture was stirred for 45 min at -78° to give, after workup and silica gel chromatog., 8.7 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-3-hydroxypropionic acid Me ester (II) (76 %). To a suspension of CrO₃ in CH₂Cl₂ (300 mL) was added pyridine and stirred vigorously for 1 h at room temperature, followed by adding a solution of the crude II prepared above in 50 mL CH₂Cl₂ dropwise, and the reaction mixture was stirred at room temperature for 16 h to give, after workup and silica gel chromatog., 3.7 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-3-oxopropionic acid Me ester (III) (43% yield) as a yellow solid. To a solution of 7.8 g pyrazolidine in 100 mL pyridine was added 11.5 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-3-oxopropionic acid Me ester and heated to 90° for 16 h to give, after silica gel chromatog., 3.9 g 2-(4-fluorophenyl)-3-(2-methylsulfanylpurimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one (37%) which (1.3 g) was dissolved in a 1:1 mixture of THF and MeOH (56 mL), treated dropwise with 9.34 g Oxone in 42 mL H₂O, and stirred at room temperature for 1 h to give 2-(4-fluorophenyl)-3-(2-methanesulfonylpurimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one.


IT 503072-98-8P, 2-(4-Fluorophenyl)-3-[2-[[1-(propanesulfonyl)piperidin-4-yl]amino]purimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones for control of extracellular release inflammatory cytokines)

RN 503072-98-8 CAPLUS

CN 1H,5H-Pyrazolo[1,2-a]pyrazol-1-one,
2-(4-fluorophenyl)-6,7-dihydro-3-[2-[[1-(propylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 61 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:154244 CAPLUS
 DN 138:187786
 TI Preparation of pyrimidinylthiazoles as antiinflammatories.
 IN Love, Christopher John; Van Wauwe, Jean Pierre Frans; De Brabander, Marc J.; Moses, Roger Clive; Goncharenko, Mykhalyo; Cooymans, Ludwig Paul; Vandermaesen, Nele; Diels, Gaston Stanislas Marcella; Sibley, Anthony William; Noula, Caterina
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003015776 | A1 | 20030227 | WO 2002-EP8956 | 20020809 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2451981 | A1 | 20030227 | CA 2002-2451981 | 20020809 |
| | AU 2002331227 | A1 | 20030303 | AU 2002-331227 | 20020809 |
| | AU 2002331227 | B2 | 20080124 | | |
| | EP 1418911 | A1 | 20040519 | EP 2002-767360 | 20020809 |
| | EP 1418911 | B1 | 20060510 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | HU 2004001160 | A2 | 20040928 | HU 2004-1160 | 20020809 |
| | HU 2004001160 | A3 | 20080128 | | |
| | BR 2002011910 | A | 20041019 | BR 2002-11910 | 20020809 |
| | JP 2005504767 | T | 20050217 | JP 2003-520735 | 20020809 |
| | CN 1633294 | A | 20050629 | CN 2002-815776 | 20020809 |
| | NZ 530772 | A | 20060331 | NZ 2002-530772 | 20020809 |
| | AT 325608 | T | 20060615 | AT 2002-767360 | 20020809 |
| | ES 2264734 | T3 | 20070116 | ES 2002-767360 | 20020809 |
| | IN 2004DN00272 | A | 20050401 | IN 2004-DN272 | 20040206 |
| | US 20040254192 | A1 | 20041216 | US 2004-486820 | 20040211 |
| | US 7138403 | B2 | 20061121 | | |
| | NO 2004000631 | A | 20040312 | NO 2004-631 | 20040212 |
| | ZA 2004001164 | A | 20050512 | ZA 2004-1164 | 20040212 |
| | MX 2004PA01400 | A | 20040527 | MX 2004-PA1400 | 20040213 |
| PRAI | EP 2001-203088 | A | 20010813 | | |
| | WO 2002-EP8956 | W | 20020809 | | |
| OS | MARPAT 138:187786 | | | | |
| AB | Use of title compds. [I; Z = halo, alkyl; hydroxyalkyl, carboxyalkyl, cyanoalkyl, aminoalkyl, aminoalkyl, aminocarbonylalkyl, alkoxyalkyl, polyhaloalkyl, alkoxy, cyano, amino, aminocarbonyl, aminocarbonyl, alkylloxycarbonyl, alkylcarbonyloxy, etc.; Q = (substituted) cycloalkyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzoxazolyl, | | | | |

benzimidazolyl, indazolyl, imidazopyridyl, etc.; L = substituted Ph, (substituted) monocyclic 5-6 membered partially saturated or aromatic heterocycle, bicyclic partially saturated or aromatic heterocycle] for the manufacture

of a medicament for the prevention or the treatment of diseases mediated through tumor necrosis factor-alpha (TNF- α) and/or interleukin-12 (IL-12), is claimed. Thus, Me 3-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]-3-oxopropanoate was added to a mixture prepared from NaOMe and diguanidine carbonate in EtOCH₂CH₂OH followed by 3 h reflux to give 76% 5-(2-aminopyrimidin-4-yl)-4-methyl-2-(4-trifluoromethylphenyl)thiazole. The latter at 10⁻⁸ M gave 92% inhibition of IL-12p70.


IT 499796-65-5P 499796-66-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinylthiazoles as antiinflammatories)


RN 499796-65-5 CAPLUS

CN 2-Pyrimidinamine, N-(1-methyl-4-piperidinyl)-4-[4-methyl-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]- (CA INDEX NAME)



RN 499796-66-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 62 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:117808 CAPLUS

DN 138:170248

TI Preparation of 4-(thiazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors

IN Fraley, Mark E.; Hoffman, William F.; Hartman, George D.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003011838 | A1 | 20030213 | WO 2002-US23882 | 20020727 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002326466 | A1 | 20030217 | AU 2002-326466 | 20020727 |
| | US 20040181066 | A1 | 20040916 | US 2004-485291 | 20040129 |
| PRAI | US 2001-309407P | P | 20010801 | | |
| | WO 2002-US23882 | W | 20020727 | | |

OS MARPAT 138:170248

AB The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tR9COR8, COR9, (CH2)tOR8, CN, (CH2)tNR7R8, (CH2)CONR7R8, CO2R8, (CH2)tSO0-2(CH2)tNR7R8, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = H, CN, halo, N(R8)2, OR8, or (un)substituted (ar)alkyl or aryl; R7 = H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted alkyl, heterocyclyl, or aryl; W = aryl or heterocyclyl; m = 0-2; n = independently 0-6; p = 0-4; t = independently 0-6; or pharmaceutically acceptable salts, hydrates, or stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, cyclization of 2-bromo-1-[2-(methylthio)pyrimidin-4-yl]ethanone (3-step preparation given) with thiourea in EtOH gave 5-bromo-4-[2-(methylthio)pyrimidin-4-yl]-1,3-thiazol-2-amine•HBr. Oxidation to the methylsulfinyl derivative using oxone followed by substitution with 3,5-dimethylaniline afforded II. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC values between 0.01 M and 5.0 M. Thus, I are useful for the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).

IT 1055062-70-8 1055062-71-9 1055062-75-3
1055062-76-4 1055062-80-0 1055062-98-0
1055062-99-1 1055063-00-7 1055063-13-2


1055063-14-3 1055063-15-4 1055063-16-5

RL: PRPH (Prophetic)

(Preparation of 4-(thiazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors)


RN 1055062-70-8 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-chloro-4-pyridinyl]amino]-4-pyrimidinyl]-2-amino- (CA INDEX NAME)




RN 1055062-71-9 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-chloro-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-75-3 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-chloro-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-76-4 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-methyl-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-80-0 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[4-[[4-(2-amino-5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-6-chloro-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055062-98-0 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-methyl-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055062-99-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[4-[[4-(5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-6-methyl-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055063-00-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[6-chloro-4-[[4-(5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055063-13-2 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[[2-[(4-acetyl-1-piperazinyl)methyl]-6-methyl-4-pyridinyl]amino]-4-pyrimidinyl]-2-amino- (CA INDEX NAME)




RN 1055063-14-3 CAPLUS

CN 5-Thiazolecarbonitrile, 2-amino-4-[2-[[2-methyl-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1055063-15-4 CAPLUS

CN 5-Thiazolecarbonitrile, 2-amino-4-[2-[[2-chloro-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1055063-16-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[4-[[4-(2-amino-5-cyano-4-thiazolyl)-2-pyrimidinyl]amino]-6-methyl-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 63 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:117807 CAPLUS
 DN 138:153548
 TI Preparation of 4-(pyrazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors
 IN Fraley, Mark E.; Peckham, Jennifer P.; Arrington, Kenneth L.; Hoffman, William F.; Hartman, George D.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003011837 | A1 | 20030213 | WO 2002-US23879 | 20020726 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002355733 | A1 | 20030217 | AU 2002-355733 | 20020726 |
| | US 20040235875 | A1 | 20041125 | US 2004-485296 | 20040129 |
| | US 7109204 | B2 | 20060919 | | |
| PRAI | US 2001-309399P | P | 20010801 | | |
| | WO 2002-US23879 | W | 20020726 | | |

OS MARPAT 138:153548

AB The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tR9COR8, COR9, (CH2)tOR8, CN, (CH2)tNR7R8, (CH2)tCONR7R8, CO2R8, (CH2)tSOO-2(CH2)tNR7R8, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = independently H, CN, halo, N(R3)2, (CH2)tOR8, or (un)substituted (ar)alkyl or aryl; R7 = independently H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted heterocyclyl, alkyl, or aryl; V = a bond, aryl, or heterocyclyl; W = aryl or heterocyclyl; m = 0-2; n = 0-6; p = 0-4; t = independently 0-6; and pharmaceutically acceptable salts, hydrates, and stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, 2-(methylthio)pyrimidine-4-carboxylic acid was amidated with dimethylhydroxylamine•HCl in the presence of EDC and TEA, and the product treated with MeMgBr in Et2O to give 1-[2-(methylthio)pyrimidin-4-yl]ethanone. Coupling with N,N-dimethylformamide dimethylacetal followed by cyclization with phenylhydrazine afforded 2-(methylthio)-4-(1-phenyl-1H-pyrazol-3/5-yl)pyrimidine. Oxidation with oxone and reaction with 3-chloroaniline provided the 4-(pyrazolyl)-2-pyrimidinamine II. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.01 μ M and 5.0 μ M. Thus, I are useful for

the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).


IT 1055062-51-5 1055062-60-6 1055062-64-0
1055062-65-1 1055062-67-3 1055062-68-4

RL: PRPH (Prophetic)

(Preparation of 4-(pyrazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors)


RN 1055062-51-5 CAPLUS

CN Ethanone, 1-[4-[[6-methyl-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1055062-60-6 CAPLUS

CN 2-Pyrimidinamine, N-[2-methyl-6-[[4-(methanesulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]-4-(1-phenyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 1055062-64-0 CAPLUS

CN Ethanone, 1-[4-[[6-chloro-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1055062-65-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[6-chloro-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)




RN 1055062-67-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-chloro-6-[[4-(methanesulfonyl)-1-piperazinyl]methyl]-4-pyridinyl]-4-(1-phenyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 1055062-68-4 CAPLUS

CN 1-Piperazinecarboxamide, N-methyl-4-[[6-methyl-4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-2-pyridinyl]methyl]- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 64 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:117806 CAPLUS
 DN 138:153547
 TI Preparation of 4-(imidazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors
 IN Bilodeau, Mark T.; Manley, Peter J.; Balitza, Adrienne; Rodman, Leonard; Hartman, George D.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003011836 | A1 | 20030213 | WO 2002-US23764 | 20020726 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002327342 | A1 | 20030217 | AU 2002-327342 | 20020726 |
| | US 20040220201 | A1 | 20041104 | US 2004-485170 | 20040129 |
| | US 6958340 | B2 | 20051025 | | |
| PRAI | US 2001-309400P | P | 20010801 | | |
| | WO 2002-US23764 | W | 20020726 | | |


OS MARPAT 138:153547

AB The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, or OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tR9COR8, COR9, (CH2)tOR8, CN, (CH2)tNR7R8, (CH2)tCONR7R8, CO2R8, (CH2)tSOq(CH2)tNR7R8, oxido, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = H, CN, halo, N(R8)2, (CH2)tOR8, or (un)substituted (ar)alkyl or aryl; R7 = independently H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted heterocyclyl, alkyl, or aryl; V = bond, aryl, or heterocyclyl; W = aryl or heterocyclyl; m = 0-3; n = 0-6; p = 0-4; q = undefined; t = 0-6; or pharmaceutically acceptable salts, hydrates or stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, 2-phenylimidazole was coupled with 4-chloro-2-(methylthio)pyrimidine in the presence of NaH in DMF and the product oxidized using sodium tungstate dihydrate and H2O2 in EtOAc to give 2-(methylsulfonyl)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidine. Substitution with 2-methylaniline and purification by reverse phase chromatog. afforded II•TFA. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.01 μ M and 5.0 μ M. Thus, I are useful for the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).


IT 496795-25-6P, 4-(2-Phenyl-1H-imidazol-1-yl)-N-(pyridin-4-yl)pyrimidin-2-amine 496795-34-7P,
 N-(2-Methylpyridin-4-yl)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine
 496795-35-8P, N-(2,6-Dimethylpyridin-4-yl)-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tyrosine kinase inhibitor; preparation of (imidazolyl)pyrimidinamines as tyrosine kinase inhibitors)
 RN 496795-25-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-phenyl-1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)



RN 496795-34-7 CAPLUS
 CN 2-Pyrimidinamine, N-(2-methyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)




RN 496795-35-8 CAPLUS
 CN 2-Pyrimidinamine, N-(2,6-dimethyl-4-pyridinyl)-4-(2-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)



10/552,317

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 65 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:746614 CAPLUS
 DN 136:95578
 TI Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
 AU Adams, J. L.; Boehm, J. C.; Gallagher, T. F.; Kassis, S.; Webb, E. F.; Hall, R.; Sorenson, M.; Garigipati, R.; Griswold, D. E.; Lee, J. C.
 CS Department of Medicinal Chemistry, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(21), 2867-2870
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Optimization of a series of N-1-cycloalkyl-4-aryl-5-(pyrimidin-4-yl)imidazole inhibitors of p38 kinase is reported. Oral administration of inhibitors possessing a cyclohexan-4-ol or piperidin-4-yl group at N-1 in combination with alkoxy, amino(alkyl), phenoxy and anilino substitution at the 2-position of the pyrimidine was found to potently inhibit LPS-induced TNF in mice and rats. The selectivity of these new inhibitors for p38 kinase vs. eight other protein kinases is high and in all cases exceeds that of SB 203580.
 IT 186314-88-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pyrimidinylimidazole inhibitors of p38, cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity)
 RN 186314-88-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)



proviso

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 66 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:278036 CAPLUS

DN 134:295821

TI Imidazole compounds useful as cytokine inhibitors.

IN Adams, Jerry Leroy; Gallagher, Timothy Francis; Sisko, Joseph; Osifo, Irennegbe Kelly; Boehm, Jeffrey Charles

PA Smithkline Beecham Corporation, USA

SO U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 636,779, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 6218537 | B1 | 20010417 | US 1998-973594 | 19980513 |
| | ZA 9604723 | A | 19970617 | ZA 1996-4723 | 19960606 |
| | WO 9640143 | A1 | 19961219 | WO 1996-US10039 | 19960607 |
| | W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1314728 | A1 | 20030528 | EP 2002-79535 | 19960607 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI | | | | |
| | IN 1996DE01674 | A | 20050311 | IN 1996-DE1674 | 19960726 |
| PRAI | US 1995-473396 | A2 | 19950607 | | |
| | US 1996-636779 | B2 | 19960419 | | |
| | WO 1996-US10039 | W | 19960607 | | |
| | EP 1996-921517 | A3 | 19961219 | | |
| OS | CASREACT 134:295821; MARPAT 134:295821 | | | | |
| AB | Novel 1,4,5-trisubstituted imidazole compds. I and their compns. for use in therapy as cytokine inhibitors are disclosed [wherein R1 = 4-pyridyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolin-4-yl, 1-imidazolyl, 1-benzimidazolyl, all bearing a substituted amino group, plus an optional addnl. substituent; R2 = alkyl, N3, heterocyclyl, alk(en/yn)yl, haloalkyl, etc.; R4 = (un)substituted Ph, 1- or 2-naphthyl, heteroaryl]. I are useful for treating a variety of cytokine-mediated diseases, particularly those mediated by CSBP/RK/p38 kinase, and may also be useful as antivirals (no data). For example, 2-(methylthio)pyrimidine-4-carboxaldehyde (preparation given) was condensed with 4-amino-1-methylpiperidine-2HCl to give the imine (98%), which was cyclized with the tosylmethyl isocyanide derivative 4-FC6H4CH(Tos)N.tplbond.C (50%) to give imidazole derivative II [R = SMe]. This underwent S-oxidation with K persulfate to give 83% II [R = S(O)Me], which was condensed with PhCH2NH2 (82%) to give title compound II [R = NHCH2Ph]. | | | | |
| IT | 186314-86-3P 186314-88-5P 186314-90-9P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of imidazole derivs. as cytokine inhibitors) | | | | |
| RN | 186314-86-3 CAPLUS | | | | |
| CN | 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME) | | | | |



proviso

RN 186314-88-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)-1H-imidazol-5-yl]-N-4-piperidiny- (CA INDEX NAME)




proviso


RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)

10/552,317



IT 186314-81-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of imidazole derivs. as cytokine inhibitors)
RN 186314-81-8 CAPLUS
CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)]-1H-
imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidiny] (CA INDEX NAME)



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 67 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:137207 CAPLUS

DN 134:178569

TI Preparation of as isoxazolylypyrimidines and related compounds as inhibitors of c-JUN N-terminal kinases and other protein kinases.

IN Green, Jeremy; Bemis, Guy; Grillot, Anne-Laure; Ledebouer, Mark; Salituro, Francis; Harrington, Edmund; Gao, Huai; Baker, Christopher; Cao, Jingrong; Hale, Michael

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001012621 | A1 | 20010222 | WO 2000-US22445 | 20000811 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2381882 | A1 | 20010222 | CA 2000-2381882 | 20000811 |
| | EP 1218369 | A1 | 20020703 | EP 2000-957485 | 20000811 |
| | EP 1218369 | B1 | 20080723 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | BR 2000013551 | A | 20030617 | BR 2000-13551 | 20000811 |
| | HU 2003000340 | A2 | 20030628 | HU 2003-340 | 20000811 |
| | HU 2003000340 | A3 | 20050428 | | |
| | JP 2003531103 | T | 20031021 | JP 2001-517519 | 20000811 |
| | NZ 517694 | A | 20050324 | NZ 2000-517694 | 20000811 |
| | CN 1222520 | C | 20051012 | CN 2000-814178 | 20000811 |
| | AT 402163 | T | 20080815 | AT 2000-957485 | 20000811 |
| | NO 2002000713 | A | 20020412 | NO 2002-713 | 20020212 |
| | US 20030149051 | A1 | 20030807 | US 2002-74177 | 20020212 |
| | US 6693108 | B2 | 20040217 | | |
| | ZA 2002001248 | A | 20030220 | ZA 2002-1248 | 20020213 |
| | MX 2002PA01565 | A | 20050714 | MX 2002-PA1565 | 20020213 |
| | IN 2002KN00245 | A | 20050916 | IN 2002-KN245 | 20020219 |
| | US 20050026967 | A1 | 20050203 | US 2004-779532 | 20040213 |
| | US 7169798 | B2 | 20070130 | | |
| | AU 2006203676 | A1 | 20060921 | AU 2006-203676 | 20060824 |
| PRAI | US 1999-148795P | P | 19990813 | | |
| | US 1999-166922P | P | 19991122 | | |
| | US 2000-211517P | P | 20000614 | | |
| | AU 2000-69096 | A3 | 20000811 | | |
| | WO 2000-US22445 | W | 20000811 | | |
| | US 2002-74177 | A3 | 20020212 | | |

OS MARPAT 134:178569

AB Title compds. [I; XYZ = NOCR2, ON:CR2, N:NNR3, OC(R2):CR2, NN(R3)CR2; R1 = H, CONH2, TnR, TnAr2; R = (substituted) alipharyl; n = 0, 1; T = CO, CO2, CONH, SO2, SO2NH, COCH2, CH2; R2 = H, R, CH2OR, CH2OH, CHO, CH2SR,

CH₂SO₂R, CH₂NH₂, CH₂CN, (substituted) aryl, arylmethyl, heterocyclyl, heterocyclylmethyl, etc.; R₃ = H, R, COR, CO₂R, SO₂R; G = R, Ar₁; Ar₁ = (substituted) (fused) aryl, aralkyl, heterocyclyl; Q = Q₁, Q₂; A = N, CR₃; U = CR₃, O, S, NR₃; Ar₂ = (substituted) (fused) aryl, heterocyclyl], were prepared. Thus, 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylamine (preparation given) was refluxed with PhBr, tris(dibenzylideneacetone)dipalladium, BINAP, and NaOCMe₃ were refluxed together for 16 h to give 36% 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylphenylamine. Several I inhibited KNK3 at <0.1 μM.


IT 326819-56-1 326819-60-7 326819-61-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of as isoxazolyipyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)


RN 326819-56-1 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 326819-60-7 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 326819-61-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-4-piperidinyl- (CA INDEX NAME)

10/552,317



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 68 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2000:725459 CAPLUS
 DN 133:296373
 TI Preparation of 3-phenyl-4-(heterocyclylmethyl)pyrrolidine modulators of
 chemokine receptor activity
 IN Caldwell, Charles; Chapman, Kevin; Hale, Jeffrey; Kim, Dooseop; Lynch,
 Christopher; Maccoss, Malcolm; Mills, Sander G.; Willoughby, Christopher;
 Berk, Scott; Kim, Ronald M.
 PA Merck and Co., Inc., USA
 SO PCT Int. Appl., 202 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2000059498 | A1 | 20001012 | WO 2000-US9074 | 20000405 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6498161 | B1 | 20021224 | US 2000-543019 | 20000404 |
| PRAI | US 1999-128172P | P | 19990406 | | |

OS MARPAT 133:296373

AB The title compds. (I) [wherein R1 = CO₂H, NO₂, tetrazolyl, hydroxyisoxazole, SO₂NH(alkyl)R₉, or PO₃H₂; R₉ = H, (cyclo)alkyl, benzyl, or (un)substituted phenyl; R₂ = (un)substituted piperidinyl, tetrahydropyridinyl, piperazinyl, or 1-oxa-8-azaspiro[4.5]decyl; R₃ = (un)substituted Ph or heterocyclyl; R₄ = H or (un)substituted alkyl, (alkyl)cycloalkyl, alkenyl, alkynyl, Ph, alkylphenyl, naphthyl, biphenyl, heterocyclyl, cyclohexenyl, etc.; R₅ and R₆ = independently H or (un)substituted alkyl; or R₄ and R₅ may be joined together to form an (un)substituted C₃-8 cycloalkyl ring; n = 1-3] were prepared as modulators of chemokine receptors, especially the chemokine receptors CCR-5 and/or CCR-3. For example, 2-(R)-((3-(R)-formyl)-4-(S)-3-fluorophenylpyrrolidinyl-1-yl)-3-cyclobutanepropionic acid benzyl ester (preparation given) was treated with Pd/C and dissolved in ClCH₂CH₂Cl.
 4-[N-(pyrimid-2-yl)-N-(prop-1-yl)amino]piperidine•HCl (4-step preparation given), NaBH(OAc)₃, and TEA were added, followed by di-tert-butylidicarbonate, to give II. I showed binding activity to the CCR-5 or the CCR-3 receptor, generally with IC₅₀ values of < 1 μM. The present invention is directed to compds. which inhibit the entry of human immunodeficiency virus (HIV) into target cells and are of value in the prevention and treatment of HIV infection and the resulting AIDS syndrome (no data). The invention is further directed to compds. which are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders, including asthma, allergic rhinitis, dermatitis, conjunctivitis, rheumatoid arthritis, and atherosclerosis (no data).

IT 301223-28-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-phenyl-4-(heterocyclymethyl)pyrrolidine chemokine
 receptor modulators by reaction of 3-phenyl-4-formylpyrrolidines with
 heterocycles)

RN 301223-28-9 CAPLUS

CN 1-Pyrrolidineacetic acid, α -cyclohexyl-3-phenyl-4-[[4-[(4-phenyl-2-
 pyrimidinyl)propylamino]-1-piperidinyl]methyl]-, (α R, 3S, 4S)- (CA
 INDEX NAME)


Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 69 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:262172 CAPLUS
 DN 130:306613
 TI Cytokine production blockers for the management of uterine contractions
 IN Alvi, Samir Ahmed
 PA Imperial College Innovations Ltd., UK
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9918942 | A1 | 19990422 | WO 1998-GB3015 | 19981008 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2316296 | A1 | 19990422 | CA 1998-2316296 | 19981008 |
| | AU 9894493 | A | 19990503 | AU 1998-94493 | 19981008 |
| | EP 1021173 | A1 | 20000726 | EP 1998-947651 | 19981008 |
| | R: BE, CH, DE, ES, FR, GB, IT, LI, NL | | | | |
| | JP 2001519381 | T | 20011023 | JP 2000-515577 | 19981008 |
| PRAI | US 1997-61614P | P | 19971010 | | |
| | WO 1998-GB3015 | W | 19981008 | | |
| OS | MARPAT 130:306613 | | | | |
| AB | The present invention is to the novel use of a cytokine inhibitor for the prophylactic treatment, or management of excessive, undesired or inappropriate uterine activity, such as contractions, in a mammal in need thereof. An example of a cytokine-production blocker is SKF 86002 [6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo[2,1-b]thiazole], a CSBP/p38 protein kinase RK inhibitor. | | | | |
| IT | 186314-81-8 186314-86-3 186314-88-5 186314-90-9 | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cytokine production blockers for the management of uterine contractions) | | | | |
| RN | 186314-81-8 CAPLUS | | | | |
| CN | 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME) | | | | |



proviso

RN 186314-86-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 186314-88-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)

10/552,317



RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 70 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:7994 CAPLUS
 DN 130:66503
 TI Preparation of imidazolyl-cyclic acetals as TNF-alpha inhibitor
 IN Bamborough, Paul Lindsay; Collis, Alan John; Halley, Frank; Lewis, Richard
 Alan; Lythgoe, David John; McKenna, Jeffrey Mark; Mclay, Iain Mcfarlane;
 Porter, Barry; Ratcliffe, Andrew James; Wallace, Paul Andrew
 PA Rhone-Poulenc Rorer Limited, UK
 SO PCT Int. Appl., 292 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 9856788 | A1 | 19981217 | WO 1998-GB1711 | 19980612 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2293436 | A1 | 19981217 | CA 1998-2293436 | 19980612 |
| | AU 9879259 | A | 19981230 | AU 1998-79259 | 19980612 |
| | AU 742293 | B2 | 20011220 | | |
| | ZA 9805148 | A | 19991213 | ZA 1998-5148 | 19980612 |
| | EP 988301 | A1 | 20000329 | EP 1998-929548 | 19980612 |
| | EP 988301 | B1 | 20060809 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO, CY | | | | |
| | TR 9903098 | T2 | 20000721 | TR 1999-3098 | 19980612 |
| | BR 9810007 | A | 20000815 | BR 1998-10007 | 19980612 |
| | HU 2000003309 | A2 | 20020128 | HU 2000-3309 | 19980612 |
| | HU 2000003309 | A3 | 20020228 | | |
| | JP 2002503245 | T | 20020129 | JP 1999-501908 | 19980612 |
| | RU 2221795 | C2 | 20040120 | RU 2000-100951 | 19980612 |
| | AT 335735 | T | 20060915 | AT 1998-929548 | 19980612 |
| | PT 988301 | T | 20061031 | PT 1998-929548 | 19980612 |
| | ES 2270520 | T3 | 20070401 | ES 1998-929548 | 19980612 |
| | TW 235751 | B | 20050711 | TW 1998-87112466 | 19980729 |
| | US 6602877 | B1 | 20030805 | US 1999-456360 | 19991208 |
| | NO 9906120 | A | 20000124 | NO 1999-6120 | 19991210 |
| | MX 9911515 | A | 20000430 | MX 1999-11515 | 19991210 |
| | US 20040038991 | A1 | 20040226 | US 2003-436609 | 20030513 |
| | US 6989395 | B2 | 20060124 | | |
| PRAI | GB 1997-12270 | A | 19970612 | | |
| | US 1997-52185P | P | 19970710 | | |
| | GB 1997-24678 | A | 19971121 | | |
| | US 1998-85499P | P | 19980514 | | |
| | WO 1998-GB1711 | W | 19980612 | | |
| | US 1999-456360 | A3 | 19991208 | | |

OS MARPAT 130:66503

AB Title Compsd.[I; are described in which R1 is optionally substituted heteroaryl, 4-pyridyl; R2 is optionally substituted aryl, 4-fluorophenyl, or optionally substituted heteroaryl; R3 is H, a group -L1-R7 or -L2-R8,

where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, etc.; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl; R4 is benzylaminocarbonyl, a group -L3-R14, where L3 is a direct bond or an optionally substituted alkylene linkage and R14 is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy, cycloalkyloxy, heteroaryl, R5 is hydrogen, Me, alkyl or hydroxyalkyl; or R4 and R5, when attached to the same carbon atom may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C:CH2; R6 represents H, alkyl; m is 0-2], N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates are prepared as TNF inhibitors and pharmaceuticals.


IT 218160-32-8P 218161-31-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolyl-1,3-dioxanes as TNF-alpha inhibitor)

RN 218160-32-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-2-[trans-5-methyl-5-(4-morpholinylcarbonyl)-1,3-dioxan-2-yl]-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 218161-31-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(cis-5-amino-5-methyl-1,3-dioxan-2-yl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)

Relative stereochemistry.

10/552,317



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 71 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:226813 CAPLUS

DN 128:282837

OREF 128:55991a,55994a

TI Preparation of imidazoles as cytokine inhibitors

IN Adams, Jerry Leroy; Gallagher, Timothy Francis; Sisko, Joseph; Peng, Zhi Qiang; Osifo, Irennegbe Kelly; Boehm, Jeffrey Charles

PA Smithkline Beecham Corp., USA

SO U.S., 33 pp., Cont.-in-part of U.S. 5,658,903.

CODEN: USXXAM


DT Patent

LA English

FAN.CNT 5


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 5739143 | A | 19980414 | US 1996-764003 | 19961211 |
| | US 5658903 | A | 19970819 | US 1996-659102 | 19960603 |
| | ZA 9604723 | A | 19970617 | ZA 1996-4723 | 19960606 |
| | EP 1314728 | A1 | 20030528 | EP 2002-79535 | 19960607 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI | | | | |
| | IN 1996DE01674 | A | 20050311 | IN 1996-DE1674 | 19960726 |
| | ZA 9711092 | A | 19990722 | ZA 1997-11092 | 19971210 |
| | CA 2274655 | A1 | 19980618 | CA 1997-2274655 | 19971211 |
| | WO 9825619 | A1 | 19980618 | WO 1997-US23157 | 19971211 |
| | W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9857033 | A | 19980703 | AU 1998-57033 | 19971211 |
| | EP 961618 | A1 | 19991208 | EP 1997-953241 | 19971211 |
| | EP 961618 | B1 | 20040804 | | |
| | R: BE, CH, DE, ES, FR, GB, IT, LI, NL | | | | |
| | JP 2001506239 | T | 20010515 | JP 1998-527045 | 19971211 |
| | ES 2226008 | T3 | 20050316 | ES 1997-953241 | 19971211 |
| | US 5869660 | A | 19990209 | US 1998-12946 | 19980123 |
| | US 6369068 | B1 | 20020409 | US 1999-319859 | 19990611 |
| PRAI | US 1995-473396 | B2 | 19950607 | | |
| | US 1996-636779 | B2 | 19960419 | | |
| | US 1996-659102 | A2 | 19960603 | | |
| | US 1996-32766P | P | 19961211 | | |
| | US 1996-764003 | A | 19961211 | | |
| | EP 1996-921517 | A3 | 19961219 | | |
| | WO 1997-US23157 | W | 19971211 | | |
| OS | MARPAT 128:282837 | | | | |
| AB | The title compds. [I; R1 = 4-pyridyl, pyrimidinyl, quinolinyl, etc.; R2 = heterocyclyl, C2-10 alkenyl, C3-7 cycloalkyl, etc.; R4 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, heteroaryl], useful in treatment, e.g., inflammation and osteoporosis as cytokine inhibitors, were prepared Thus, reaction of 4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-5-(2-methylsulfinyl-4-pyrimidinyl)imidazole (preparation described) with PhCH ₂ NH ₂ afforded 82% I [R1 = 2-benzylamino-4-pyrimidinyl; R2 = 1-methyl-4-piperinyl; R4 = 4-fluorophenyl] which showed IC ₅₀ of < 50 μM in cytokine specific binding protein assay. | | | | |

IT 186314-81-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of imidazoles as cytokine inhibitors)
 RN 186314-81-8 CAPLUS
 CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




proviso

IT 186314-86-3P 186314-88-5P 186314-90-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazoles as cytokine inhibitors)
 RN 186314-86-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 186314-88-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)-1H-imidazol-5-yl]-N-4-piperidiny- (CA INDEX NAME)



RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)

10/552,317



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 72 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:650347 CAPLUS

DN 127:314828

OREF 127:61489a,61492a

TI 1,4,5-Substituted imidazole compounds for treatment of CNS injuries to the brain

IN Feuerstein, Giora Z.

PA Smithkline Beecham Corporation, USA; Feuerstein, Giora Z.

SO PCT Int. Appl., 40 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9735856 | A1 | 19971002 | WO 1997-US5820 | 19970324 |
| | W: JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP | 889888 | A1 | 19990113 | EP 1997-917899 | 19970324 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO | | | | |
| | JP 2000507558 | T | 20000620 | JP 1997-534693 | 19970324 |
| | US 6096739 | A | 20000801 | US 1998-142877 | 19980918 |
| | US 6387898 | B1 | 20020514 | US 2000-627940 | 20000728 |
| PRAI | US 1996-14137P | P | 19960325 | | |
| | WO 1997-US5820 | W | 19970324 | | |
| | US 1998-142877 | A3 | 19980918 | | |
| OS | MARPAT 127:314828 | | | | |
| AB | 1,4,5-Substituted imidazole compds. and compns. are used for the treatment of CNS injuries to the brain. The preferred method of inhibition is the the inhibition of the CSBP/p38/RK kinase pathway. Compds. of the invention were active (IC50<50 µM) in a cytokine specific binding protein (CSBP) assay. | | | | |
| IT | 186314-81-8 186314-86-3 186314-88-5 186314-90-9 | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (imidazole derivs. for treatment of CNS injuries to brain) | | | | |
| RN | 186314-81-8 CAPLUS | | | | |
| CN | 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME) | | | | |



RN 186314-86-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 186314-88-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-piperidinyl- (CA INDEX NAME)

10/552,317



RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



L17 ANSWER 73 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:119170 CAPLUS

DN 126:144274

OREF 126:27881a,27884a

TI Imidazole compounds useful as cytokine inhibitors.

IN Adams, Jerry Leroy; Gallagher, Timothy Francis; Sisko, Joseph; Peng, Zhi-Qiang; Osifo, Irennegbee Kelly; Boehm, Jeffrey Charles

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | WO 9640143 | A1 | 19961219 | WO 1996-US10039 | 19960607 |
| | W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | IL 118544 | A | 20010808 | IL 1996-118544 | 19960603 |
| | IN 186434 | A1 | 20010901 | IN 1996-DE1210 | 19960604 |
| | ZA 9604723 | A | 19970617 | ZA 1996-4723 | 19960606 |
| | TW 442481 | B | 20010623 | TW 1996-85106749 | 19960606 |
| | CA 2223533 | A1 | 19961219 | CA 1996-2223533 | 19960607 |
| | AU 9662726 | A | 19961230 | AU 1996-62726 | 19960607 |
| | AU 699646 | B2 | 19981210 | | |
| | EP 831830 | A1 | 19980401 | EP 1996-921517 | 19960607 |
| | EP 831830 | B1 | 20030305 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI | | | | |
| | CN 1192147 | A | 19980902 | CN 1996-195882 | 19960607 |
| | CN 1130358 | C | 20031210 | | |
| | BR 9608591 | A | 19990105 | BR 1996-8591 | 19960607 |
| | HU 9802259 | A2 | 19990928 | HU 1998-2259 | 19960607 |
| | HU 9802259 | A3 | 20020228 | | |
| | JP 11513017 | T | 19991109 | JP 1996-502174 | 19960607 |
| | AT 233561 | T | 20030315 | AT 1996-921517 | 19960607 |
| | EP 1314728 | A1 | 20030528 | EP 2002-79535 | 19960607 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI | | | | |
| | PL 185515 | B1 | 20030530 | PL 1996-323916 | 19960607 |
| | ES 2194106 | T3 | 20031116 | ES 1996-921517 | 19960607 |
| | IN 1996DE01674 | A | 20050311 | IN 1996-DE1674 | 19960726 |
| | NO 9705716 | A | 19980204 | NO 1997-5716 | 19971205 |
| | US 6218537 | B1 | 20010417 | US 1998-973594 | 19980513 |
| | IN 2000DE00081 | A | 20050311 | IN 2000-DE81 | 20000202 |
| PRAI | US 1995-473396 | A | 19950607 | | |
| | US 1996-636779 | A | 19960419 | | |
| | WO 1996-US10039 | W | 19960607 | | |
| | EP 1996-921517 | A3 | 19961219 | | |
| OS | MARPAT 126:144274 | | | | |
| AB | Novel 1,4,5-trisubstituted imidazole compds. I and their compns. for use in therapy as cytokine inhibitors are disclosed [wherein R1 = 4-pyridyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolin-4-yl, 1-imidazolyl, | | | | |


1-benzimidazolyl, all bearing a substituted amino group, plus an optional addnl. substituent; R2 = alkyl, N3, heterocyclyl, alk(en/yn)yl, haloalkyl, etc.; R4 = (un)substituted Ph, 1- or 2-naphthyl, heteroaryl]. I are useful for treating a variety of cytokine-mediated diseases, particularly those mediated by CSBP/RK/p38 kinase, and may also be useful as antivirals (no data). For example, 2-(methylthio)pyrimidine-4-carboxaldehyde (preparation given) was condensed with 4-amino-1-methylpiperidine-2HCl to give the imine (98%), which was cyclized with the tosylmethyl isocyanide derivative 4-FC6H4CH(Tos)N.tplbond.C (50%) to give imidazole derivative II [R = SMe]. This underwent S-oxidation with K persulfate to give 83% II [R = S(O)Me], which was condensed with PhCH2NH2 (82%) to give title compound II [R = NHCH2Ph].

IT 186314-86-3P 186314-88-5P 186314-90-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. as cytokine inhibitors)

RN 186314-86-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)]-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



proviso


RN 186314-88-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)]-1H-imidazol-5-yl]-N-4-piperidiny] (CA INDEX NAME)



RN 186314-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)-1H-imidazol-5-yl]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




IT 186314-81-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of imidazole derivs. as cytokine inhibitors)

RN 186314-81-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidiny)-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidiny]- (CA INDEX NAME)



L17 ANSWER 74 OF 74 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1994:435528 CAPLUS

DN 121:35528

OREF 121:6563a,6566a

TI Synthesis and biological activity of some
4-(p-chlorophenyl)-6-(o-hydroxyphenyl)-2-aminopyrimidine derivatives: Part
1

AU Abdel-Halim, A. M.; Tawfik, A. M.; Ibrahim, S. S.; El-Kazak, A. M.

CS Fac. Educ., Ain Shams Univ., Cairo, Egypt

SO Indian Journal of Heterocyclic Chemistry (1994), 3(3), 165-70

CODEN: IJCHEI; ISSN: 0971-1627

DT Journal

LA English


AB 6-(O-Hydroxyphenyl)-4-(substituted-phenyl)-2-aminopyrimidines (e.g., I)
were prepared from their corresponding 2-(substituted-phenyl)chromones.
Acylation, alkylation, reaction with chloroacetyl chloride, phenacyl
bromide, and nucleophilic substitution reactions of I have been
investigated. The assigned structures were verified by elemental anal.,
IR and ¹H NMR. Some of the newly synthesized compds. were screened for in
vitro antibacterial and antifungal activities. Only I showed
antibacterial activity against gram-neg. bacteria.

IT 155733-42-9P 155733-43-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 155733-42-9 CAPLUS


CN Phenol, 2-[6-(4-chlorophenyl)-2-[(7-chloro-4-quinolinyl)amino]-4-
pyrimidinyl]- (CA INDEX NAME)



RN 155733-43-0 CAPLUS

CN Phenol, 2-[2-(9-acridinylamino)-6-(4-chlorophenyl)-4-pyrimidinyl]- (CA
INDEX NAME)

10/552,317



10/552,317

=>

---Logging off of STN---

Connection closed by remote host
END

Unable to generate the STN prompt.
Exiting the script...

---Logging off of STN---

END

Unable to generate the STN prompt.
Exiting the script...